var title_f14_6_14432="Infantile psoriasis";
var content_f14_6_14432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infantile psoriasis of the diaper area",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14432=[""].join("\n");
var outline_f14_6_14432=null;
var title_f14_6_14433="Complete cleft lip and palate";
var content_f14_6_14433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete cleft lip and palate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal view of a late second trimester fetal face demonstrating the fetal nose, lips, and chin. A unilateral complete cleft lip is shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14433=[""].join("\n");
var outline_f14_6_14433=null;
var title_f14_6_14434="Osteomyelitis limp fever";
var content_f14_6_14434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Lytic lucency in osteomyelitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 510px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) A plain radiograph at the initial evaluation of a 9-year-old with fever and limp demonstrates a lytic lucency in the distal femoral metaphysis. B, C) Axial and coronal MRI images delineate the area of osteomyelitis and adjacent marrow edema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Jeanne Chow, MD. Children's Hospital-Boston, Copyright &copy; Jeanne Chow, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14434=[""].join("\n");
var outline_f14_6_14434=null;
var title_f14_6_14435="Traction tracheomegaly CT";
var content_f14_6_14435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Traction tracheomegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 320px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFAAcYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5eghV4wSOTUwtos/d/U0loP3I9zVlaAGJaQlgCn6mp4NNinkSKOPLucDk8ep69qmRcDJOMe1bVlH9jtPNk4nnXC8fcXPX8f6UAZ8+kWKT+VFGGCcFtzZY9+M8VZ03w3DqVzHb2dqZJXOBhm/xrb8O+H7rWr3yrSM5zgkds/8A1wK+hfAPgy18OWbSSLFLcTDliMFQaAOO8K/A7w8LaOXXLZpXYZaPz3XHHGMEe9dBF8GPArfM2h5Xp8t3cdef9uu+MZiKqMMOTtzk/X/CrDI6yREJtODx6/8A16APPx8FPAhA2aEGJ/6fLgc/990x/gt4FC5OgEHH3ftlx1/77r0SF32MWQlc9c5BNWJXDqM52t90j0A6YoA8yT4M+Ahv8zQjjop+2XAI/wDH6enwX8BEjOhds/8AH5OM/wDkSvR+GGOOR0HPNKyAKGwwcJjA6nqOh+tAHmL/AAY8CqBjQmbnk/bJ/X03/wCc0o+DngDCn+xCR0/4/Jxn/wAiV6SuVOcEZbJAGcAfWkl8pt2B8oB68UAeat8HPAhVivh9ugx/pk+OT1/1lO/4U14DWXy/7CDuo5BvZxz/AN916HblQdm7chOeR6GrluqTPKXjwuTyTnv0oA83HwZ8AttB8PbCev8Aptx/8cqvN8G/AiPj+wAAcAMLy4P6eZXqBMSyNhTkAht3alW1EkAZQWyQFX3z9aAPNIPgv4DH+s0EMB3+23HP/j9Jd/BjwBFGpGif7x+2T8f+RK9ksfDaIyPcNle6DvWu+n2TxGJrZChGOR1oA8Gtvgv4BliyNCGT0JvLgdv9+i1+BHhO8lAt/DzbckMWupwo/HfXudpo9lbMSqs4zwGOcVf3DGAAF9AKAPFrD9nDwQrb7+wLDP8Aq47iYfhnfWqP2f8A4ZgY/wCEbLH1N/c//HK9THuaOtAHlg+AHwy/6Fr/AMn7n/45QfgB8M/+ha/8n7n/AOOV6mQMZpFPFAHln/CgPhnj/kW//J+5/wDjlNHwA+GgOD4cP/gdc8/+RK9TZh705SCePSgDytf2f/hoR/yLnP8A1/XP/wAcp3/CgPhnn/kWv/J+5/8AjlenFj/D0zTtwx1xjr7UAeWSfAL4aKhKeGGc5AAF/cg9cZ5l7dfwp/8AwoD4Z/8AQtY/7f7r/wCOV6cX4wPzpxBOBnpQB5d/woH4ZZ/5Frj/AK/7n/45R/woD4Z/9C1/5P3P/wAcr05lO7jNSqOOtAHln/CgPhn/ANC1/wCT9z/8cob9n/4ZsuB4cdT6i/uf/jleqUH8qAPGbv8AZ28DLlrXRy6/3Wu5wR/4/WNP8BvCcLN5nh9gmeGF1P8A/F17/S7jxz34oA+b7n4O+BrVZPN0YDYM/Pdzgn/x+oIfhP4DlGV0QKCPl3Xk+T1/269t8TaZFd+JNJJXMcoKyDsQOelW7rwrYSSK9qDA4446EUAeFf8ACn/BDSbU0M8cYF3Oc8/79PHwe8DpCWk0PDAZAN3P835PXqmsabLpznB+THLE/lVFGZ2WSTAIP3Qe+Men+fegDzdfg94JOf8AiRnb/eN5Nx/4/wDX8qk/4Ut4HMbMNIfaO/2ubJ/DdXod2CJFaXbtYnCEY+nSkWTO5XXaAB9fpQB52/wX8EmIMulBSOuLuZj9cb/85qKf4MeCxEjxaWWy3zZu5QB24+evRzsglEhRsqCMADj8ajjm327kZJB3BQenHWgDzi0+D/gwySLLpG5lO7H2mcDHYffouPhF4JXIj0YlsZAF1Mf/AGevQLJX84ycRgk8Z3FQe386ddhBIiL5nycDHAAPrQB58/wg8FJBvOjfN6fa5sfj89Qw/CPwZJER/Ykgc9ALuXP/AKF19q9CmZEjRcx7emBk89+amsA6y7EGdwyCADntwT07UAeY3XwP8LXNtILdHs5QCwLTuSMezHmvNfFXwjvNGkLWVvLe24z+8XOf5/WvpoRMTJ5m5kA5LDqef0p08qyqyMSxK4GORj3/AMKAPimTS4IpCrw4I7MWz/Oo5tMtzzCjA/3STmvoP4h/DmLUlkv9GVYrlOSuM+ZXhdxDJb3DxOu2SNtrA8YPpmgDDa1iB+4SPqaiaCMfwnHrnitqUJMPmj/ek580s2WH93GdoH4ZrPljIOG4OOo7+/0/GgDNmQIRtoqS8GCv40UAT2nMA9eauxLntkVTsv8AUr9TV6EZAPQfzoA0dItReX0cZGY1HmP7gdq6jRNJuPE3iBILdVXOCWI4C/5wPwrJ0yI22km43Ylu2wg77Aeo+uf0r3v4OeHk0rRW1CWIm7uiNpbqEyeg/GgDqvC2gWOg2yRJboHTq+OQfY1tB3eHaEBVexGMr/kUsuFaOX5gSevHHtU6pGzjIKhuCM+1ACxohkjGzLqOvXFTLJhU3na46HHINUx8sgXdlWICk8ECp921tm4FSBjJ/OgCwSYEfcqFCcjBIOPwprOSdijceoXPQ0wyZjcM5KDIHOc1XOPtUZZij/xY9O1AFwMsaAE4cgcEfKD61JGN8O8sePlJzx+VU3Mj3AOMKBwOOfwqW5CCMHzAAD06elAE/wC72hWblidu0cVUhU+YMkkBx+Pt+tTkRqkZjbjsD69ac0qSh2O0so5KjgUAV/L84tlDkY27D71atgQdwJJzjB4B/wDr1JZSpP8Au4vvvwuMVrReHyCGe5ZW7qvNAGLJbG4kADEGTsB0rptO05LQKTgnHfsfapLawht9uAWYHqauHn8aAA/0o/GjFNizs2nqKAFFLjIzmgE8469qXHTigBO9Heg9KAMfhQAD1NJ+lLngUAZ6UAQTxnYShOfeqTyzQ4YqCPWtUI1UdR1PTNPIW/u4ImPRGYbvyoAryXYLEqORzycU+C4CwNJKQvPTrisa7+IHhq1lMbzsxGQWWLiom+IfhJ7kWk18I3JAw6HAJoA6iMFxuGduOKmA685FV4tQ0541aK9t2RuRiQYP05p9veWlzIUtrmGV16hGBoAm6dsCjil/pTd655OOaAFoo3D15ooAO1Koz60lU9XvDZWe5BmR+FoAjixPqpkYgiMbU9q0DknPY1kaNbNBAXkbdK5yee9anmYOD+dAEV3ardxlHPbvXE3VrPp1zJFJHsiJIVyOv5/Wu+z6Uy4giuYWjuEDxn1oA80ny5IYMzJ37CnW88bIrbA7E4G7t6mug1rQzbofKctC5I64xXNpaSwqq712E4yMH/IoAld0I+dwH6njn/69V4rlBIyowO0YJAwe5P8AOrCRyRkMVUQZOc9TVWUwRzhoUcpn5gF9fegCokrreAkAB9wwxJzk9atXUEZceezZbAyDz2/wrL1CZ1vMurRjOVz1x/SraSG7VQ2Aowd5xn0oAluGihXy9uMdSecDPpTra5laREiY+Un8RGOn+RVOQReY5C7mwOS3etOPzfIJYCMjgDGc/wCf/wBdACpbXEjLlUVSMEsadDbxxtt3FoznnP8AOrBja4CF5CF53AHA68U9YkVSGC7uQozzQBlTRIm5wocnAOOnJryb4m+CYbtJL+xRFmxuKIo555zXsE8EhhuAoXcQcAjp/n8KotCCzCX5yF+f0Jx/n9KAPkG5gaN9sqMrL2K4warsglQo3EnZsdPavb/iX4JSa1a+sIsSpy2DwfavE54mjYqQQwz0FAGFqAKlQwwQSCKKsa3gtC/cgg/pRQAyyH7hfxrU0+2e+u7e1jJDTOEz/dB6n8s1m2R/0dfxroPDr/Z2vbgErIkJVCPVuD+lAHSbY9T8SW1naqTaxOsMagfwjA6/XJ/Gvpy0s0tBa28JOIkAIycdv/r14F8HLJLzxL5rxhmhTIHb0/oK94ikLXLyAAMcdOCPWgDSTYCUkLDnsMrmpklEUWFcSEtgnH51RZnMquvmFeB8vr/XtU3mMMb2blueMGgCeNi8rqoxt+bJHQUojJIlUDbkkANwWoQoE44kIwAx61Yc+UPujaQBnOM/h+dADJBKi4QqFHJPPP0olljaZXaUkKNpx/8AXpZz5MKurfNnhB1PFYkzxwXYFywRpCeD6Hnp/h6UAbLXMLuBEQHYZC57k8f1plxL5KobgKoIOc+tZazwaazSXGZJlBMbKf4e2f8AP1rzzxj8SE+1SWtrtlkX5ctwE4/XvQB6iNRsoYy13Nt56g/p+X86pr4hsJLspbTqy4xjgk5+teFzarPeH99c5HGVyRg+gx1rT8Lxzapr9paaeGa5nlVflY4xnBP0AOc0AfQXhvQ76a/i1OScR2yHMUeOWHvXbEkk+vqKEQQwxxL0RQOD6Uf55oACO/ejHGe1KemKaeaADOMZNMdjG+4n5TwafjI60uAVwefWgAGCODxSUuPwHtRxjtQAUHHr+NQzxkjcDzVV7lUwCcnNAF/K561i+LL/AOzWBhjYrI4zuB+7TzcTKMqR0yCDWRLA0krzXI356EkkUAcxLrHiJ4p/K1Aqqg4zj19QPpXmH2uU6zLdX0zzTBmyWJJ9eBXomvXZhhlVAqD7oIJGP85rgdLs7MzSzSOWckkxt/F14/LJoAlvbh2tRNJH5auCyhvvYHQmuJF5C+otcTuHIJJB9OfX6/pXUeK5lSxkynlyZIUoOB0yOfw/WvNJkugj/KyIePrzigDu7HxLCYRBaZdugAIAGOnTvxXo3hm8aFrW4spPKmi+aQnnOR0+leH+CopoNS826iYwdCMV7Tp0QlGbdjH0ODzk9cfl6kUAewW2stdwKVj/AHh/LpU0aTXM3zsyoDn61zfgSS4ku3WdWIRcg9sc4rtiQvQ4z3oAZFCsZ+8WqTOaAMfSk79aAFFZ1zGl3qscT4KwjcQR1PpWhv2g45YDgetcTpGqNH4nukmDbpDjJ5HFAHZsMEBRwPWl255NCkNhvX0p3Yc0AAyKO9L3pqsScEdKAEmjSeJ4ZRlGGDzXDa/bDRLrLZkhl+5jtXd9Af8A9dYnjW2kn8PyyQp5k0JDge3egDjZb6CUI2/Hfaw7+uKgwLlA8AzH7AE5/EfSvJ9Y8QXkeqOnlkIgyrY5HX863PBPjNVv5bW5bET/ACl8Hap9fx6f4UAdLr1mZLVZDJtmThdo4/GqlhcgYfK7yu5vmPPHb2rJ1DXbRdXEUsz7GO5VDcEdPxrR0+0j1FJlhO51TcpJOeOg46Y5+tAGlLMqfvIlikIPJ688Y5rdtZGLK7ldzDoAP6Vx1nePDBKZlbMbbSWzgc+nbp/nitO11ZYkiuNuLd2++RxjqSKAOtlKGQRxx5BXhR2OKemGYHafNJ/DGaq6fqtlcWu+3JbnAOce34VdS4CopC7RjhcdBzQBWl/1s6szL8pOBzz/AJzWFe27FlkaXgZXaTg1tT3I+0GQLyeMAdegrn9aYrdJN93dztGAP/r0AUtT8qa3kjcNtPAOOv8AhXivxK8KtBbx6rbxEBjiRe319hXsV0+642OSUPAUEcN2zitPT9Fj1G0eK8SMoQVbd3544NAHxbrQ/wBSRyDu5H4UV0vxd0J/Dvid7Ij91lnjOMcE9PwooA5ezz5K+lbmg7XvDCzBRKjBT74OKw7T/UJ+NW4Zmt5EmXl42Df/AFqAPZPgWfJ8Q3JZsuEwpHXOa99VSJXVlIyPmJAY5/rXzLY6pJousRXdpIqCUrKQoBIGAePSvY9K+JcV7Zt5iKspHyg4GCPT+f50Ado0BjSOWSTEQcnrn/6/6VT1TUI7eDKzKwRlXsQc+teZeJ/Gvngi38xWc8gYUYxkGufGoak7ERyNNFIcZI7Dt/KgD0+LWLsX0pdw8TD5fL7emO3rVi4vnNvJKssiLjkgZA7/ANa5zwvBcSQNcSAnzFKGMjk49/xrrbLQHW0YTkuCQQ/3cj2HrQBztxeXjGO8SWUqASFbB3EDoTnApdM1W91fWxe6pJGLWHkLjnocD9Kn8eRroXh9riJ8rkKULDrnHc14trHjae+WSNVMSHAO3uMY/lQB3fxF8ZW1xvg0mcrJJ8rnOdq55wcd/wCleYwq80zSEMztyTgn/Paqtss1zcK8m6Q5xk84HbmuuhtCIkWBAdwzkHnigCrbQx/aAu0oT1LHGOP8n8K+mfgd4Sg0rSW1uaMG6uxthJXBSIHt/vHk/QV5n8NfAc/ifU4nubZotMgcNNKT/rMfwD3r6aREijSKJQkaAKqgcADpQAH8qQn0FHX60D2oAQHNKR7Ud6D1oATp+NDkBCxIA9ar6rf22lafLeXj7YoxnHcn0FcMniO+1l2kg3QQNwiEc4560AehD5kBHcUjEA8VR0qdpLONJhh1AB96vfzoAOeeaxtWsmJ8xTnuRW3wOP61maveRwQMGPLcAigCKGIvBtYdPSs6/l8u3YLjA9e3vVL+2UjZUf5ctyxP8qb4hukOmMbaSNmPfA44/wA80Ac7emG/doZQN6nJfO05GT1/wrk7/QFMx+xYkXk4UdTjufT39qtXGpwxusM7mPIIyuBtA/X16+lZej+IDFrGYZiYwSH3j6cj8MYHuaAMPX5pdGs/P1rarE7Qrjgc8j6ehrjLbXdJ1y6gtbOCYXUhOGLcc8YxXXeNJV8S3f2G6DyRu4KMByT6/wA/89aHhjwnZ+HdchuJGkldTkluMHPGMUAem2HhWHT9Kjgn2tK4DcYJyB1H0z+tXtH0WOARyLKzMByNxKgY/n0rLbxPp93MEcmUhtowQAOOp7+tblteKbbzTOihV+UA9T6g8c/WgD0TwsD9hc4QHdgsvfitBwTIT2HArivhvqu2S7tLyVR5pDx545xz26/4V288UjHCOAKAKMZnimkJcmPPArQR98YYEZPegRHZiTBH0pAqoMIvFAD16Z614/44gnXUy1tJ5ShwSQcMen+FerXc4toWckcZrz/WHa4uWuI0Dpg5D9x/kUAbvgjxI2qf6JcRgSxqPnzjd7kda6414bo2spba60llMqsmSx6ZH417B4d1q18Qad9ps3BZTiRM8qfcUAaRqP5g3I4qQDB560jgnjHtxQAoNOBHRsFTwQaYOgI9acVOaAPn/wCMPhUabrMc0blbK7LMoAHyt6Z7Dn9a8luJo7NmdTtiBI5+v+OK+tPiLo0XiLwfqFkRmZEMsTDqrAZFfF2t3DJax2//AC0RjvJXGTnvQAa7qk91fQXKyOCnGQMDP+RXpHwy1ySG9dwqOxT7rZHbJ71xHhzQpfENg8SbSY8vyBk+1ReGr2XSdeaKbJZHKuqnGePx7UAewaxfSzpdpHDsJGTg9cd8Y56cVtLplve+AdlsVafZkquPTt/n1rmRe/axat/qXc/6vGNq5PXtnitOPUxo80duMRwSkIWbgAt3/KgDk7FNV0Q5jnBtj0BGQO/88/17V3X/AAmdtPokBjw1zuCuQvK/1rYj0BJbF4Yijs3zFhk4z6V5n428LyWjMkW4yHnPRX59Oefy6UAeiaHqX9rWrusrZQdM8gk8/wAqku7drowhC2Fx/EM9/wD69eHadr9/osr7WypH7xMYOAcnHpXr3gTxJa63bwq3lJOqHcN2Mnvj8xQBeEYW4kQIAM8Hr+eela2kHbNIvygY4QYI6dfcdOKwvE+23mIQ43DLMDnBHvVDSL6KTUrZIQUaRwMk9AccUAeYftdRKuuaDL8u94pg2MdinJ/Oirf7YsHk6n4ZIxhop+/oY6KAPBbT/UJ071bhge5mS3hQtJIdoAqpYhmiURgls9uTXU6HcRaGWuFjWW/KHDNyIwQeg9aAOmv7KNo9iTpIbeJUbA9B/wDrqPSLa7luFmsZWglUfK4yCPauaGp3Lykuy7nyWwOef513fhS5mMO11jdcccc5/AUAaWneHL1VicRtd+by2ASc59ex5PP+Fd54f8JJJ9nknWRpDjcrcDI9fXFMsr8Wd3by/ZlCMFxs52nB/wDr1039uzLKHhhJULyW6qPy/wAKAOks9OhijWIRRkoQWOccZ4q5JGCIhbPuX+5u+vauUt/E32xmZoxEQB8rcBvX60y48Srp8Ae5QIQu5nT8R+fTGM9KAOB/aM1OBbWy0va6yeZu+XsAeh/GvE0t4Fk3F2YN39K0viD4pn8TeIZbiQExINkQPHfqfesSOYsUBQLzgkenagDsvD1hPfosVrEFZTkOQeBz6V1MPhm9iCPJK25uAo5H4Y55yOtaHw0VRYxl4kZyNwfGSQM9uB6/SvU9EFvf39nZ2kW1s5Y5JK4x6/jQB6R4RsV0zwxp1oMErEC5A6k8nNavuOvWmgCCELk4QYql9ouGk+UYT1NAF6gmkRiyZbg0o5FAB+NJNKkERkfPHT6+lMvbmKxtJLmf7iDOPWsPT7q51WYTzr5dvn92g9PU+9ADdY099bwZMCNTlEboPemR6GY44kVFAUetdEseCDmn9ee9AFO2tf3aqeCvT2q0qkdTTh0/pR/IUABGc5FQ3FnBOo8xAcdKmHWgmgDn7zwfpV4VMolBX7uH6VkXvw4s5lnW21G6t0lXbjO7aPQf59K7fOAaO4HSgDxTWvgzcxI01hqD3jjLYkADN9a83vvDfiXR5Q99pToiycMc4I/z9a+swSOhpJljniaOdFkRhggigD5NtriOCV7iRPLm6xkeo7c05NQZbtbu5IJRhtIB5Gc9B/WvoLXPh3ouqRMqA25Jydorm9T+D9qdOm+yXBmuQpMayD5SccUAfNWo+IPst0HtJCufmcseT/n+tEXxCYyKJtwRemOce3auX8SQXmnaldWGowvDcROVZWGOh7e1Ybt19DkGgD6H8I+M7e9gkvYHMZtRkqzE4Pc10+m/HXRnEsd/ctahOFIOS2PTH5/jXylBdz2yusM8kayDa+xsbh/hUYxzwP50AfYekfGzw3c3DRrq4RR0eYEbqf4i+OXg7SkxDqs99P8A88rVC2Px6elfHJ245XB9xQpUH5RtHXr3/KgD3zW/2iHuQ6WOiytE3Rp5QpP4Crd78etCfwmYBpl0dUIKrHjCZ9S2a+d2kPGDgj06VEZMHr19qANy68VaxdiT/SmgWQnKx8ZHpn0qfwt4z8S+FdVTUdD1i5inB+dGO+OUcfK6ngg4HuO1cyXOf4vy4o3nPPpigD6k079qeL+yR/aXhib+1AMf6PMDC59RkZA9jn61haR+0zr9vq0s2r6TbXOnuxKwwna8Y7YY18+CQ5FOEhAFAH1Le/tTWJjA0/wzdiVhkmeZcA49B1rndO/aP1VtVWXVbVBYM2Gij6oK+fBKR2H5UNL1BPbmgD9EfBniXS/Fekw6jpU4lglXBB6j1BGOK+T/AI4+HX0fxreeUoW2mcyKMYGe4H51wfgbx54g8E3JfQ7sLA5JeCRcofUgdjW142+Jd94zSBtTto454gfnTv0+tAGj8NPECafqdvEzYEhK5B68VzfjJprPxpqCOTE4k3rngkHkGvZf2ZfBOneIYptb1GItFYy7I06Av1yfXA/nX0Drfgjwprkm7WPD+nXj4275YQWH49RQB88fDl7jxDoscpmO8ZU4wAeTwD9OtdVfeHQ1iYblw6pyoVuOM9qi+I/g+bwTqdjc+GS0GhXLhTCDxBJ6bj2I6ZPrWxoupyajceWYh9n3bM7ujCgDo/h5ffa7AQTbd6HDM3Vqn8WaMk0O5G4U9SM8eo96Y+iS2LR3USmMqeVB611tjHFeWiFwXyORQB8p/EDQH065ndFxFIMkn731rg7LVbvSb5biCV02H7oJ9q+l/jF4deWwkmAJQLwB0yOlfLV/E6yuGHIPQ0Aez6F4ltvE2nbZHdbjIUIOM88nnrUsCTaTr2nyufkEoVgAcjpj9a8S8P61c+HtZhvLV8BD86knBHpivV7jxfpl5a2moNsDJIu7d8u05+vPagCL9so7rvwm2zaDFckHHJ/1VFM/bFvrW8n8F/ZZVl/0OWQsp7MUx/6CaKAPH9Emt49Jt1VF807vMYDn7x7/AExSEiQc/K3oKzdNIFnGOc8/TrWnbKXI2qWIoA6Xwb4fOs6okQ+ZS3OD719DaX4L06ysYowgEqrtDr1/X/PFeb/BG0hXUXmkVgyocg9F7Zr2U+ZIA75ZSxKg8YA/nx/OgDIn0z7GYxlZMELyB0/D1OasSwQoVijRgQRtPIGM4xz24zVm4uFgZJJxIm3G0jAAGM8+nYU9riSRomtxHIdmVYgbvTn8B+lAGYbYGazZrfIXqF4A7Z/XFcR8TtQtYdOmEXmBkYsqHrx0H8v85rvddlijtgGdImdOQO3U8E+/868A8f6kb24a1ilaZQu0Hr2//VQBwsEZmmfcDsJJL45HNdPoujvcOojdGUdj3P51Bp2nyMhCDZgcFuM88DPb8a63StJW0QlotzY3Zzyf6/pQB0GkKNJsle3kAz8pAPBz1H869T+C8bz3d/qbnKn92oUd/X+Q/CvHtJL3B8mTElrnIPfB549OK+hPBUNnpfglZLYFSDuIb7x9BQB2N7dJGEDMNzHpmiORJZODwPQ1zOlrcX1w1zdMTGeUU9uvar6XSWW1WkGS3NAHRY46VXvLyG0hLFlJ7DPWua8S+IntQkdsWDHkN/WsDTr43Mw+0F2XcD8/Pp/9egDYvEvtV1BBK37gtymeMfSuss4BDEqqANvYVU0+SFUDKDz3xWmrAjIoAKXpRz6UY5x/OgBM0tJRmgA6j3oA9aM0fSgA6GkPXrmg5o9qACl7UgpR3FAB2oLrEjSSMERRlieABSgE44ri/i7r8GheC9Ukk5fyWVVDfxEYHT3xQB8y/tD+MNE8S+IfI0WMSSWzFZbkDhjnoD3/APr/AFrxt/vYHHtUvITJHJyenUk1AeuRQAnrmk3UlHFAC59ABQScdqYW6+1NL9aAHFuODzUbuV6jj0zSGTB4wfWmMcnk5oAXewJPQn2o3Ekc/himEgHBODQWA+6QfYg0AO3cdMd6cH4BGKiDjuvPsaN/tx355oAmEgzg8fWlMgGMEk1DuBJ6KB06k0gPHXr7UAWN+PbHenSPhGKnJ/yarhsDjj6VKOVA9Rzx096APvj9ne2t7X4MeHHtlVftETTSY/icsQf5Y/CvQzwfp3ryD9k3Vk1H4NWlmrgzaZcz20i9xlzIPwxJ+levn8qAMXxzobeJfCOo6XE4jnmjzC5HSRSCPwJGD7E184+HPEF94bL2d5GHubaU+cHH3cdRn+XtX1Spx0Ncr4j8GaLeveX7WSfaZhumK/xkdCfegDgdK+KVrr04stvku3HzHtXW+HNXMVwYNmYc4B6+teR+LvBtnaNJdaPIYpVG5wSDnHXHoavfDvxbpc11a2t1OyXOfLO84DdOeeh6UAe2X3l3wa3uYg8TDHK18w/HTw4ug+IY/JiCW8ykrjkevX/PSvqTTp7e9iJhmR5FGcg8H0ryH9pPT/temxXEqLshU7XP+fcUAfK9wvPABBqpcFjamEN8vUDpWlLHk8Hk8Z9apSxMcgKTj29qAG+LLq6vNK0aS7keTYskSFzyFXb+nP60VH4otZbfT9NaQMFdpdoJ6EBM/wAxRQBW084s484A5/nXf/DgWP2tpb0oDGufm4BGT+tcBp6g2SHgnn8Oa2ra9MUSbFAIHJBxnp+tAHvXgS6jfWLpLbyliZCNo+ua76UIzoYxJGwbdtzn+X+ea+W/Dmt3FrrdtcGSRVRhuXJIIzzmvo3T9Xi1axN0lvHIEbgbM7CAeRk/SgDWmka4tgBmYlgSMZAGe3r/AC4qvPeG1RlePypAPkbb1wetZV54itYol82TyXUgbU52kn+XHb+ted+NvGjySMkdyzQMOB90579s4oA6TXtTuLi3klulHlFf3fTPXtXkUg+0ak+yPYWJ2nqOvP09fyp8+v3GqsIzIVijPyEcY/p3FWLV5rwu6zqoB5UAcj09uv40AdLpOlIVjuJpEeFVzjALYBB6D/8AXT9S1G0nic28TRzKNu3J56c/l/8AWqKDy0Z4pgR8uTx8pHb9aht4SZ1cxq+CF2hcgZP1NAHW+EobaKxZ5pAkm0cA4ySe/btXpmg6jDLpscE1zvTdkBT8pJ/yK8X1otGjCI+WZOnPPTORXpPgCCMab/pK7pVOeOnQfnQB6pGwS1XyXG7GM8VmSWdxcXAaR9qE9VNMsopmkJZXZEGF9PrWwI0KKFBBPUA85oAz9QsDLbtukGEXBIPJrm7YT20uxFJwc5A4/nXYeUJE8tQ28fKWNZFxp0jbypO1QeTwRz2oAkj8RyROlrLChkc4BFdBa6zAsCGfCHpyK5FdPh3pKRl4umeTVO7tL3UZQxDpCvRR1/KgD0iTVtNjXMl3EgAycsOKWHVdNnYLDewMx7BhXnsfhOa6hLSFlYg8lucVND4OsrBZJA7vM/8AFnGPw/OgD0hdrAbSGH1pQpJ6V5Vf6nfaUpMMsjY4+U52iuW8V/EvXtJihEMnzScEsv3aAPfthz0o24FfPuk/FHW5rPzZLhJGPO0qQGHp7das65471EItzLdiMRYZ0DEZ/D86APdyQCATTDLx0z9K4LwP43sNdiWOObFz1YMeOnWu1inD5/iUdxQBZSRGOFbB9DRPJHbQtLMwVF5JNZ93biUcEr9OteUfHmTVLDwJcy6a0m1DiQgnIB6nPtQAz4n/ABytNCVrTw8kd1d9Gcn5UP1FfM/i/wAY634quHk1a9ldGOfK3HaD+B/CsaaTdyx398nv7n3qnIxPQc0AQyHj3qJjjpTmYnqaYefpQA08Uh+uDSk1HI2OpwaAEL4BwRmo+T3J+ppMklsmjqaAFHJyRj2prMAGHQjikZyG4PH0ph4A+YfTFAAxJOcUhz6YpCc0lAC7j3pc57frTaKAH9PvfnQPUGmUoOAaAJRnG7Hf9akQjp+nNQZ9OKeCAM5oA9w/ZX8dQ+E/HU2kanMsWma4qR+Y3Cx3C58s57Bssp9yueBX2o4w3NfmbpNmdT1W0svNSFpmC72OMf5/w7V+jXhN7tfDul2+r3CT6mlsgmlDZ80gY3/j1PuaANamzhmtZ1QbnMbYX1OKcQc89c0oODnt+tAHyn4l1WeKe9hnZo5Y3w0fQjnkc15ffOUuzcWzbWB4ceuc19a/Fr4aReLbSS+0fy7bXUXKseEnx2b39D+dfKmuade6HeyWWr2slpdx/IySL9eh6H8KAOm8H/FG/wBEvoRco0sQKh2JyfT+Vdr4y8f2njDTW0+1gF0JUyFTJZTjpx7g14aLea6m8q0tpbiXskKFmyRwMDp1r6f/AGa/AGoeGtOvdV1+zEFxe7TDDIPnjXJ6g/d7cdaAPErL4ceK79Q8Wk3fkj7hePHX61Wl+Hev25VbnTJt7PsAx1zX3EZD7UxwkjAyIjMvIJGcUAfEH7RPhibwxo/g63uMeZIlyzADjdiHP8xRXdftwhQfBe0cf6b/AO0KKAPFYPDzw+BtM1toy0M5kU4znIkYf+y1X0XS7zV7hYrKBmHQkdO+K9Rh06LUf2adEMRiSe38+VmbnOLmXgj6Yrf/AGfYrT+w5TPBC9x5pId1zjOcD6fSgDxW90S90+5Mc8TK6nBODkdO341uaF4qv9IjkjiZwpyBg564zn8K948Z6JBqEhURIe5dlwOBwTivENc0AxXmVyybj7Zxzx+FACX3iKTUYZHdispUBgfX2Nc08Nzc5eRGxj7w6Y6Ae/8A9f610OmeHZruVo1jctnOFXP+eor0aH4asdKhube4LyLjzFwCO3r/AJ/WgDzLRNP3+WRHuUEbgeQP0/TrXWLbxWsSl4EAbHzqMEY9BXXT+E5tK0K5vIYgQoG6QjhuOT/KuSt4HuZUlkmCpnAXJO/joR+ooAvyJEIooYoyysOWJ69+cdvp6+1XFhNq6q0LRSPy2QCO2ce3+FZLEwynbJvlRcblyMZHQjt9BUl3fyyacnmOTESMrjkn/I6igBNQubO4lVjFJ58YwwOPXPAz25Hpz9K9W+H5+16YoVEUKevTuMH/ADxXjNt51zL58SgOOjEHkfWuw8L+IbjQNTT7UhNu7cp0B9SP88cetAH0PYKzRIJcL16d6leLy8lFGB1J61k+HPENprloJLNlCYyAxPFbKoSSckqeaAGxeWx/djdjrmm35TyiUOGI6epqwsbFSchFJH41YtoIGIl25YHjcOhoA57T9LvUSWaaJQp5Qd60rRBn5kO4jjjpW1knvx7mo1Cg44oAhUOUH8Ix0FVp4GkUoFzxzxWjUcjAd+fagDl7/So3QliEHXGM5wPevE/iZ5DeZDGBIFcrwM/UjHPfmvbPE908Fm7FlVGGB1r518W3Au9TSGP7oOAcE8cnk/5zQBU0m1kG0MMq5GAv8ic109x4dn1XTZVuw0D8CNV6gDuf1qXweLC2mJvW2ZPytt2jaR05/GtnV7SUXYOj3DPEi7sdu/H6UAclpGkf8I5eJdxSSEx9FTHzH29f/r17b4X8RSajEiyo0fAClsjPua5DQfDP9s7WmysyfNxnbnFeh6ZoCQQIhJ4A5IoA3Y0LLy2feuE+OTSRfDDXXRyuy3JwAOn+TXexRmJAig7R69687/aEFy3wo1sWsJlzF+8x2XjJ/KgD4nLfux6Y79qquxOR29KsM37sYIIx1/z7VUY8nHSgBpPNMNKSfyphOGGDQArH9KgYlmOOQMUruSWHHNMBOOeBjHpQAKCSfc00vjIHP+1SuWAHQZzzUR4IHT1zQAc8Y5pGzxmgnP0HSkNABRRRQAUUUUAFFFB6DbQA4HPWnAjHJqP3p3UY70ATqfQnI+YY9RX1V+zf42vtftP7M1W5eeWxBxI3B29sn8q+VI2AHJPPb0r1X9nbWrXS/GVzaXs/kpfxeXG+cAMDmgD7Z0zUluPNSRv9WcBvUf5xWn0AOcisPQbWNbBVR1bj6ir9rMLeZreVgF4Kkn86ALqnBHWqWr6PpWtQ+Vq+nWt4npNEG/nV4AMCUYMPUGm45oApaPo2laJCYtI061s0PXyYwufqetX2YnrTefzooAPzooooA+Wv24f+ZL/7ff8A2hRR+3D18F5/6ff/AGhRQBg/DQ2+q/COHT5EAlh85c55YGRm4HfrWV4K8THwhrk1teRZtH7nIAHvXPfCq9MFukBk2LITjd93dk9f89q9i174cTa5p8bxvAJI1IJT+IYznn+fNAGq3jWweHeLiLyXQAgjdjp0A/zzXn+saha6rqCyWTtCDywPLHoM47dP1rmrvw3qmg3hhkikZ3GSR6ccZ/PpVVBfktGYniGMN2xjnHr/AI0Adzoev/2W8vlTBt6nKEd+nBr074YahNOlxGwzbSS7gDyQMfy/xrwzQ9G1LWtSt7WzgaSV2UgDJGPXJ9+a+oPDPhoaLbwJIirIoG4qO+OT+eaAJfGGiq/gDVlyAHjLYJwBXg+loY4UQvFtjIVWIG7gV9P+I7RbnwtqNrjINuwwOOgz/Svmy4sJbY7kjjaJUwI15OfU/kaAM3UZ1WQFiMSHa2SE78EVQtkN/ePE/m+So8tc4O49PT61ZEUF62JgwVm3PuG3GOmB3600aibCN/ssxldDtRXX69KALmqRyWFqERwxUYVCuCQScfz+tafhzS4tQU/akCwhlDkt98gduK5SQajLfQtcq4WQqzEnJP07fnXYaVr8dnEYXMbsDnG3BHHp/hQB0VnZS6cSLBnXndhSQc4wBn0/CtPw94q1a2kNlqbBwE3lwc9O3vXMy68HspnZfKySFbPJOAeM96qw3LTQxxQOnnOo3O3bPYA9R/8AXoA9UtNfF3cGEjcxIOBwR74zXc2U6yQoqqcjr/jXCeCdFis4I5JG3EqAHYk+vH+e2K7mzjCNtj4Hc9c0AWz+eOabIGI+XAPrTvQc/SlGfTrxQBU8xt5DctUd3PHBD5kjhRjrnrVW41BpZXWxjMzDIyp6H/Oaqp4fub68W41OUCJfuQL0/GgDFu4b3Wp9iW7fY1POcjcPp+FQeKRpPh7R/Ou9HjES43OyZ59c1L8XPiHZ/D3w1JcQzWU2qLhYbJpB5jE99vXFfJXi34w+MvFIKanewJaltwt4YQFGO2TQB6Z448QeGfEEIfT5Rb3GRhAx49fp0rd+E/imL+1Do2pLsyQY5M5zkYxmvl65upLicyuWVic4Xgfh6V0nhLX7i11W0Mrb3RxsJ+vAz+FAH3bZ28MUgeHGDgnHetVGDD5enrXE+DtQnvrT96wQsMjvxj/PFdRp5YJsdslTjmgDRY+tUtUsI9W0m+sJv9XcwvEc9twxVp2Ozimed5Ebyt0VSTQB+b93bNpt5e2Ex3PZzyW7H12MRVMsD9TWx4zu0vPGXiC6iUiOe+mcDHTL1gyHHQZx70APZhkD+lV5DlhntnFIGPOCRSHkepzQAi9SO9G9RnjPp70q8EZ4JPFREYOCMUABOTk801hg06kbtQA2iiigAoooPSgBMj1pcj1plFADj0pAcUlFADgSRSjg5xTQcdKdQBIuSMYqVZGRkkiOyVCCjDqD1/pUPXHvUikbuhBPp1FAH2n8G9d1LWPBun6hJcR+XswUB+bcOD/KtHVdXuL/AMR/Z4pEjc/KFduT68V4n+zbrtxPFfaApXaoMybgMYOc8euaj8ea/e6V4rb7NKxmT5ztGMnJx07f4UAe7R2msaXqUV5pt8EjDfvImOVYemPzr1Ozn+1W8coABYAkCvjOx+JmrbVjnlKKwwTnrzyck13vh74qy+HLF3cG4jY5VCM8emaAPpZUJ9MUBMj5SCPrXy74j+Lmr67p0/ly/ZYZfljCEo2Of8K8nfVL3Sr9Luz1K4S8jcOskcpGD1yOefpQB99BDk56VSfVNMSTy31KyD9NpmXP5Zr5k8f/ABJu/EXhDSIHvJELY+0eUdm8gfxY9ee+KwNPtPs2jXGqIrONu1W+8wP8+KANT9tTU7C/l8Ix6fdQ3DwG8EojOdpPkYz+Rorx74mTSSw6UZdxc+a5Lep2f4UUAM8PM1tpFlNg4OSGwcffYdfqK9U8LfFK6tLVrS7HnIg2g5Oc47n/AD0rS+Fvguy8Q/CLRrmRiLlfPHftNJ0/DFYHi34a3ukMZbKKSa2xkbQcp9eKAPUNJ8WaRq8CySpHLcLwEc54PX+Xsfao7p9Ha43ItsVPLA5BHpivF9OD6fbebIDE7cbsYra8OyXN7q0ax4fznAKj+LkZ5/KgD6Z+H/hixtLZNVESiaZfkYA8Lz/n8K6ydd0yAk5zz6YqawhMGnWsRXaUiVSB0GBSrGPNLk5oAdcgG0uA3IMbZH4V8x6hf/adRaCEsqR7t2OAM9vf6V9QoASQRweDXyvrr+X4k1OC3jGBcuOeCOuMUAZt2qQW0kSSMJ8/KXBwvPOfyqhZmO2nBkHmFmzs5yD6Dn61r6rbkTwLKiyA5yx/hJ7HHSufaWddbEixkREEKy9EOfX8RQBvXwt9Qvrc2yFSoG9SDg9ccfXv7VzviO2eLUZIYFBuY/maRTkYxwM/0rTupb6K4ilSNfs8m1nHq3oB1xW/Fb6dcLNOoKXDJsaMAc8HPP8AnH40AcZc32oq4aYjbExOVBHQ9f1zzXWeAra912+EhiyEA3ZbAAx/D9f6Vh+IZklvII7KFJHRtrLjt3z+v5iup0K41G2+zpYfureTG9R3A6Z/pQB7npNu9pAlvwflyc/lWlC5hOTISMdulcNF4jm06JVuk3l13Ag9D6VJpN/NqswMkjbehVcYH+eaAPQ7O6W6jOOGHyketWHVyhCAA4xWHpG1isMQwAcsw9vX3r5y+PPxsvb3Ub7wx4OvVi02PMF3qEHLynoyRt/CvYsOT/MA9I+IHx58LeDJ307R4Tr2rISJYbSQLFGw6hpSCM9eAD74rxDxf+0F4615JbfT5LPQrR+P9DUvPt/66N0PuoU15GmyJAqgDjp61G0vPoPQdqAEmJknkuJ5Hnnkbe8sjFnY9zuOT61GWOQc0jN6cVHkknOR6Z60ASA/hiplkMa7x1U5HPpzmqob8qdMwEDnPbH/ANagD7G8D6rJb/D3T7u6Yxkx7kmbgMOgJJ7/AONcXH8fobDUZFFnNdQRuUDh+oBxnH51L8UbmfQv2aPCNs5Nve3cUKMCdpxt3Efka+dI22rjpgetAH2Lof7QfhDUoyt2Z7O4AyElU7TgdiOP/wBdcb8RP2graexubDw3A7l0KiduByOT+pr5tZ1wcjt19aidgBgAc+1AETlmLO/Mjksx65J61VdgTxg8/nU0jZyPWoWOT0oAYpBY54zQ7YwBj34ptI1AAXY456e1BJY5PWkooAQdTSN2pR1NI3agBKKKKACg9OlApDQAlJS0lABRRRQAU+mU+gBw6U9CcgAgcimDoKenBB7ZoA6j4a6pLpHjjSbiEqPMmWFgzYBDHHP417j8RfA2o6hftPEY12DllXPFfNcUhhkhmDYMbqwI4OQc/nX6KeHdHhm8JWNw+WuLm3jkdm7krmgD44g8CaqblFki2xsCS2M/pVjxBC+moLWXmPaMMBjPrX1nr3hm2ubMqnysBn5a+XvilbldalVBtVcDmgDh7m8ZYljjPAHOe+Kz4PtF3dxQWytPPO4VI16sTwKdfOscRZmVQBknrjnrjv1FfRnwa+Gdp4S8HP438UwltZuYQ9jbOT/oqN9zju5yD7DjjmgDmrLwTFby6ZbagcGML5gxwG7jnr/KvZ7Hwhp8uisCg2suUjxjB9a4fQrabV79ri/Z9m/fnG78K9HW/CRLHEhOMD5+AaAPmj9p7R4NJfw4bcr+9NyCFXA48r/Gitj9r4hh4SYbefteQO3+pooA7H4CtJD8KNFeJiDicnI/6eJBxXoxa3uVVnYk8kqeCDjkivNfgLMzfC3Ro3yIVSfGVHJ8+Q13t1AdnnSwgBRy4fHPb25oA83+IHhyytorm4t4ndd2VC8kDnr/AF+tN+A1kbrxwgYZiiTeVI3DjP5HNbnicgxukylIGHy9TxnP9a6H4D2sa6pfyxmM5iHGBuHJ/SgD2V+ScU08ClPPX07U08AkUAPi+9Xylq8zx+NtdjXc3+ku2QD8p6j6V9RtcLFbXEzMAiIWJz7V8j61PPbeJ7uTYZIJJGfIOOM8ZFAHWQ6VFNYNPIHznIYkktkZyBWOl7FY2U9uUASbAUscgH/OK0dLZ77RFkt+ZkB3bjtH+z/MVyN/eyWSTQzW7yOxALKcEE/n70AaTSyTJBEZFCqvUgHGD1/z61Mbe5t/MMUxMrqWiUnAXPPJ9s+9c/bzxpcRlpCEyOHA+U+p/StvT7KW6umE1y1xMT/CMhcY/h79uf50AGl2TPdTzHazk5cpg5985+vbtXRRXbWht1Y5A5Z0yRjP0+n5VX0rTmtpLmO6YqexAyCc88d//wBdWr1riELDFEjh0JLAkMD2P5UAV/EWotYeSZbhpBIOQx5I9vrk07w541tLJry5WQ/ZkGAH6nP9K4nxbZtJbW0pZk8oY2HjBz/nnv8AhXll/q95K80LuUiyV2DgYyaAPRPiN8WtS1pZ9K0O4ls9Of5biZDteX1UY5C8fU15XuWOMKo4xjGOKiLhVxngdO9MLZbr29KAHl6YW9se9NLbSd+OmRTVkHJIA6YH/wBegBxIBBcgelJvUnBwB61F7knNB5oAnbg55yO1avhfTDrfibTNNXO2edQ/GflByf5VknBbIPTnnv8A5wK7X4a2ixXbaxOAYoWIQA4yf8nr/wDXoA6/9o7xLJqOo6NocTbrLTIjsAX+LAX6dq8iz/IV0/xHupL7XftcgAEiYXGCeD0z/nrXLAEAZ9KAHF8N70xn6d6DnHJpCDnNAEbNkH5f61Ex461Kcg8n/wCvUbKzEE0AR0fWlIwaACelADWA4xSUrCkoAKa3anU1u1ACUUUUAH6UdeTSgGl2+9ADcCkwPSn7TxgZpvYUAIR6U2nim4NAAOadSAEGloAcOgqRM44phpy8FccmgB0v+pwe3Xiv0p8IEyeBtAJJJbTrc5PX/VrX5rzD9zX6Z6Db/ZfDmlW4IxDaRR5+iAf0oAuRomCrBeRz718h/GzT7u28UXbTIqwu+UCjt719bhiHzxXm/wAcPCSa/oa3EO2O4hx8/tQB8veANDtdY8ZaUNVUPpUFyk1zGRkOqnO0/X+tfQnjTXJ/GmvQWNm5h0q3YlDkhnfABbHYjJAry7wbpha+EFohLhgXdVJAx/jXrcdsNOtUkmiQzNkAKoJB57AfSgClpUyaYPKsSMhvmL9q1Le4BiMkxfGcEKOQPp+Nc9bwmQyGceTGr5YkY56449RVq41FbGFZml3xt8qc556c0AeRftVSiT/hF15yv2rg+/k0Vj/tF3v2uTQQF2rH9oAGc/8APOigD174BKX+EWhlxlE8/BPQfv5M13WxsOFmDAqW2MT90j0z+v1rhvgGEX4Q6HI0zJgXA2Lzv/fyV3ojRSyCIKGGCxPIHOf0oAyHt21MMksUKIilRzk49f51d+F8FvZeJpmhVoxJGYcY4yDkD+Z/GhY44QdzFIPu785znsPrn0rntDuJtI1xLyK5Sa2M4JQnnOQP5H9KAPd2H+NMf0BH41IxzgjowyDVW6bYSfQZoA5Hx/qq2uky2yvtlkBUqAMn/AV8xyoV1K5Z5QYyzBEdiT1Pt0r134t6op1a3SN2Uk7enUdSf5deK8e1ALb6ozXJ43ZLZ+8Tkg9f/rY6UAeheGZGGnNDGTLuOAFGOOo6DtXEfEQSWQlKRkgsG8wA9+wrrvC+rxPb2+B5ayMdswxk/X24rS8S6Ck2jXIil/esS6M4BBOM/hQB4roglv75Y3f5MgtvOdteh6LFPaXMMcZch3OXwDnnHH+e9ctpFssOohLhgNp24GODzgcds/zrc1Wa6sUiuYwY7feeST1z14oA9Cn3XdoqrsZQAAcg4/zz+dUrqCSyspJ4vMkxz1zj14/Sjw3qdvcQIMtux99RwR2Jwav6y7keRb7HSTqxGdnHp09etAHkPjLVEGk3N35iNLEoCMfm2knG368j868d3tISScsx3Mc9z6V7H8aBaaZ4L02wtbdBcXt2ZJJcnLBB2/Ej8hXjAZiMrjB4z39cUAPZxng5NMLtz2zTaKADJznqT60eufw+tFFABTlU9x9OaAvIz36VIo45PAPNAChWKkKuWbAUDkknp/n/AOvXrtr4bu7Lw9bW+U/dx+YVIw289eOvfFcR8PtGbV/EduWOy3tn8x2wevYfp1r17VNRsob8QXd24uyB+5BzkH1PqaAPOvEfh68ax3uhZ48EYXr6/wBPyriVjPQ8EcV9B6ncLJbJiMHyx8mVzng8dcenNYsnw4k8Q6NdT6VCxvM4txj7/egDxfy+OOajdCOvSvU0+CPxHa2ab/hHhhR9z7VEHP0BauA1XTb/AEq7a11jT7uwuVO3y7iIoSfb1/CgDIKZPIBo2ADtVpoxzjt75qFlOD6UAV3Qdc8+lRlTk4B/GrJHHpUbDt1zQBWYdhTKkYEHBBJ74FN4Izj3oAbSU7BpQMAGgBoXPSlC4NOJBxxj39aT65oATbkkc+1G33pfrkfWl9KAGHtg5/pSEcAClII60UAMooIxRQAUUUYNAD6cvbvzTaenBUmgCRV81kj4wWAyew+tfoh8MPFtl4q8OQvZzGWW3jSOT67RX53R8kY3YIHI6V9AfsvXnly3lkZ1R5pVaNB37Z/n/nFAH1dq8xgtlkXnkDGP5Vj+I5Zb/RpLWMbfMXaWPOBWlrrfZbCKIfPJkAD1x1JpbRAdNM8kRGxSdg5PrQB454T0qPSb2fahYtJ8x69h+Xeuw1GP7VcDABRegPY1h3E8rXVwHIhUvuYfxdeMH1rcgBjtQwbfI4BLMeg9cfhQBzOrQrG6xqyRxg5Y+vv71h6lcLdW/lLIqIWz8qDI49q1tXsJnnkUMAAOgOQT1rA1b7LFDtZV3gHDcFSeKAPHvjvMkkmirGFwomJcdWJ8vqPwoql8YyWfS2fhmab5cngfIB1ooA96+ASSN8JtDIwI8T7m25I/0iSu3YRySElpI/4jn6Z7/SuF+Aruvwl0Ix7iyi4OD0I8+Tj+deg+c8au13Fh0bOcjOMdf/re1ADTJIM+U8E0ZGSrJjpk/nXPwW4ka4Z7Vgr7sbDgDB9K2r68jHmmWIABMBgMMCQO49KxPDFk1xFdSpJM0bnmRm6H2XNAHdfC/wATx67o0ljK23UdPcwyIzZJXna3ryB+ldNqZP2Z9pBbHAP0/lxXhX9oy+H/ABDBqNk0Jw+2UZwWBGcYPPavS9a8RW8+mgL5paRNylAT/LmgDxfxXqLLrMsWrQ7yzkR7Xxuz/SuL8U2Amvo5UlyqjaRndgA/Q1u+KJBHqX+lDz45PkDhslAcg9/c/kKkv7WyvNP+zi7VJfvZ28Zycrn/AD0oAZ4VktLiKO3CMICSj856YPbHQjp716AzPao6WlyssRXBVxnb7Z9etea+HNPubKfHlll3nqfvEenYV29neRRRPb2kaTMzgMpwWz7ZoA4HXpreDxNIi5zK5YlwOPYfpW3cB7i1NoEIibqsnbOOhzx07VL440Ipe293bqst24GUIA2YHFR6XJeQzq1/EMA7fMJxtJPPIH0oA6HQLGC30ZUgJnlwTIB1Hb8aIUkafKrMsKLgvjkc88VuaPHapb+fETDcD5VUj5WOTz6CteW3D6esjoEcLuLDqRz2+poA+e/2kNyt4VQRlIzDNjcxJOGUZJrxk9e/Tv8Ajj9K90/aZaa5tvDM8jAxxGWJVA+6TtPX8PavC+g546Y+n+c0AFFFB6d6AAf1pcHOO3cjtQoUnk9OelSADHygHn1oAdjcRgHA44qVVYsqxqXcn5QBnJ/z/KmuAqEtxz1zz9P5V638MPB0Udg+s6tEhuWAMEDnG1T0bFAG18MfC8dhoMpuz/pUhy20fNz/AA/yrTfwvpza9/as0r/bAoPllQwXsDmuitLKICOVm2YLbVByT/nFdF4S8OR6zrJh2MYY1EkkpH3FOfl/HH+eaAMzwp4Jl8SXULzWvlWSnDuTnP4+9e56XpdppNukNpEoCDAIHYVPbQw2dslvboI4kGAoFLuyMjrQBLvbd1rK8TeH9J8U6VLp+uWFveQSDGJUyV91PUEeoq/hgwx3NOz09c8UAfAXxM8HXHgLxleaHOZHthiSzmYf62Ijj8R0PpiuSmTGQMcV9yfHrwLH458Ez/ZUX+2NPBntHCjLED5o/o1fEOCy4dSjDIZT1BBwR9e34UAUSM96jfGOTipZAQenFQyd+cd80ARt1BBANREHmnsOB3x1ph54FADaKUjFJQA4ZA4OKMEn5iaUdKQkY56etAAwAPH8qbSk8AccUn9KAEbtSUrHpikoAbyaCMU6kPNACAE9KUdqBxnml7e9ABTh0pvXpT+poAemeB09/wA69X/Z0cxeP4Z9rssSlto9cV5SOeucY6e/NfQ37KGgRXN9LqUy72MhjQ9cY6/0oA+pbItfObiWMZx8lUvGmpppejiFOZ7j5E4zgY5Jremlhs7d5ZSqQxqcntivH7jVNQ8Qa5cXt5m0tE+SBM8hcH9aAJdFDSTTzNFGdvC5bAzWjLKQ6tdsGx0VOB19KxbKUSTFYt7oWIJDEbj2/rWlBC7XGJFEYVgRuO79aAM7xPG6h0t4THEy5Zzxjjv+dchfWamxjcsZCv3QPu/XJrvPEhxp0jq5cg87Tx/niuC1eGRNM3ZZSWPy4PFAHivxmaTbpCzBA6NOML0/5Z0Uz4wW8kcGjzyqQZpLg/l5f+NFAHuPwOYt8H9FiDdftAPcj9/JwPx/n9K7dpJomEluw5+XEg549/xNedfBGUQ/DHRnVm37ZzgcZHnyd+1egRx5Cu7KhU8KHyc/j68UAWrh5V090IVywG4sADjHT3/+tWToZkNxILNQEDfOucAnj/OauzeddkEynAyfLOAMDFSwQxG7kCqViYZZweGwelAHIeJZLe8nW0mieGQfdkQZGT2/pWyLRZ7b7JbXTyAR/MVfG3A55+p6Vd1a0t2s2Nw4jiAHzMu7cfb8ulUtIsFs4FW2JQbMuzEkuTnv269O1AHDa/ol7pqSpFL5/VsseR9PequnRSQ6NdG7tWDbd6vwMkHt6kjmvQtbiQxvJkbQCCrjdk88/nXJa3JdiYpI8bQTKqKd+1iFPAAz70AYNpdTIj3M8QVARtCN3PTPv1rstLWzVI9QtyJJ24dS3Jz6D/CuFeaOVHhkR7QJu3bSTvBx+o/rWrpyFrXfHcJHMvOQ2ep988Y9PSgDt/E1ms+lPPEd8/lffAzsBHGP8a4i0a+s/Lt7qQTLnc0b9+ehHP59K7GzuluN1vN5g3H5nBH3hznj8qwdasWgkEqxtOinYSr/ADbeg+vrQBq2Bu5DvaLbEH6sc49cD/PSuttJHnWONz5sPAGSPl49vx4rktJubW1jYJMSC23ypG4Xn/8AXXUaabaKGXeJApOFKdTxj+v+eKAOI+MfhZfEfh24trBH+223+kW6nHJAPy/Vhn9K+VhyvPy4yCMd/wDPH4V9vvODf7o1zGMbTJ16+v14r5Y+MPhabw14zuXSIDTtQYz2zR/d5PK/UHt7igDhRjOM0oXLY7d6ey5OTyCcZ7H/AD/SnovtnPBIoARAFbJ4AHNSYEaZOBj8jwacqs0ixRI7zSfKiIMsWPYDGc17X4G+E72MEWqeJRB9pkUPFZsxKw56bx3bnoOnNAGH8KPAcV+w1rxDGVtYiGtrUjHnN13HPbgce9e0XUMBihkeIo/BGeMD0HtWhp0EjpCHi4hGCqrwQOlcl478Ux2Gr/Yre382ZeWP3QO3Hrnj8qALeuzTPbxw6dEZLqVhHGiAksx46fnXt/w/8Ov4Y8MwWd1N59/IfNuZPVz2HsOg/wDr1xPwe8KvNIPE+rRFZTlbWJwflHTfg16uxyTQA0jPOeabGgXP86eaWgBOQOOvrUcikoSOuKl/lSCgBlruUDzCCfWvjz9pfwRF4U8bxapZKF03XC8ojA4jmXbvHsDuBH/Aq+xcg8j9a82/aN8LnxP8Lr+SBS19pJ/tC32jJOwHev0KFv0oA+Hpk4J6lRVOQcn071pHDxhxyrDI/LNUnUA0AVWBIIFRkZx2GOtWCuSMDjPrUTp3GMj2oAiIANJUmzPb9aQjjgc0AN5AHvQTnGaDnoe1J9BmgBetNIxn0oPIHFJQAHGeKKKKAEyPWjIpME0YPpQA6jkgiilHHXr1FAC/xZpwHGTx/WmkknPc1ImARuAI+vP1oAV+FwFBY8Y65P8An+VffHwC8HN4S+HmlxXcOzUJo/OmyMFS3IH1xXzT+zJ4DHirxodZ1SFH0fRzvKsOJZuSi49BjcfoPWvr3xb4oi0PRp7uNBLOBhEz0PbPtQBxvxf8Subyz8P2BdmmfM+0kdMcZ/Ws2FEtbHKEMVXhBxk/h9a4fw9cy3+oXesakxluSWxt525710N1eSR23mvC6gfcUjH8/wClAGnoKeas3mOqz53KEHKj+vGK0rOBvtzLJ5vlsclumf8ACsbSBciyWUBEkkIyeeeK1DmOVBNdiYtwoj4x9cfjQBd1QwjSngjUNtkBYnn+n+c15/4glubjdBAigbsHHYY5Oe1d1q8LCwLPI7IWBwvA4rnI4I0vcodyy856kGgDw74+2j22j+FDI5cubrk9ePJ4orqP2ubBbGz8GKq4yLznsf8AUUUAdd8DIUu/hLocUkTHb9ow5PHM8nT/AD/Ou+TS7Y7WUqJDxjdu5/x9q4b4EWiy/CXQXUSM2LjftzwPtEn+H613t1btaOFKyMueWVs5bsaAKd7afZgv3w7fKOcZP+cVs+E9Gln81WmGEGApXp9T3qnbXEIuUWVWYfwqw+7x6f1rpvB07teXcflBFwDnPJoAlu9CkcFHSOROy4/z6frXD61pxgmbbmB416f3u/59fyr1stgjINU9W0y21a3aK5QGTaQkmPmXNAHiiyW11Epknb7SmVRW4yfcd+RXC+NLj9wySwq3ln5SnUe3t2r0LxR4dmikaCVws8DhkXoGHUEGvMPGMRtZmIGJZCGAyT17j/69AFGOxuGSI72ljYbvLlU8DtkccfqfzrTtLWF3JicyOeCOFwc9vbgVs+HbG6u9Mw5imLjKZwpXj3/L8ar67oTLn7IjxXKsBtDYXAHbHpn260AdNoX2iJVi8olEG7D89+a1tS06WW28+MZjQFioP8utcBpeo3VuSDMxaL74YZ9OfXFd1oF/di0imdRIWBLKCAOf8+1AHMO6W88r3CKrMwZVJ5HAx9ByfSujgXzrKJ7SXyZQAVO7IIz0x1/OofFHhz7fIlzCjQvtzg85yPz/AFrDtUfQZ0M0rOp+TDk/IO3BNAHU2968Ua29+DvyAeAewPp7/pVW80HRvE+m3Ona5bu9pIThkXDxv2dD2xxx3q1pt0blnaO4jkCkFQ+MYx0/IV02n29rMAptgrlceZ2NAHyX4s+Fmv6HqMiaZGNYsGb93cRjaxB/vKeh+mRxT9L+EXi/UAry2sFnC3BaWUMQPoM19W65Cmmaabi4SN4F54bBPr/n3rjr3xdo+nwrLFM1vG3/ACzQ7h78DOOo6daAIfh58P8Aw98P7VdR3nUtckXH2uWPb5R7iJcnb9eTXSWum/2lfC5kLqgG7HPHJ/Lv9c15PrnxJfVJPssMJihDgNNnDMOPw/8A11614Q8Q2F9aw20RPmRJk7hxj37c0AdnYWCxRBLWFmGMrtOOcdK47Q/Dtpf/ABIkGs2Dh7dDLEJFIRueOvXHNem6DJHNpkc8P3WPbHSrrqpIkKDeowG7/nQA4gDaqqoVRgKOAB9KKanK5GaX+dAB+VFFH86ACigHNFAB1HSnKqurRyAMjjBVhkH2xTaAcEUAfn74/wDDbeE/Gus6GY2WK3uHNvkY3RMdyEevBxXKzLz7+tfZ37QPwu/4TXTk1rRyI9csYyNhGVuY+uw+/ofevjedHQvHMjJLGxV1YYKkcGgCg4GffrTD1qZxycVG3Q0ARHg8dKaVUAdRTmB60hO0dM0AMyc800j8qcetITwaAGjjn1ppGKce1NbOaAEoopOh+tABkDqaWkIB7U7Gce/SgBKceooIFL6c80AAx1OePSp4Le4ubiG2tY3kuJnCRoo5LZxTABj5Ryf8Pz6169+zj4bN74in8QXMKta2CkRlxkeZjtnqR/WgD6B8F2Vj8O/h1Y6VEym8CebOQvMkjck++Olcn4n1eXU7FmWJpCTwT3OOlb/jCWWSEFgignCkZHv+XH86paLYC5s/Mnl3rD8zbOmccZ/WgDA8Pw3WnWx2gbny5DHgDHb6ZFS63O9ykSxiadmOVAPy9R8uM5x1OaZNq1kl04tv3jv8rEjoPwoa5ubt4hGYpIl9OPwoA09LEqQxLdFYYgcEbvmB/wA+n41sRzRJcFkVmYPhT2wetYumWrGKGVir9z5oK85POCfeth8SKqW6jaoJLLn5moA2Wc3diGmnUsDwoHHHal8L2KtPHI4zJv8A7vSk0+SKez8m3QrliflTk12fhfSjbWaSuNrNyBjt70AfO37bUZQeCwep+2n1/wCeFFP/AG3v+ZL/AO33/wBoUUAa/wABL+RPhbodrCpZj5+5c448+TkV6JHqqWgFubdwzDncc7fXmvJ/gld2C/DTRkntZTNH5+ZgPl5lk/lxXfusco3W91uiIxuI/E+woA257uzliBaOVGHUrwD7/jjFaHgmSNdSfyFcK/BDdc1yYtJ2w6yCW2VOAeSxOMd/f9at6beSWupQyRBozG/zA9Gx2/nQB6446g9KToOOlJFIs8Ecy9GGaU8AY5oAwPGvhi28UaTLAzGG9RSYLheGRuwJ7jNfJ+sy6/omp3Vhq1r57w8FduO5wR3Pf86+zsnI2nBryT4+aZNLZR39nbq0oXazAckUAeX6D4gtzBGXjNvMxH3iM8duD75rX1HVILhynnIW5Xf0IPp168V59ovmXU8RukZB0Ibjj1//AF10V3brKQ0KMxj+Q7T147Hn36UAalhPHFKWVVk3nCqy4J6A/wCTWvbeK9LsJ1068he1kJ/hcHPOeg/l1rzzxfqMWm20aRJMjqgXGCNpyf0/wrhdC/4mniW3a4mZt78bny35nv8ASgD6hOoRKMieTDKCqAbhjHY5qtq+lLrViVm8sKwznID/AIH+dYNlNPZWNsVXDkjcr+meo4zjFdGt79sQSNGBIoyQnTGO1AHGXngLXNIBltLsSRtksFYk5/rwe1Ry65rejwIGlIdgAFAPPTH489K7GfVWw6Q3DRlcjy3GAenSudupVdWM8JYl85C5w2O2ePx9+KAOW1XW9d1cut1fiS3K5KYwMZwQP/rVxs72UDMLhHLZ3AAkqcdMdu9ddqszzAGIIcH7g+XaPr1I56fzrib63kEiOiMgJ+6zZwf8/wA6ALNrJYTzCTylRl7Jnk9a9E0fxBFpulyPLZyF24Upjp7/AJ/pXA6bZwSEMx2Mctt3HP1/z616v8K/CFz4i1ZPtCONFtWDzMQQJGHIQfpn2oA988LQ+R4Z05dhRnhVyvoSM1fhkWUMO4JDU6Z1SM4wqjgAdAKpWU6ecR0LYxnvQBYt1aORkYkr2qalNJQAUUE4+lRmX2oAkopqSK4GKcfagA9aD1qvqM0lvZvLEFYr2Y4qSDK2yNM3zFctQBLGcMAORXw9+0TZ6bY/GLWoNHjWNfLhkuFX7qzsgLY+oKnHqTX29aTJMSU6Cvgv4r+d/wALT8Z/asiX+05cZ/ucbP8Ax3FAHCzDDe3aoWHYVZnHzfpVc9aAIjyDTTjaRjOaf0NMoAa3XpjNNIPP4U5zzTe9ADKO596Ug0h560ANwaXkdQPzpRx0ooAbxxzk04dMUoBJ6UqgEE9cdaADGMEjPt0p6r1z06cd6QDI56Dg+5qTaPmDbQcY5PSgBwilmkSGFGaaRhGqr1YnoP5V9i/C7wrdeHPCNlpZMcUo/ez7Tk7j6/4V4T8BvhvqfjjxGl8kRg0ezbc90wIUuOQq+rcA19r6bo1ppluFjDSy/wAUr9WPrQB5b4p8PT3ssUSyEucqvGFAI704aQ2n6a9o24QdHGAc8da9TkiQgysiDYDjI6V5Nd3tzfapqQd5JEydiKMIAB3oA4O9kMEszQrEZNwG49PrT9LuLuSR5LyeNoyfkEY4xn9OlY/iCFo79mYOwlO7Zj5Rj19OtdXoH2a3hVUsZJsAcu2Ovb8yKANGzi+0LhYpJWRclf4QMDFbdvBPHC3mGGJQ33RjPtx61RhvGDSeVE0W8ZVlwTjPTjjr/Op7GK5ulV2lxGM7pJOrHnkUAdRoaRwnZ80khPOOP89671F2RIv90AVwnhSJlvINzKy4H4E13rHJ+h5oA+W/23v+ZL6/8vv/ALQoo/be6+C/+33/ANoUUAXPgmof4U6KkpSSLbcYjOAR++k6mu3l0+CELDEWjjIGFAPzDPpx/k1x3wPsLeb4S6JJPFwftBLA4J/fyf4YrvRarM0qiLCIDtbOCBn/APX9aAMsQjy2Nm7MsI5CnjOOM1HAsou5DOzwSLwueV/DHfmr0NmizuGeaGBgB83yA+v1qeOy2RsR+8HUYI5NAHYeDtdR5Dpd3Onm43QMTgsPQ+9dYQRnjFeQ3TvvtpBDGsiNkSDggj0Ndt4a8UreqttqC+VcKPlkLDbJ6Z96AOhlYxHPGOvNea/FfxPBbabJCUlTauW4yG9sV6bPGpjIdTg8V578S/DUOq6Y7GB8j+NecemRQB86Wmr297fIPIaUFTsC/KQSK0rhbG0zLcx39rhjtfP3vTj9eayW0p/Dur5t/MuYN3zEritPxN4hlu5FAuDPEIzmArgZ556daAEhuINZgnsLhzKpXPmSLk5PA+h6Vk+HfhvcwarFfPfosEL5RR1PJ/Tip/Dd+Ybl3mBj84ghR0zzjP0r0G1UR7FgjjkRxvVpBkg+mR+NAHTadpxmslM4jkjA+8VHHHJBxmlOmGKEfYiAjDAZgcjg9vSorG5u4YjFGIok25wz9OOR/Os651RY22STT4Y/KVGQecfhQBcv7eb7MXuYoGOdy7cZBB964O8vUuXCRXfleUwWSNzy5+uelaeo6vFIr2/nqZgcKuSNx+nf/wCvXF6tJqGp3i20VhAse393LnHPsPrigCpq08sEsw8oGTO7ejdSM8/kRWEsxnnQebslPG0jHNF5ZXqXSQGVDklRlsV2ngTw1YC+hbVjDPGX3FQ4J4POKANb4UfD3VfE18ov45INIwHa4HG4ZyAvua+p9N0+00rT4bHT4UhtoVAVB/M1zun6zAmnR2mkwHYibY1VRxj1qhL4p+xWczarHJDLGSuM8tz1H6UAdHrd2gtmUhiM/MR6VR0GeG5udkb7inTPYYrzS88b3n2sRpDJ5MmACjdcnpz3rq7cyR+H447QBNQuvlyOdufX0P8AKgD0JXV8hWU44+U0v+NUdD0/+ytJgtWcySquXc9WPetBBzigCrf3UVpDvmIHcA965y48Z6aj+VIrJJnHJrB8XaoNQ1eexMcheHgbeh/zjtXNajYM0KtMFjYjKYf5h0xkD+RoA9N03XIbuZRFKpP908H610Oc4Iwc+leJ6C0un6rAblhMrSDJTGQDXtpxtG0YUgEUAR3ESzxGOTlT6e1E5GzazYB7e1P+lU9R+VVfG7HagAsES3nKK2dxyM/WvlP9q7w+2mfEW21mNCLXWrVQzgdZ4vlI+pQp9cGvp6OaWK5XEWSePcCsX4weB0+IXgefTFaOHUYnFzZTt0jmXpk4PBBIP1oA+CrgHBP61UbritG8t5La5uLW6i8m4gkaKRP7jKcY+n+NUZFIPf8AGgCB+O2fpUdSt1ORimMDnP40ARP1pKewLEADnvTSpHXA+poAQ9KbgjrxTj1ooAaBnvSgDnNKT70owerY9BigBAAOacuQcngetKFxz3HrxTjgYY8Z6HHA/wA8UAKrDIYEEn0OP1/z1r3H4GfA248ZrFrvinz7Pw596CJDskvR7f3I/fqe3rXPfCH4WX3jC90/Ub4ouiLMDIrN80wByV+hx2r7eScJGkFrAkcMahFVAAqgDgAdAAOKAHaZY2WkadBp2k20VnZWyBIoolwqgf560uXkbHCr6ChHlkXsD7VNEmDjJJ7mgDE8ZXjWGhuY1zI/yjP6/wBa81sr5og8R2FpOoHfg9/xrc+IWrm41RLeEK0VvkkFsZNclprzPcsTDb7zkqWPT6+tAHH+KJphqKw8LGxz8q5LD39vp61uaVOxtN4jB3Djc3PpyfWqniOKdLmSU3FuHGOgzg8cD2qlpdpvgkd2dlGWIz8p+n6UAdDBqsEeUSFXnKksytz9M9K042up9qpbGJB94EjAHJ4HesHw7FFGg3FIkRtobIdzn1/zxW0k9vE6eZeM02MFUA65xQB2Hg6Z7nWY42UBYlxz9Ow9etehHqe/NcF4ASL7dI0e55Ocsx44ruycE8GgD5c/bd/5ksen23/2hRR+27/zJf8A2+/+0KKAN34ChG+EmiI8j7m+0EL2x50n/wBeu8WNsFllTegPEjcfzrz/AOBBC/CbRZCQNouB83/XeSu8aRJUD7VVSpLNnBH4fhQBKSDGsV6HlA+YED5c/h16kVVkgVSrRXJiG/5o8kkdhj9KV5gV3PMQi4KlRjNVJ/tyHEMsA/iDHnPrn/61AF97KdrSTynjdlAVuoJ9cen/ANb3rPgkghuEt76JsAEh9xH0q3Bc3S2/mxbXdz97HXA56VMLu4nhZZWiMuOFK4A49etAGjpXiQaW6wXFxJNaMflDZYqPr+Nb8+tWBi8yO7R4XHKkiuQtjDIjreywkMCo9sdcmoZrGAqYo0SVApw2dvPr7UAYPi210su8gVUWQ9gDjPfrXF65o1rbW8kkU0c6uVC5XGCfQ+teiT6HHeNuubUgIoO8SYJH+f5VzOv2FpbW+YzI5VsjJGAecH+QzQBxfhfR1aWWVItxUklQQfXjnoc16LYafq4tVuIIYBHjhG5/DFchYaok17cfv/siu4IxwCB/D+vX3rrtLN68YlS/aSAtzHuJGM+o9KAF1iG7gtGkmjjkCg4aPt65rlJNQuI45m+3hQCcKRkLyOn41Z1nW08x4ZoXcbTuYMdp46cdyRirOjeH7rXLB207S2kR3I/eZCrnnnNAHFa5qd6YEMtrbzxhwBIhG9eB6c+tYWmsTctcTO8SIPlQNnGOo/PFe0N8JtSHlSRzwwlSGMeSRjuKztc8ESrgGFWRThincetAHit/eLLfMtpBICCRnJ/+v6iu38AaFBPcxzXs08WzLg5IHXnFHiBtA0WTynVklQBNinPOBk1z8s7ai8TafcyKo6ruwAvH4560Aevah8QPD+loLPTp5XvFIAl2ZX868+8S+LNU1LUR5k7XCjAKx9DzkD/PpVzwt4dttcvDHe262zohYylwAOe3t/hWYfDmoW+vS2unMsqRvlJAwwcc5/WgD3T4UeCrhtNTVtbh8qSdA0ELnJVSM7iO2cj3rvLLRfsuqLcsc7c7ccgVp6W0h0exM+DL5KbyvTOOasEnvQArHOaFPzZ5pKKAOC8Zacba/e4jtmkE3O5TjB+tefXWnz5FxA+ApJCu/J/ziveb23W8tngkLBW7iuci8HWBIEvmEZz1oA5LwVoq6rqMMssTiODDuSeD7fpXqzHLH3qppun22mWxgs02oTknuas565NAC1VvIZGImgwZFH3D0arX0qCS6SNv3gK5PpQBBZXkF1iJ9sdwOGiJwc1fGUYZ6CqV9aWt6PnTMnaReG/MVGjT2WFmczwjvj5l+tAHgn7THwvjnVvFnh+zP2k838cQyJRx82PWvl6Rc8k7SODkdDX6TW89tfWziN45oXBVh1x9RXz38Wf2fZdSmu9b8HXES3hG82LjasvqFI6H60AfKzLz71G3J5zV+/trmwu5bXUrWe1uoiVkjlTBBHX/APXVYrnpgjnpzQBWYZIxz700qSORx71Y2nGetJt5we/FAFcqM0gC5A5qwUB57U3ae4B70ARgDGRml5zjB6Z5pzYAOeB1yat6Ppd1q9ytvZr153twBQBVt4ZJ5kjgQu7ZOAO1dN4Q8G3mtalGtzbyC23DftBGRnpntXc+BfBFtAHzqtq1xKm1mOAQM9vevePBWk2mnW8Ma3UWAfmKJ973Pv0oA0vAmnwaXY2tnZwbI1UDA6DFd+bZmQBSV6ciq9hBEpUW+D6nFawXC5chQONxPFADI0WNAq4471meJdag0ewZnb983yqPTPc1S1/xdZaYqx2jrc3TcBV6D3rz2+1C41m7Mt3bbyDleenegCG7u4nd55bdpWOep6DPaqGmGaa4ZILbAGSxfI4pb+0nnf5pBEGznPQD3/HFQafb3AuPLe93ooB++OeOg9qAF1yCYKZN0TkLjAXIAOKybaDdAVmkDKh3EIcc9AK3L6EvpWIQAyj5mYg8cf41zunwzRzbd8bHhmw3Ofpx3oA0LO0jS4KpAxycjLcn/OK6CKz+UusNvAmMncwLVm299bRmOOSEq8jH96fvZ79ulXpbmMxOlnbJgnOJcjP0P4UAd74BS1US/ZQSTyxA4z9a644z14rl/ASTLpxaVUXdzhe3NdOT6DigD5e/bc/5kv8A7ff/AGhRSftuHP8Awhn/AG+/+0KKANH4ETyxfC7RysavHmcHe3HMz9q7kDUHSRkt1J5IRjgEV558F7qaD4VaMBAZYyZ+R2/fP/XFdtNqkasFnF44dcjyucDnjp2oA04r6Vwolt0WRRudUGe+ABVSfV/JuGEluXgxtGUwf8/4VXiv7csVXzbcA4/eRkE+vP41NLqNvGFhlVdoOUaRc8DvQBJFrUMqGNIJVTuCMbevP0qm5inkDAP82cc4APuO1OSW2uGNyjSHd90MMAj2/WmJFu3bonA3HjocD+tAG54Z0h7piHjDB+vcEfWumPhaXYywSeWOSo3cD2qz4MdZ9NV0hkiYfKQ3Wui5HTr656UAee6n4V1x8iNldNuDskwfy/8Ar157quheLoL11i0i5ugo+QYznr+X519C5I9acXbBAYfU0AeD6F8N/El/efatQsbOwibkLJJ82PoM8/Wu2tfhbp6ybr7ULh17xw/u1z+FegliTyaaTgZoA5jS/AHhzTbh5o7RriR+T57bx+A9a6eJY4EEdvGkadlRcAUMQB6iq91fW9om+WRR7Z60AS3TRpGWncKncng4r53+OPi3+y7poNGklMz/ACnaPl2+v611nxB1LV9Qti9kNluW2rk4DD19epH5818/+Ibq/uZsXMqCRTtYdzgeufrxQByd5f3F9IXuklMmclmxz+NGnu0bqwaRG25AAzVia4lS1274RJHjClQc81Ugnvbm4RWVmUnAwnNAHS6ddXcW6SO4fBPzKpOSK9D+HMcjahLNNHiBfmkLk554H1rktC8MX0bK89ksqONwH8WPX9a7GaS50jTjbQyxRSzHYInIY9R0NAH07pwB021KqApjBAHYYqfrXmun+K7jwroum22po1/AkKmWVR86D6d69B0rULXV9NhvtPmEttKNyt6eoPoaALNHakz0x1pRz9aADvntSelB6Yo/WgAPXpzQfeiigA9ajlQyZAx+VSAbunSlkxFGXmdEQclnOAKAKrIEXA4HfI4FRh13EIysehU96sW9xaXSEwXVvMnTKSK38qzdStBCN0EgjbPXrmgBLPTBDqRvbRliWQfvYgOGPrj1rUk3AFom+YdvesiyuZ7WZBK4kiPX/wCtWi4KzLKkuInHzADj60AYmveHNC8TI0Oq6ZbPKRguVXcfx61474o/Znsbt5ZdA1M2btkrG4yvXOP517Nqdu0N158FwpI5Kk9Pxqzpepzy4W6UKGOAwPBoA+W/+GZ/FTTLG2rWCEnh2Ulf8apeIP2cPHGk2yzafJpusYyXit5DG6+43gA/gc19jDJXP54pQxU9TQB+dlz4T163uDb3Wmzw3Cn5kdSMUv8Awieo5DTGOJe5Y1+ger6Pp2tQGLUrSOUn/lp0Ye4avI/EvwQnmeSfQ9baXg4t7tc/gGH/ANagD5p0rwksskYjRruTPQHGTXollo91b2RiOnPApXDRgD5x6Z/+vUt/4Z1Xwtf7NStri3lGCJOsfbkHnJHNS2e8eX52rNvbBLEAnvxQBveGNPtdNzK+kATEDLO24EZ557d/6V3em+KliiJsdPtIwvyfP/n9a5mKK+IUWkckikbSZOA3X/GjUI4bYQrqKJE3ZYwMY96AOvvfiFqNlbhIbazErj5CrZJ/Csa51zW9WyNRvGSJhjy0XA6jrXJC2iuL1XFzHktkLnjHtx16V0Fok6ZhFwibMr867uOOeOKANaKLT7GPzNxmkWM4D/hz61nXGp+ZuQvGo4AUcGluLe5ciIX0YVz87Hg49BU4S02kFTLICMZXlj65oAzLy3hkiQyNMByWCjIOOmT6UljHZ290BbW5yc7jkEjv+VacskeUWTZE7HIUjnFZ001jHOnlCRmkOCyDBGfT/CgDYvvKOmqqK7uCAzYAXB7H865+G7Nu7RwWEAU8szHn8Py/Wt03sZ01vJE5HQAjnJ4x9eK5y5gMlyZrzzAw5wvT6H16igDYgmSe4k+12+ADwFGcg4GBVj7VC0ZSK3kMSggFjjP5/wD1ulVtKa9+0NHBbJBa7RjeMlvfNauk6Te37PGyfu92MjjA9P8AIoA6/wABSCW1OD8oXoO1dX/KsrQNKTSbVkUAsxz16Vp5HGSBmgD5f/bb/wCZM/7ff/aFFJ+21/zJn/b7/wC0KKANL4GzQL8KNJjlDknzv4SR/r35yK7S1u7cTpbxmSN4ySML1/L6ivNfhb8R/BWjfCXQ9L1TXfsmr2wnE1v9knf708jr8yoV5Vh3rVufir8P7mLMuqsGznKwT7j6D/V8fnQB3uTcvJL5y5HTeAq57ZpsltcNGiDycv1dhwv/ANauBh+Jnw3CYk1WRy33w8NwQf8Axz6VMnxa8Bt+7Oqxxpj732W4P5fu80Adylr8hWcrOFORtHBPc5Hp7UCJrrc1pJNDNnk5+U4HeuLj+L3gW3YLHrSND6C0nyPzjFQ3fxd8EybCmt4bjdi1n6en3KAPW/BOoXltcvb37wtG5Gz5sEfX9K7p/XrXzTafF7wRE2f7VVZN2d/2ec/j/q66/Qf2gPA62/lanr8asv3XFpcnP5R0Aez555oyD36V5YPj78NMn/ip1x/143X/AMapf+F+/DTt4nX/AMAbr/41QB6jnIzR1ry7/hf3w1/6Gdf/AAAuv/jVJ/wv34af9DMv/gDdf/GqAPUQvGOD+Nc948ls7Hw/O07xpMRlAxGa8/8AEP7Q/gW00iZtE1kXmoMNsa/ZLhQpP8R3IBxXlE3xR0PVJ2vNa8QtNO3Hl/Zphj8kxgUAdPqXjy7XS4ba8shLbxMCr5IxwQNwH16H0HFcTdSw627T2sQVmUsQCAByOPf/AD0xWYvjbw29zumv/wB0x+YeTIc89fu/jTbzxX4SiAaw1SXzOmTBIAPp8vuaAIJ9MkuH8v7IkcwJJaRsKMZ5JrQ06K1sJC0d3bxnnDjnAz0964zWfEVlqcj+ZqsnkkBVTy3GAPXj2/Wqmm32jfbYnu9Q2xj737l/y4HTpQB7NoupwecLi3me5ljXaQpxuzwfb/Iq9YX9jNqRu9QgEixjEYx0I/rXEaf408K6OuLG/jcOpVsW8oKj2ygq5B8QfCkto8d1dpEWOB5cEuR7n5cHP9KAPR9Q8Rl7KUyJ50brgJ128cZ5+v5U34a+NtQ0K/Ftcqh0ieQkp0EZJxx/WvNdP8c+FY33S6rIp5+U20hX9Fq3c/ErwnPE0JeMBc7ZPKl5/wDHKAPsG3uIbuBZraVZI2GQVOakPXsO3pXzF4N+Mfhjw5B5A18y25OfLNrMdvryUrvbT9oT4eNGDNrTxycZzZznt7JQB6/2PGMUE/WvLD8fvhocH/hJf/JC5/8AjdH/AAv34Z4/5GX/AMkLn/43QB6k4yjAsQPUdRVPUNWsbGNpLi5jTbztY4JryzWf2hPh/Bpsh0zXBc3R4EZsrhR+ZjFea3vxn8N6ojDUbkFieohlPGf92gD0fxZ8VNSV/K0WCHysYMgbJrhdWvdS19H+0anLKrY2xNIfm+mK4648d+FY7lmt9TZ4HJOzyJRt/Nfb9ajvPHvhkMj22oD5BkBbeQEnr12/WgDYh8OaglmZtHvZICnBiOQze4xXYeDPEGt6Tp1xd6k0t3DbD54j8zjkev1HSuGHxU8PqqbLtie+6KQ4P/fPpWVqfjrQTbXEuna1JHcyE5iaCTaw/wC+fYdaAPpzwr4u0fxTYK9ozRuRgxvwVNdVZz7P9HlVkj7MT16f418TeH/iDbaTdJNDqARl/wCmT4J/Ae1ekzfHTSb6yWK61XZKuPn8iXB79loA9A+M+o/8IsiXFnI0s0vCxhuh7E+1ec+DvjDd218kGvQr9lkbHmR8lSen4daxNY8f+FNXVP7Q1nzWB5xbzdPYlK5TVde8JZ32F4ryY/jil689CVoA+19IlttV02O80m98+KUBtwx6enatCIOi4kIJHvXyH4K+L1n4ft444dXEKpn5DDIQfyWvWtK/aM8FS4TU9QELY5kjtpyPy2ZoA9lz+dJu2815efj58Nf+hmX/AMAbr/41R/wvz4a/9DMuP+vG6/8AjVAHpd0lre27QXsUcsJGNrjNcRqnw406aaS5022hE7EEB/ujFZR+PXw0P/Myrj/rxuv/AI1TT8evhr28TgfSxuv/AI1QBX1DwzfWcLrNHOE7lG4Fcbfo9rK6i0muCDk75M4/Cuz1D47/AA2mtXT/AISIS5GNv2G5H/tMV5HrHxF8KXmqSS2muy28G7IzDN8w9PudKAOs0uzmkupLh7A7UOEZDntWvG17GVEti5J6AEcmuItfir4Q0+28q3vjIdwJcwzZP5rS23xb8OPcGS51qRVycAQS/h0WgD0NLtSyRz2KxE9SeeO/8quLc6fHGrOcnPQDoa4GH4s+DAWkl1oNIVxzaTfz2U6f4ofDpl3JqbCXoSLWbnp/sUAdbMbO5lK7Gc7SQwx61nvbQwS4EUqYPMjDcCfb06Vy8nxS8FIFW31U7cHrbzDB/wC+Kgf4p+EldGi1gkIc7DbTEdP9z60AeiW0tu24yahGdoBChOmf89etYt00L3xbEszgcdl9uf61iQ/GDwaY2Wa7gyQMH7NNnr/uVmXfxN8KTxskGtLbbsZZbac4A7fc+lAHoun20s5UGS5dn42jJA9s16n4f05dK09I97ySt8zs/XJrxLwT8WvAWmjzdT8VkuBxF9iuSB+IjrrT8e/hsf8AmZPw+w3P/wAboA9QPuaVcE4A5ry7/hffw1x/yMn/AJI3P/xug/Hz4bKpKeIwT2zY3P8A8boA8l/bTufN1PwvCBxCtz+vlf4UVw/7QvjfR/Gd9pMmh3QuEtzPvPlyIRu8vH31H909KKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest computed tomographic scan showing massive dilation and displacement of the trachea following right pneumonectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14435=[""].join("\n");
var outline_f14_6_14435=null;
var title_f14_6_14436="JE MRI";
var content_f14_6_14436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thalamic lesions in Japanese encephalitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance image of a child with Japanese encephalitis, demonstrating characteristic bilateral thalamic hyperintensities (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. James Sejvar, US Centers for Disease Control and Prevention.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14436=[""].join("\n");
var outline_f14_6_14436=null;
var title_f14_6_14437="Canakinumab: Pediatric drug information";
var content_f14_6_14437=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Canakinumab: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"    see \"Canakinumab: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/53/12116?source=see_link\">",
"    see \"Canakinumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7874024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ilaris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14946785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ilaris&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13333947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Interleukin-1 Receptor Antagonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Monoclonal Antibody",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13334002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"      see \"Canakinumab: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cryopyrin-associated periodic syndromes (CAPS):",
"     </b>",
"     Children &ge;3 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     15-40 kg: SubQ: Initial: 2 mg/kg/dose every 8 weeks; may increase to 3 mg/kg/dose if response inadequate; if residual symptoms continue, higher doses &le;8 mg/kg/dose and/or an increased frequency have been used (Kuemmerle-Deschner, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;40 kg: SubQ: 150 mg/dose every 8 weeks; if residual symptoms continue, higher doses &le;600 mg/dose and/or an increased frequency have been used (Kuemmerle-Deschner, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Juvenile idiopathic arthritis:",
"     </b>",
"     Limited data available: Children &ge;2 years and Adolescents: SubQ: 4 mg/kg/dose (maximum dose: 300 mg); repeat dose for disease relapse approximately every 4 weeks (Ruperto, 2011; Ruperto, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Cryopyrin-associated periodic syndromes (CAPS):",
"     </b>",
"     Patient weight &gt;40 kg: SubQ: 150 mg/dose every 8 weeks",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9512584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ilaris&reg;: 180 mg [contains polysorbate 80, sucrose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7884596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13334004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Reconstitute vial with 1 mL preservative-free SWI; swirl the vial at a 45&deg; angle for ~1 minute, then allow solution to sit for 5 minutes. Continue product dissolution by gently turning vial (without touching rubber stopper) upside down and back 10 times; do not shake. Allow to sit at room temperature for ~15 minutes until solution is clear. Solution may have a slight brownish-yellow tint; do not use if distinctly brown in color. Final concentration is 150 mg/mL; no further dilution required prior to administration. Administer subcutaneously by a healthcare provider; avoid sites with scar tissue",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13333977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vial at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; protect from light; avoid shaking product. After reconstitution, protect from light; stable for 1 hour at controlled room temperature or 4 hours under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13333958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS) (FDA approved in ages &ge;4 years and adults); has also been used for juvenile idiopathic arthritis",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7883698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Calcium decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, gastroenteritis, nausea, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Eosinophils increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: ALP increased, ALT increased, AST increased, bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular and skeletal: Musculoskeletal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Creatinine clearance decreased, proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Bronchitis, nasopharyngitis, pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Influenza",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13333959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to canakinumab or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13333961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use may affect defenses against malignancies; impact on the development and course of malignancies is not fully defined. Patients should be brought up-to-date with all immunizations, including pneumococcal and influenza, before initiating therapy; live vaccines should not be given concurrently. Influenza reported in 17% of patients during clinical trials. No data are available concerning the effects of therapy on vaccine effectiveness or secondary transmission of live vaccines in patients receiving therapy. Vertigo has been reported exclusively in patients with MWS (9% to 14%); events appear self-resolving with continued therapy. May cause diarrhea (20%), nasopharyngitis (34%), and rhinitis (17%).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13333960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity reactions, excluding anaphylactic reactions, have been reported with use; symptoms may be similar to those that are disease related; use is contraindicated in patients with known hypersensitivity to canakinumab. May decrease immune response to infection due to interleukin-1 (IL-1) blockade; serious infections have been reported during canakinumab therapy. Exercise caution when considering use in patients with a history of new or recurrent infections, conditions that predispose them to infections, latent infections [eg, tuberculoisis (TB)] or oppportunistic infections. Patients who develop a new infection while undergoing treatment should be monitored closely; discontinue therapy if serious infection develops. Risk of serious infection increased with concurrent tumor necrosis factor (TNF)-blocker (eg, etanercept) use; manufacturer recommends avoiding concurrent therapy with TNF-blockers and other IL-1 blocking agents (eg, rilonacept). Avoid use in patients with active TB; patients should be evaluated for latent tuberculosis infection with a tuberculin skin test prior to starting therapy. Latent TB infections should be treated prior to initiating canakinumab therapy; monitor for signs/symptoms of active TB during therapy. Canakinumab contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals; infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7899286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-TNF Agents: May enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interleukin-1 Inhibitors: May enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interleukin-1 Receptor Antagonist: May enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7883688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7883689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated fetal skeletal development delays. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit to the mother outweighs potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13334005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, C-reactive protein (CRP), serum amyloid A; signs or symptoms of infection; latent TB screening (prior to initiating therapy), body weight",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13333978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Canakinumab reduces inflammation by binding to interleukin-1 beta (IL-1&beta;) (no binding to IL-1 alpha or IL-1 receptor antagonist) and preventing interaction with cell surface receptors. Cryopyrin-associated periodic syndromes (CAPS) refers to rare genetic syndromes caused by mutations in the nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3 (NLRP-3) gene or the cold-induced autoinflammatory syndrome-1 (CIAS1) gene. Cryopyrin, a protein encoded by this gene, regulates IL-1&beta; activation. Deficiency of cryopyrin results in excessive inflammation.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F14197638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maximum effect: Within 8 days CRP and serum amyloid normalization",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13333979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Varies according to body weight: V",
"     <sub>",
"      ss",
"     </sub>",
"     : 6 L in 70 kg adult",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Binds to serum IL-1&beta;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: SubQ: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Pediatric patients &ge;4 years: 23-26 days; Adults: 26 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Pediatric patients &ge;4 years: 2-7 days; Adults: ~7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Clearance: Varies according to body weight (NCT 00685373, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pediatric patients &le;40 kg: 0.083 L/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pediatric patients &gt;40 kg and Adults: 0.18 L/day",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13334006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/53/12116?source=see_link\">",
"      see \"Canakinumab: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform prescriber of history of tuberculosis. Patient may be more susceptible to infection. May cause headache, dizziness, diarrhea, nausea, and irritation of the throat or nose. Report persistent fever; signs of infection; flu-like symptoms; persistent nausea, diarrhea, or abdominal pain; skin rash; or pain at injection site. Concomitant use with IL-1 blocking drugs (eg, rilonacept or anakinra) or TNF blockers (eg, etanercept, infliximab, or adalimumab) is not recommended.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Furst DE, Keystone EC, Braun J, et al, \"Updated Consensus Statement on Biological Agents for the Treatment of Rheumatic Diseases, 2010,\"",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2011, 70(Suppl 1)2-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/6/14437/abstract-text/21339216/pubmed\" id=\"21339216\" target=\"_blank\">",
"        21339216",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al, \"Two-Year Results From an Open-Label, Multicentre, Phase III Study Evaluating the Safety and Efficacy of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Across Different Severity Phenotypes,\"",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2011, Aug 21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/6/14437/abstract-text/21859692/pubmed\" id=\"21859692\" target=\"_blank\">",
"        21859692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al, \"Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(23):2416-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/6/14437/abstract-text/19494217/pubmed\" id=\"19494217\" target=\"_blank\">",
"        19494217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NCT 00685373, &ldquo;Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-Associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease&rdquo;, Unpublished data. Available at",
"      <a href=\"file://clinicaltrials.gov/ct2/show/NCT00685373?term=NCT+00685373&amp;amp;rank=1\" target=\"_blank\">",
"       file://clinicaltrials.gov/ct2/show/NCT00685373?term=NCT+00685373&amp;rank=1",
"      </a>",
"      . Date Accessed:  October 29, 2011",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruperto N, Brunner H, Horneff G, et al, &ldquo;Efficacy and Safety of Canakinumab, a Longacting Fully Human Anti-Interleukin-1&szlig; Antibody, in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features: Results From a Phase III Study,&rdquo;",
"      <i>",
"       Pediatric Rheumatology",
"      </i>",
"      , 2011, 9(Suppl 1):021.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruperto N, Quartier P, Wulffraat N, et al, \"A Phase II, Multicenter, Open-Label Study Evaluating Dosing and Preliminary Safety and Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features,\"",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2012, 64(2):557-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/6/14437/abstract-text/21953497[/pubmed\" id=\"21953497[\" target=\"_blank\">",
"        21953497[",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17066 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-658DE962AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14437=[""].join("\n");
var outline_f14_6_14437=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874024\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14946785\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333947\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13334002\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9512584\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7884596\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13334004\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333977\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333958\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883698\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333959\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333961\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333960\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298949\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7899286\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883688\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883689\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13334005\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333978\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14197638\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333979\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13334006\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17066\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17066|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=related_link\">",
"      Canakinumab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/53/12116?source=related_link\">",
"      Canakinumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_6_14438="Orbital cellulitis PI";
var content_f14_6_14438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Orbital cellulitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 508px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Orbital cellulitis is a rare but dangerous infection that affects the tissue behind the orbital septum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14438=[""].join("\n");
var outline_f14_6_14438=null;
var title_f14_6_14439="Pericarditis myocarditis spectrum";
var content_f14_6_14439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Pericarditis myocarditis spectrum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 444px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 53-year-old man with apparently idiopathic acute pericarditis: nearly ubiquitous J (ST) elevations with corresponding J (ST) depression in lead aVR. As is common in leads III and aVF when the QRS axis is horizontal (or these leads are of small voltage), the J (ST) is not elevated. The height of J (ST) is &gt;25 percent of the height of the T-wave peak in leads V5 and V6. Most PR segments are slightly depressed with respect to the T-P baseline (corresponding PR elevation in lead aVR). In the clinical setting, a spectrum of myopericardial inflammatory syndromes can be encountered, ranging from pure pericarditis to forms with increasing myocardial involvement (sometimes mimicking an acute coronary syndrome).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Imazio M, Spodick DH, Brucato A, et al. Controversial Issues in the Management of Pericardial Diseases. Circulation 2010; 121:916. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14439=[""].join("\n");
var outline_f14_6_14439=null;
var title_f14_6_14440="Sclerosing mesenteritis";
var content_f14_6_14440=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sclerosing mesenteritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/6/14440/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14440/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/6/14440/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14440/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/6/14440/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14440/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/6/14440/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerosing mesenteritis is part of a spectrum (including mesenteric lipodystrophy and mesenteric panniculitis) of idiopathic primary inflammatory and fibrotic processes that affect the mesentery. Pathophysiologically, these processes may affect the integrity of the gastrointestinal lumen and mesenteric vessels by a mass effect. These are uncommon disorders that predominantly affect men between the fifth and seventh decades of life and may result in a variety of gastrointestinal and systemic manifestations, including abdominal pain, nausea and vomiting, diarrhea, weight loss, and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nomenclature of this pathophysiologic continuum has been beset with confusion since the term \"retractile mesenteritis\" was proposed in 1924 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/5\">",
"     5",
"    </a>",
"    ]. Subsequently (in the 1960s) a report described seven patients with recurring episodes of moderate to severe abdominal pain, intermittent nausea, fever, and malaise, and, in over half of cases, a palpable abdominal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. On pathologic evaluation, patients had \"extensive involvement of the mesentery of the small bowel by a chronic nonspecific inflammation.\" On the basis of these findings, the condition was called mesenteric panniculitis.",
"   </p>",
"   <p>",
"    Since these initial descriptions, other terms have been applied to describe processes with overlapping clinical and histologic features, including mesenteric lipodystrophy and sclerosing mesenteritis (",
"    <a class=\"graphic graphic_table graphicRef64321 \" href=\"UTD.htm?9/4/9291\">",
"     table 1",
"    </a>",
"    ). Most patients have a range of pathologic findings, although usually one feature predominates at a given time. Histologic progression has only rarely been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/7\">",
"     7",
"    </a>",
"    ]. It is quite likely that these features represent different points in the natural history of the underlying process, with adipocyte necrosis (mesenteric lipodystrophy) evolving into a chronic inflammatory state (mesenteric panniculitis), and finally to fibrosis (sclerosing mesenteritis). Although consensus has not been achieved on the classification of these disorders, sclerosing mesenteritis may be the best umbrella term [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will provide an overview of sclerosing mesenteritis. Unless specifically noted, the same discussion applies to the entities designated mesenteric lipodystrophy and mesenteric panniculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of sclerosing mesenteritis is unknown. An autopsy series reported a prevalence of one percent, suggesting that many cases are undiagnosed during life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/10\">",
"     10",
"    </a>",
"    ]. A more recent report described a prevalence of 0.6 percent in over 7,000 abdominal computed tomography examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/11\">",
"     11",
"    </a>",
"    ]. Although mesenteric panniculitis has been reported in persons as young as three years of age, most patients were white, and in the fifth to seventh decades of life, with a median age of 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/12\">",
"     12",
"    </a>",
"    ]. The rarity of this entity in childhood and adolescence has been attributed to a lesser amount of mesenteric fat in comparison to adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/13\">",
"     13",
"    </a>",
"    ]. Most reports have found a male preponderance, on the order of 2:1, although female predominance (65 percent) was described in at least one study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/8,11\">",
"     8,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of sclerosing mesenteritis remains obscure, although several mechanisms have been suggested based upon anecdotal reports, small case series, or extrapolation from animal models of inflammation. These include previous abdominal surgery or trauma, autoimmunity, paraneoplastic syndrome, ischemic injury, and infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Abdominal surgery or abdominal trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antecedent surgery or abdominal trauma was implicated as a potential contributor to the etiology of sclerosing mesenteritis in a large clinical series (n = 84) from the Armed Forces Institute of Pathology (AFIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/8\">",
"     8",
"    </a>",
"    ]. Previous abdominal surgery or abdominal trauma was described in 5 percent of patients. In another report, 41 percent of patients had previous abdominal surgery, most commonly cholecystectomy, appendectomy, hysterectomy, and colectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/12\">",
"     12",
"    </a>",
"    ]. In the first published series, 6 percent of patients had a history of abdominal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/5\">",
"     5",
"    </a>",
"    ]. A case report described an association with the use of a pneumatic jackhammer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/14\">",
"     14",
"    </a>",
"    ], while in another it was felt to be triggered by occult ileal perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/15\">",
"     15",
"    </a>",
"    ]. A reasonable speculation from these reports is that sclerosing mesenteritis results from surgery or trauma in a subset of patients who have abnormal responses in healing and repair (perhaps on a genetic basis) to connective tissue trauma. Other authors have suggested a possible association with powdered surgical gloves in the development of abdominal fibrosis as a precursor to sclerosing mesenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenteric panniculitis has been reported in association with a number of presumably autoimmune conditions, including Riedel thyroiditis, primary sclerosing cholangitis, retroperitoneal fibrosis, and orbital pseudotumor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, it has rarely been found as part of the initial presentation with autoimmune hemolytic anemia, minimal change nephropathy, systemic lupus erythematosus, and relapsing polychondritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/17-21\">",
"     17-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One series described an association with elevated serum IgG4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autoimmune pancreatitis in some patients, suggesting a possible role for IgG4-related immunopathologic processes in the pathogenesis of sclerosing mesenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/12\">",
"     12",
"    </a>",
"    ]. In this report, 9 percent of patients had multifocal fibrosclerosis.",
"   </p>",
"   <p>",
"    A possible autoimmune etiology is also supported by a clinical response to immunomodulatory medications including glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. An association with T-cell lymphoma complicating celiac disease was described in a case report [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Paraneoplastic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of cases associated with an underlying malignancy has ranged from 1 to as high as 70 percent in several reports [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/1,2,8,11\">",
"     1,2,8,11",
"    </a>",
"    ]. A variety of malignancies have been reported including lymphoma, breast cancer, melanoma, squamous carcinoma and adenocarcinoma of the lung, renal carcinoma, multiple myeloma, hepatocellular carcinoma, prostate adenocarcinoma, ovarian carcinoma, endometrial carcinoma, cervical carcinoma, pudendal carcinoma, angiosarcoma, and gastrointestinal adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/2,11,28\">",
"     2,11,28",
"    </a>",
"    ]. These associations have led some investigators to speculate that sclerosing mesenteritis represents a nonspecific response to an underlying malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ischemia and infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A process mimicking sclerosing mesenteritis has been duplicated in laboratory animals by a variety of methods, such as interference with the mesenteric vascular supply and injection of bacteria and bacterial toxins into the mesentery. A possible infectious etiology is consistent with case reports showing an association with a previous history of typhoid fever, dysentery, tuberculosis, syphilis, malaria, influenza, and rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of sclerosing mesenteritis are varied. Thus, a high degree of suspicion is required for diagnosis. The following summarizes some of the largest series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/1,8,12\">",
"     1,8,12",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 68 patients, 75 percent had abdominal pain, 36 percent had nausea and vomiting (due to small bowel obstruction), 20 percent had anorexia, fever, and weight loss, and 20 percent had altered bowel habits (either constipation or diarrhea) with associated rectal bleeding in 7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/1\">",
"       1",
"      </a>",
"      ]. The duration of symptoms ranged from 24 hours to two years.",
"     </li>",
"     <li>",
"      In another report of 84 patients, only 35 percent of patients had abdominal pain while 20 percent had an incidental abdominal mass on exam [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/8\">",
"       8",
"      </a>",
"      ]. The duration of symptoms ranged from days to 10 years.",
"     </li>",
"     <li>",
"      A third series included 92 patients seen at the Mayo clinic over 25 years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/12\">",
"       12",
"      </a>",
"      ]. The most common presenting symptoms were abdominal pain (70 percent), diarrhea (25 percent), and weight loss (23 percent). Ten percent of patients were asymptomatic at the time of diagnosis while small bowel obstruction was seen in 24 percent and chylous ascites in 14 percent. The diagnosis was more common in men (70 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of other findings have been described, some of which may reflect associated conditions, such as underlying malignancy. Examples include a pleural effusion associated with mesothelioma, fever of unknown origin, protein-losing enteropathy, hemolytic anemia, jaundice (due to biliary obstruction), and indurated subcutaneous nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/17,18,30-34\">",
"     17,18,30-34",
"    </a>",
"    ]. Other patients may be minimally or asymptomatic; the diagnosis is revealed when they have undergone radiologic procedures for other indications or for nonspecific abdominal complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abdominal mass (typically in the left upper quadrant or epigastrium) can be palpated in up to 50 percent of patients. Masses tend to be deep seated and poorly defined [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/1-4,8\">",
"     1-4,8",
"    </a>",
"    ]. As a result they often transmit aortic pulsations, which may be misinterpreted as an abdominal aortic aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other findings include abdominal tenderness in about one-third of cases and distension in about 10 to 15 percent. Signs of peritoneal inflammation are reported in fewer than 5 percent of cases. Ascites (usually chylous) is rare. Detection of peripheral adenopathy should prompt consideration of alternative (or coexisting) diagnoses (such as lymphoma and metastatic adenocarcinoma).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have reported normal laboratory parameters. Nonspecific abnormalities, including anemia and hypoalbuminemia, may be found. The erythrocyte sedimentation rate and C-reactive protein level may be elevated and serve as surrogate markers of a therapeutic response to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is established by histologic evaluation in a patient with compatible radiographic findings (typically a soft tissue mass in the small bowel mesentery). Given the protean clinical manifestations and nonspecific laboratory and radiologic findings, the diagnosis is rarely made preoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/1-4,8\">",
"     1-4,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal imaging is an essential component of the diagnostic evaluation, although many of the radiologic features are nonspecific. Ischemic, neoplastic, infectious, and other inflammatory conditions (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential Diagnosis'",
"    </a>",
"    below) may give rise to similar findings.",
"   </p>",
"   <p>",
"    Dual-phase abdominal CT is the most sensitive imaging modality for detecting mesenteric panniculitis. However, its specificity is limited since a broad differential diagnosis exists for mass lesions of the mesentery. The CT appearance of sclerosing mesenteritis varies depending upon the extent and severity of inflammation and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common CT finding is a soft tissue mass in the small bowel mesentery. Mass lesions may be homogeneous (more fibrotic lesions) or heterogeneous (more inflammatory). For unclear reasons, the jejunal mesentery seems to be most commonly involved, although cases involving the sigmoid mesocolon have also been described. Focal infiltration may also occur in the region of the pancreas, simulating a primary pancreatic malignancy.",
"     </li>",
"     <li>",
"      Two CT findings, \"fat ring sign\" and \"tumor pseudocapsule,\" are considered to be somewhat specific for mesenteric panniculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/16,37-40\">",
"       16,37-40",
"      </a>",
"      ]. The fat ring sign describes the common finding (in 75 to 90 percent of patients) of preservation of the densitometric values of fat nearest the mesenteric vessels. A tumoral pseudocapsule (seen in up to 60 percent of patients) refers to the finding of a hyperattenuated stripe partly surrounding the mass. These features are not seen in other mesenteric diseases such as lipoma, lymphoma, or liposarcoma.",
"     </li>",
"     <li>",
"      Vascular displacement, encasement, or thrombosis may be seen in over one-half of cases. Multidetector CT with three-dimensional volume rendering can provide information about the relationship between mesenteric mass lesions and surrounding vasculature [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calcifications are present in about 20 percent of lesions, probably resulting from fat necrosis.",
"     </li>",
"     <li>",
"      Cystic components may be present, possibly from focal necrosis due to vascular obstruction. Lymphadenopathy (mesenteric or retroperitoneal) is present in 20 to 40 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/37,42\">",
"       37,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The term \"misty mesentery\" has been used to describe the finding of increased attenuation of mesenteric fat with small lymph nodes but without evidence of a discrete mass [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. The increased attenuation is due to infiltration by inflammatory cells, fluid (edema, blood, lymph), tumor, or fibrosis. Thus, it is not specific for sclerosing mesenteritis, because hemorrhage, edema, or malignancy (particularly lymphoma) can present in an identical fashion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI has not been extensively studied in patients with mesenteric panniculitis, although the findings appear to be similar to CT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. A case report described the presence of a fibrous capsule that may be useful for distinguishing sclerosing mesenteritis from other mesenteric diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although less useful for diagnosis, plain radiographs often demonstrate signs of mechanical obstruction of the small bowel, colon, or both. Contrast studies of the gastrointestinal tract may demonstrate fixation, angulation, thumbprinting, separation, tethering of the bowel, and concentric bowel strictures with tapered, serrated edges [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/49\">",
"     49",
"    </a>",
"    ]. Mucosal preservation is a key finding that distinguishes sclerosing mesenteritis from malignant processes. Ultrasonographic studies may reveal a focal mass lesion but are generally inconclusive for the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/50\">",
"     50",
"    </a>",
"    ]. One report suggested that the combination of PET scanning and CT was helpful in differentiating mesenteric panniculitis from involvement of the mesentery with tumor in patients with cancer since PET scanning was negative in mesenteric panniculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/51\">",
"     51",
"    </a>",
"    ]. However, a case report described a case of sclerosing mesenteritis with a positive PET scan [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/52\">",
"     52",
"    </a>",
"    ]. Thus, its specificity is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal pathologic confirmation should be obtained in all cases of suspected sclerosing mesenteritis. Although percutaneous biopsy may be used to obtain tissue, laparoscopy or laparotomy is usually necessary to provide a definitive diagnosis, because fine-needle aspiration specimens often lack sufficient architectural representation to exclude malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gross findings are variable. Three general patterns were described in one series involving 53 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type I (42 percent of cases) &ndash; diffuse mesenteric thickening",
"     </li>",
"     <li>",
"      Type II (32 percent of cases) &ndash; a single discrete mass",
"     </li>",
"     <li>",
"      Type III (26 percent of cases) &ndash; multiple discrete mass lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to this classification, the 84 patients described in the largest reported series were 17 percent type I, 70 percent type II, and 13 percent type III [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/8\">",
"     8",
"    </a>",
"    ]. Focal lesions ranged from 1 to 40 cm in size, with a mean of 10 cm.",
"   </p>",
"   <p>",
"    On microscopic examination, the most consistent histologic findings in the series from the AFIP were fibrous tissue and chronic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/8\">",
"     8",
"    </a>",
"    ]. Granulomas are generally not part of the histologic spectrum, but may be present in patients with a history of trauma or foreign bodies.",
"   </p>",
"   <p>",
"    Flow cytometry may be used if lymphoma cannot be excluded on histologic evaluation. More recently, immunohistochemical staining for",
"    <span class=\"nowrap\">",
"     CD117/c-kit,",
"    </span>",
"    beta catenin, and smooth muscle actin has been proposed for distinguishing sclerosing mesenteritis from gastrointestinal stromal tumors (GIST) and mesenteric fibromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/54\">",
"     54",
"    </a>",
"    ]. Unlike GIST and mesenteric fibromatosis, sclerosing mesenteritis does not stain for",
"    <span class=\"nowrap\">",
"     CD117/c-kit",
"    </span>",
"    and beta catenin, respectively, but retains staining for smooth muscle actin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of sclerosing mesenteritis (and related disorders) is broad and includes all processes that can affect the mesentery (",
"    <a class=\"graphic graphic_table graphicRef81532 \" href=\"UTD.htm?28/32/29196\">",
"     table 2",
"    </a>",
"    ). The most common mimics are lymphoma, peritoneal carcinomatosis, carcinoid tumor, mesenteric fibromatosis, and mesenteric edema. Mesenteric edema can be caused by a number of conditions, including hypoalbuminemia, cirrhosis, congestive heart failure, and trauma, all of which appear as hyperattenuation of the mesenteric fat on CT and thus may mimic mesenteric panniculitis.",
"   </p>",
"   <p>",
"    A multitude of other diagnoses must also be considered. These include primary inflammatory diseases of the pancreas (acute pancreatitis) and bowel (inflammatory bowel disease), systemic diseases with fat necrosis as a cardinal manifestation (Weber-Christian disease), peritoneal lymphomatosis, primary mesenteric mesothelioma, mesenteric fibromatosis (desmoid tumor of Gardner's syndrome), inflammatory pseudotumor, idiopathic retroperitoneal fibrosis, lipoma, liposarcoma, metastatic deposits, tumor infiltration from adenocarcinoma of the gastrointestinal tract, sclerosing peritonitis, Whipple's disease, mesenteric cysts, and peritoneal mycobacterial diseases (Mycobacterium tuberculosis and Mycobacterium avium complex) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/1-4,8,9,16,38,55-59\">",
"     1-4,8,9,16,38,55-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following features can help narrow the differential diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-Hodgkin lymphoma may present as a nodal mass in the mesentery. However, unlike mesenteric panniculitis, there is usually retroperitoneal lymphadenopathy and lack of tumoral calcification. In addition, the fat ring sign (described above) is not seen in lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"       \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carcinoid tumors may be associated with a misty mesentery and poorly defined mesenteric mass lesions, which arise in the setting of a desmoplastic tumor reaction. The presence of focal bowel lesions and liver lesions supports the diagnosis of carcinoid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"       \"Clinical characteristics of carcinoid tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carcinomatosis is usually associated with ascites and multiple enhancing omental nodules.",
"     </li>",
"     <li>",
"      One study found that liposarcomas could be distinguished from sclerosing mesenteritis by their tendency to express the MDM2 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mesenteric fibromatosis (desmoid tumors) are tumor-like fibromatoses that are most commonly found in patients with familial adenomatous polyposis (FAP). These lesions can be distinguished from sclerosing mesenteritis on the basis of a paucity of inflammation and a tendency to involve the bowel muscularis propria. In addition, desmoid tumors tend to be multifocal and commonly recur following resection. Desmoids also lack the dense sclerosis more commonly found in mesenteric panniculitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7352?source=see_link\">",
"       \"Gardner syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of sclerosing mesenteritis is not well understood in part because of the rarity of this condition, the disparate nomenclature used in reporting, and lack of adequate follow-up. Although there are case reports of fatalities and patients with aggressive disease phenotypes, the breadth of clinical experience suggests a benign, slowly progressive course in most patients. Cases of spontaneous regression have been reported, with times to resolution of the abdominal mass ranging from a few weeks to over a decade [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/1\">",
"     1",
"    </a>",
"    ]. In a five-year follow-up report of 47 patients with mesenteric lipodystrophy, 65 percent were still alive, and in those who died, one-half of the deaths were due to malignancy (50 percent carcinoma, 50 percent lymphoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/2\">",
"     2",
"    </a>",
"    ]. In another series, 12 percent of patients developed malignancy on follow-up, including lymphoma, carcinoid syndrome, lung adenocarcinoma, and mesothelioma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/8\">",
"     8",
"    </a>",
"    ]. Fulminant cases of sclerosing mesenteritis have been reported and are largely due to complications of intestinal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no uniformly recognized standard therapy for sclerosing mesenteritis. Treatment is empiric and should be individualized (",
"    <a class=\"graphic graphic_algorithm graphicRef53162 \" href=\"UTD.htm?40/14/41198\">",
"     algorithm 1",
"    </a>",
"    ). Beyond diagnostic sampling, surgery has only a limited role. In the vast majority of cases, complete surgical resection is impossible because of associated vascular compromise and disease extent. Surgical bypass may be indicated to alleviate symptoms in those whose symptoms are dominated by focal intestinal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/1-4,62\">",
"     1-4,62",
"    </a>",
"    ]. Radiation therapy has had equivocal success [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/7,63\">",
"     7,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of pharmaceutical agents have been used in an attempt to stabilize the disease. All of these experiences have been reported in small case series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids alone (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    30 to 50",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    and in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (50 to 100",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    has been reported to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/12,22,24-26\">",
"     12,22,24-26",
"    </a>",
"    ]. Patients with the greatest inflammatory component, as demonstrated by the acuity of presentation with fever, weight loss, malaise, elevated erythrocyte sedimentation rate, and prominent inflammation on biopsy, appear to be the most responsive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hormonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A response to hormonal therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and progesterone (10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for six months) has been described in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Combination therapy with tamoxifen plus glucocorticoids was beneficial in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/12\">",
"     12",
"    </a>",
"    ]. The authors used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    40 mg daily for three months followed by a taper over an additional three months plus tamoxifen 10 mg twice daily for six months. The proposed mechanism of benefit from tamoxifen is the increased production of TGF-beta which appears to decrease inflammation and down regulate fibroblast proliferation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case report described successful transition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    (1 mg daily) for maintenance therapy in a patient who had responded clinically to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A response to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    was described in two patients, including one who had not responded to glucocorticoids&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/23\">",
"     23",
"    </a>",
"    ]. Prior to the initiation of therapy, both had a progressive downhill course characterized by prominent systemic symptoms. Initiation of cyclophosphamide (2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    resulted in clinical remission for up to 30 months. One of the two patients had complete resolution of the mass at surgical exploration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 12 weeks) was evaluated in an open-label pilot study of five patients with symptomatic mesenteric panniculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14440/abstract/36\">",
"     36",
"    </a>",
"    ]. The investigators developed and implemented a Mesenteric Panniculitis Subjective Assessment Score to assess clinical efficacy and monitored C-reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), and CT findings before and after therapy. Treatment was found to be safe and well tolerated. Although no improvement in CT findings was observed, nearly all patients experienced improvement in CRP levels and ESR and in subjective assessments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sclerosing mesenteritis is part of a spectrum of idiopathic primary inflammatory and fibrotic processes that affect the mesentery. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation ranges from an asymptomatic abdominal mass to acute, systemic syndromes marked by fever, weight loss, malaise, and intestinal obstruction. Laboratory markers of inflammation (ESR and CRP) may be elevated. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging with CT is the most sensitive diagnostic tool. Surgical biopsy is usually required to make the diagnosis and to exclude clinical and radiologic mimics such as lymphoma, carcinoid syndrome, and peritoneal carcinomatosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment should be individualized based upon symptoms, complications and comorbidities. In patients who are symptomatic, we suggest a trial of immunosuppressive therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Glucocorticoids in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      are the preferred first-line therapy while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      may be useful adjuncts (",
"      <a class=\"graphic graphic_algorithm graphicRef53162 \" href=\"UTD.htm?40/14/41198\">",
"       algorithm 1",
"      </a>",
"      ). For refractory cases,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      can be considered. Surgery is best reserved for obstructive complications and usually involves bypass rather than complete resection. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272068814\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. David G. Forcione, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/1\">",
"      Durst AL, Freund H, Rosenmann E, Birnbaum D. Mesenteric panniculitis: review of the leterature and presentation of cases. Surgery 1977; 81:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/2\">",
"      Kipfer RE, Moertel CG, Dahlin DC. Mesenteric lipodystrophy. Ann Intern Med 1974; 80:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/3\">",
"      Monahan DW, Poston WK Jr, Brown GJ. Mesenteric panniculitis. South Med J 1989; 82:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/4\">",
"      Parra-Davila E, McKenney MG, Sleeman D, et al. Mesenteric panniculitis: case report and literature review. Am Surg 1998; 64:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/5\">",
"      Jura V. Sulla mesenterite retratile e sclerosante. Policlinico (Sez. Chir.) 1924; 31:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/6\">",
"      OGDEN WW 2nd, BRADBURN DM, RIVES JD. Pannicultis of the mesentery. Ann Surg 1960; 151:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/7\">",
"      OGDEN WW 2nd, BRADBURN DM, RIVES JD. MESENTERIC PANNICULITIS: REVIEW OF 27 CASES. Ann Surg 1965; 161:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/8\">",
"      Emory TS, Monihan JM, Carr NJ, Sobin LH. Sclerosing mesenteritis, mesenteric panniculitis and mesenteric lipodystrophy: a single entity? Am J Surg Pathol 1997; 21:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/9\">",
"      Kelly JK, Hwang WS. Idiopathic retractile (sclerosing) mesenteritis and its differential diagnosis. Am J Surg Pathol 1989; 13:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/10\">",
"      Khachaturian T, Hughes J. Mesenteric panniculitis. West J Med 1988; 148:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/11\">",
"      Daskalogiannaki M, Voloudaki A, Prassopoulos P, et al. CT evaluation of mesenteric panniculitis: prevalence and associated diseases. AJR Am J Roentgenol 2000; 174:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/12\">",
"      Akram S, Pardi DS, Schaffner JA, Smyrk TC. Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients. Clin Gastroenterol Hepatol 2007; 5:589.",
"     </a>",
"    </li>",
"    <li>",
"     Adams JT. Abdominal wall, omentum, mesentry, and retroperitoneum. In: Principles of Surgery, 6th ed, Schwartz S, Shires F, Spencer F (Eds), McGraw Hill, New York 1994. p.1485.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/14\">",
"      van der Hulst RW, Rauws EA, Tytgat GN. Mesenteritis secondary to the use of a pneumatic jackhammer. Eur J Gastroenterol Hepatol 1995; 7:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/15\">",
"      Mathew J, McKenna F, Mason J, et al. Sclerosing mesenteritis with occult ileal perforation: report of a case simulating extensive intra-abdominal malignancy. Dis Colon Rectum 2004; 47:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/16\">",
"      Horton KM, Lawler LP, Fishman EK. CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease. Radiographics 2003; 23:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/17\">",
"      Papadaki HA, Kouroumalis EA, Stefanaki K, et al. Retractile mesenteritis presenting as fever of unknown origin and autoimmune haemolytic anaemia. Digestion 2000; 61:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/18\">",
"      Vidarsson B, Matth&iacute;asson P, Agnarsson BA, Onundarson PT. Mesenteric panniculitis presenting with autoimmune haemolytic anaemia. Acta Haematol 2002; 107:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/19\">",
"      Vernace MA, Bellucci AG, Mossey RT, et al. Minimal change nephropathy associated with sclerosing mesenteritis. Nephron 1996; 73:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/20\">",
"      Dor AM, Kohler JL, Aubrespy P, et al. [Mesenteric panniculitis, an unusual initial stage of acute lupus erythematosus in a ten-year old girl (author's transl)]. Arch Anat Cytol Pathol 1982; 30:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/21\">",
"      Sauvaget F, Piette JC, Galezowski N, et al. [Relapsing polychondritis and mesenteric panniculitis: apropos of 2 cases]. Rev Med Interne 1993; 14:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/22\">",
"      Bala A, Coderre SP, Johnson DR, Nayak V. Treatment of sclerosing mesenteritis with corticosteroids and azathioprine. Can J Gastroenterol 2001; 15:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/23\">",
"      Bush RW, Hammar SP Jr, Rudolph RH. Sclerosing mesenteritis. Response to cyclophosphamide. Arch Intern Med 1986; 146:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/24\">",
"      G&eacute;n&eacute;reau T, Bellin MF, Wechsler B, et al. Demonstration of efficacy of combining corticosteroids and colchicine in two patients with idiopathic sclerosing mesenteritis. Dig Dis Sci 1996; 41:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/25\">",
"      Kikiros CS, Edis AJ. Mesenteric panniculitis resulting in bowel obstruction: response to steroids. Aust N Z J Surg 1989; 59:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/26\">",
"      Tytgat GN, Roozendaal K, Winter W, Esseveld MR. Successful treatment of a patient with retractile mesenteritis with prednisone and azathioprine. Gastroenterology 1980; 79:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/27\">",
"      Garrido A, Verdejo C, M&aacute;rquez JL, et al. [Intestinal lymphoma and mesenteric panniculitis: complications of undiagnosed celiac disease]. Gastroenterol Hepatol 2008; 31:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/28\">",
"      Goh J, Otridge B, Brady H, et al. Aggressive multiple myeloma presenting as mesenteric panniculitis. Am J Gastroenterol 2001; 96:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/29\">",
"      TEDESCHI CG, BOTTA GC. Retractile mesenteritis. N Engl J Med 1962; 266:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/30\">",
"      Harris RJ, van Stolk RU, Church JM, Kavuru MS. Thoracic mesothelioma associated with abdominal mesenteric panniculitis. Am J Gastroenterol 1994; 89:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/31\">",
"      Medina-Franco H, Listinsky C, Mel Wilcox C, et al. Concomitant sclerosing mesenteritis and bile duct fibrosis simulating Klatskin's tumor. J Gastrointest Surg 2001; 5:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/32\">",
"      Sans M, Varas M, Anglada A, et al. Mesenteric panniculitis presenting as fever of unknown origin. Am J Gastroenterol 1995; 90:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/33\">",
"      H&ouml;ring E, Hingerl T, Hens K, et al. Protein-losing enteropathy: first manifestation of sclerosing mesenteritis. Eur J Gastroenterol Hepatol 1995; 7:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/34\">",
"      Hinds BR, Bahrami S, Bernardi JM, Callen JP. Cutaneous sclerosis: a previously undescribed manifestation of sclerosing mesenteritis. Arch Dermatol 2010; 146:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/35\">",
"      Lawrence MS, Stanford W, Sheets RF. Retractile mesenteritis with transmitted pulsations. Am J Med 1966; 41:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/36\">",
"      Ginsburg PM, Ehrenpreis ED. A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis. Aliment Pharmacol Ther 2002; 16:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/37\">",
"      Sabat&eacute; JM, Torrubia S, Maideu J, et al. Sclerosing mesenteritis: imaging findings in 17 patients. AJR Am J Roentgenol 1999; 172:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/38\">",
"      Sheth S, Horton KM, Garland MR, Fishman EK. Mesenteric neoplasms: CT appearances of primary and secondary tumors and differential diagnosis. Radiographics 2003; 23:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/39\">",
"      Valls C. Fat-ring sign in sclerosing mesenteritis. AJR Am J Roentgenol 2000; 174:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/40\">",
"      Okino Y, Kiyosue H, Mori H, et al. Root of the small-bowel mesentery: correlative anatomy and CT features of pathologic conditions. Radiographics 2001; 21:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/41\">",
"      Lawler LP, McCarthy DM, Fishman EK, Hruban R. Sclerosing mesenteritis: depiction by multidetector CT and three-dimensional volume rendering. AJR Am J Roentgenol 2002; 178:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/42\">",
"      Seo M, Okada M, Okina S, et al. Mesenteric panniculitis of the colon with obstruction of the inferior mesenteric vein: report of a case. Dis Colon Rectum 2001; 44:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/43\">",
"      Mindelzun RE, Jeffrey RB Jr, Lane MJ, Silverman PM. The misty mesentery on CT: differential diagnosis. AJR Am J Roentgenol 1996; 167:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/44\">",
"      Seo BK, Ha HK, Kim AY, et al. Segmental misty mesentery: analysis of CT features and primary causes. Radiology 2003; 226:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/45\">",
"      Ghanem N, Pache G, Bley T, et al. MR findings in a rare case of sclerosing mesenteritis of the mesocolon. J Magn Reson Imaging 2005; 21:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/46\">",
"      Kobayashi S, Takeda K, Tanaka N, et al. Mesenteric panniculitis: MR findings. J Comput Assist Tomogr 1993; 17:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/47\">",
"      Fujiyoshi F, Ichinari N, Kajiya Y, et al. Retractile mesenteritis: small-bowel radiography, CT, and MR imaging. AJR Am J Roentgenol 1997; 169:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/48\">",
"      Kronthal AJ, Kang YS, Fishman EK, et al. MR imaging in sclerosing mesenteritis. AJR Am J Roentgenol 1991; 156:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/49\">",
"      P&eacute;rez-Font&aacute;n FJ, Soler R, Sanchez J, et al. Retractile mesenteritis involving the colon: barium enema, sonographic, and CT findings. AJR Am J Roentgenol 1986; 147:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/50\">",
"      Sato M, Ishida H, Konno K, et al. Mesenteric panniculitis: sonographic findings. Abdom Imaging 2000; 25:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/51\">",
"      Zissin R, Metser U, Hain D, Even-Sapir E. Mesenteric panniculitis in oncologic patients: PET-CT findings. Br J Radiol 2006; 79:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/52\">",
"      Nguyen BD. F-18 FDG PET demonstration of sclerosing mesenteritis. Clin Nucl Med 2003; 28:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/53\">",
"      Weiser J, Salky B, Slepian A, Dikman S. Laparoscopic diagnosis of retractile mesenteritis. Gastrointest Endosc 1992; 38:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/54\">",
"      Montgomery E, Torbenson MS, Kaushal M, et al. Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol 2002; 26:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/55\">",
"      McCrystal DJ, O'Loughlin BS, Samaratunga H. Mesenteric panniculitis: a mimic of malignancy. Aust N Z J Surg 1998; 68:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/56\">",
"      Phillips RH, Carr RA, Preston R, et al. Sclerosing mesenteritis involving the pancreas: two cases of a rare cause of abdominal mass mimicking malignancy. Eur J Gastroenterol Hepatol 1999; 11:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/57\">",
"      Wilkinson JM, Nyamekye I, Reed MW, Polacarz S. Advanced gastrointestinal malignancy or benign inflammatory disease? An unusual presentation of sclerosing mesenteritis. Report of a case. Dis Colon Rectum 1994; 37:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/58\">",
"      Gilfrich CP, D'Elia G, Black P, et al. Retractile mesenteritis mimicking an adrenal tumor. J Urol 1999; 162:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/59\">",
"      Sheikh RA, Prindiville TP, Arenson D, Ruebner BH. Sclerosing mesenteritis seen clinically as pancreatic pseudotumor: two cases and a review. Pancreas 1999; 18:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/60\">",
"      Weaver J, Goldblum JR, Turner S, et al. Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. Mod Pathol 2009; 22:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/61\">",
"      Soergel KH, Hensley GT. Fatal mesenteric panniculitis. Gastroenterology 1966; 51:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/62\">",
"      Han SY, Koehler RE, Keller FS, et al. Retractile mesenteritis involving the colon: pathologic and radiologic correlation (case report). AJR Am J Roentgenol 1986; 147:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/63\">",
"      Pallette EM, Pallette EC, Harrington RW. Sclerosing lipogranulomatosis: its several abdominal syndromes. Arch Surg 1967; 94:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/64\">",
"      Mazure R, Fernandez Marty P, Niveloni S, et al. Successful treatment of retractile mesenteritis with oral progesterone. Gastroenterology 1998; 114:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/65\">",
"      Venkataramani A, Behling CA, Lyche KD. Sclerosing mesenteritis: an unusual cause of abdominal pain in an HIV-positive patient. Am J Gastroenterol 1997; 92:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14440/abstract/66\">",
"      Iwanicki-Caron I, Savoye G, Legros JR, et al. Successful management of symptoms of steroid-dependent mesenteric panniculitis with colchicine. Dig Dis Sci 2006; 51:1245.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2602 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-BA7A5ED351-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14440=[""].join("\n");
var outline_f14_6_14440=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Abdominal surgery or abdominal trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Paraneoplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ischemia and infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272068814\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2602\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2602|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?40/14/41198\" title=\"algorithm 1\">",
"      Rx sclerosing mesenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2602|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/4/9291\" title=\"table 1\">",
"      Mesenteric disease terms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/32/29196\" title=\"table 2\">",
"      Diff dx mesenteric masses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7352?source=related_link\">",
"      Gardner syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_6_14441="Acute cardiac allograft rejection: Treatment";
var content_f14_6_14441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute cardiac allograft rejection: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/6/14441/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14441/contributors\">",
"     Howard J Eisen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14441/contributors\">",
"     Mariell Jessup, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/6/14441/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14441/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/6/14441/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14441/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/6/14441/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the use of potent immunosuppressive agents both immediately after cardiac transplantation and during long-term maintenance, acute rejection remains an important problem. Cardiac transplant recipients have an average of two to three episodes in the first year after transplantation with 50 to 80 percent of patients experiencing at least one rejection episode [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/1\">",
"     1",
"    </a>",
"    ]. Acute cellular rejection is most likely to occur in the first three to six months, with the incidence declining significantly after this time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of acute cellular cardiac allograft rejection is generally made by endomyocardial biopsy performed either routinely or because of suggestive symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     ISHLT grading system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endomyocardial biopsy is graded using the International Society for Heart and Lung Transplantation (ISHLT) nomenclature adopted in 1990 and revised in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. For acute cellular rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 0 &mdash; no rejection",
"     </li>",
"     <li>",
"      Grade 1 R, mild &mdash; Interstitial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      perivascular infiltrate with up to one focus of myocyte damage",
"     </li>",
"     <li>",
"      Grade 2 R, moderate &mdash; two or more foci of infiltrate with associated myocyte damage",
"     </li>",
"     <li>",
"      Grade 3 R, severe &mdash; diffuse infiltrate with multifocal myocyte damage, with or without edema, hemorrhage, or vasculitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Grade 1 R includes grades 1A, 1B, and 2 in the 1990 system; grade 2 R was grade 3A; and grade 3 R was grades 3B and 4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=see_link&amp;anchor=H12#H12\">",
"     \"Acute cardiac allograft rejection: Diagnosis\", section on 'ISHLT grading system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DRUGS USED TO TREAT ACUTE CELLULAR REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major treatment modalities for acute cellular (T cell-mediated) rejection are oral or intravenous corticosteroids, antithymocyte globulin, or the murine monoclonal antibody OKT3. The dose and duration of therapy are discussed below for the different types of rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of steroids in reversing acute rejection is incompletely understood. The major immunosuppressive action of corticosteroids is to inhibit the synthesis of almost all known cytokines. Steroids appear to act by inducing the synthesis of IkBa, a protein that traps free nuclear factor kappa B, an activator of cytokine genes and mediator of the proinflammatory action of tumor necrosis factor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Pulse corticosteroids may more effectively impair cytokine generation.",
"   </p>",
"   <p>",
"    In transplant rejection, steroids act in part by suppressing the production of interleukin-1 (IL-1) by macrophages. This in turn leads to diminished production of IL-2 by activated T cells, thereby lessening the entire cellular immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Inhibition of IL-6, tumor necrosis factor alpha, and interferon gamma may also be important [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, they induce lymphocytolysis in some animal species; it is not known if this occurs in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antithymocyte globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithymocyte globulin is prepared by immunizing rabbits (Thymoglobulin&reg;) or horses (ATGAM&reg;) with human lymphoid cells derived from the thymus or cultured B cell lines. Antithymocyte globulins reverse rejection through a variety of effects. Most important is cell death by complement-dependent lysis or Fc receptor-mediated lysis and opsonization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disadvantages of using such polyclonal antilymphocyte preparations include lot-to-lot variability, cumbersome production and purification, nonselective targeting of all lymphocytes, and the need to administer the medication via central venous access.",
"   </p>",
"   <p>",
"    There are no comparative data of Thymoglobulin&reg; and ATGAM&reg; in heart transplant recipients. However, trials in renal transplant recipients suggest that Thymoglobulin&reg; is preferred because a significant reduction in the rate of acute rejection and a significant increase in allograft survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32649?source=see_link&amp;anchor=H11#H11\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\", section on 'Efficacy of basiliximab compared with rATG-thymoglobulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CD3 count monitoring as a means to adjust antithymocyte globulin dose has been found to result in lower doses and reduced costs in renal transplantation patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/13\">",
"     13",
"    </a>",
"    ] and limited data suggest this approach is also helpful in cardiac transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of both Thymoglobulin&reg; and ATGAM&reg; include allergic and immune reactions and increased susceptibility to infection, especially with cytomegalovirus (CMV) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A serum sickness reaction, characterized by fever, chills, arthralgias and, on occasion, frank arthritis, occurs in many patients during the initial infusion. However, anaphylactic reactions, including respiratory distress and hypotension, are exceedingly rare.",
"      <br/>",
"      <br/>",
"      To minimize the allergic manifestations, patients are usually pretreated with a cocktail of corticosteroids, antihistamines, and antipyretics. In addition, some centers routinely screen for an allergic response to either drug by administering a skin test one hour prior to administering the full dose if the test is negative. Patients with known allergies to rabbits or horses should not receive Thymoglobulin&reg; or ATGAM&reg;, respectively.",
"     </li>",
"     <li>",
"      A pruritic skin rash (20 percent) and presumed antiplatelet antibody-induced thrombocytopenia of varying severity (50 percent) can occur late in the course [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/10,16\">",
"       10,16",
"      </a>",
"      ]. An antibody-mediated leukopenia may also be seen.",
"     </li>",
"     <li>",
"      Antithymocyte globulins can induce both CMV and herpes infections. These infections are rarely life threatening, and can usually be avoided with prophylactic antiviral therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link&amp;anchor=H23#H23\">",
"       \"Prophylaxis of infections in solid organ transplantation\", section on 'Cytomegalovirus'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Antithymocyte globulins do not generally induce a host antibody response to the rabbit or horse serum (in contrast to the response to the murine monoclonal antibody OKT3). As a result, there is a greater opportunity for successful readministration if necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Monoclonal OKT3 antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;OKT3 is a murine monoclonal antibody that binds to the CD3 antigen that closely surrounds the T-cell surface. OKT3 inhibits T-cell function by a number of mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. It appears to clear or downregulate CD3 positive cells by attaching to the CD3-T cell receptor complex, which leads to shedding or internalization of the CD3-T cell receptor complex. The net effect is that these lymphocytes no longer carry T-cell receptors and their response to antigens is blunted. OKT3 can also cause opsonization.",
"   </p>",
"   <p>",
"    The use of OKT3 is associated with a number of important side effects. These include a cytokine-mediated first-dose reaction and an increased incidence of infection, including lymphoproliferative disease associated with Epstein Barr virus infection, and pulmonary edema. The first-dose reaction includes fever (70 to 100 percent), rigors (30 percent), nausea, vomiting, and diarrhea (15 to 20 percent), hypotension, and chest pain, dyspnea, or wheezing (10 to 20 percent). Steroids, antihistamines, and antipyretics are usually given prior to OKT3 to minimize these side effects, all of which should decrease with repeated exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS FOR ACUTE REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of therapy used to treat an acute rejection episode depends upon the histologic severity and the degree of hemodynamic compromise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hemodynamic compromise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic compromise is defined as one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in cardiac output (&lt;4.0",
"      <span class=\"nowrap\">",
"       L/min)",
"      </span>",
"      or cardiac index (&lt;2.0",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      per m2).",
"     </li>",
"     <li>",
"      A decrease in pulmonary artery saturation (&lt;50 percent).",
"     </li>",
"     <li>",
"      An elevation in pulmonary artery or pulmonary capillary wedge pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the presence of new symptoms of profound fatigue or dyspnea in association with cellular rejection has often been interpreted to represent hemodynamic compromise as well.",
"   </p>",
"   <p>",
"    Therapy varies with the pathologic grade and the presence or absence of hemodynamic compromise. According to the revised 2004 ISHLT grading system, grade 1 R includes grades 1A, 1B, and 2 in the 1990 system; grade 2 R was grade 3A; and grade 3 R was grades 3B and 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'ISHLT grading system'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Grade 1 R",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grade 1 R rejection (grades 1A, 1B, and 2 in the 1990 system) is generally not treated unless there is concomitant hemodynamic dysfunction since corticosteroid therapy does not increase the likelihood of resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In one study of patients with focal moderate (grade 2 in the 1990 system) rejection, for example, resolution occurred in 85 percent of patients treated with corticosteroids compared to 87 percent of those who were not treated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, another report suggested that the outcome of grade 2 rejection, even late after transplantation, was not necessarily benign [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/23\">",
"     23",
"    </a>",
"    ]. Grade 2 rejection was the strongest predictor of the development grade 3A (now grade 2 R) or higher rejection on a subsequent biopsy, with an odds ratio of 2.4 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy for mild or focal moderate rejection associated with hemodynamic compromise includes high-dose corticosteroids or antibody therapy as described below, depending upon the severity of hemodynamic compromise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Grade 2 R without hemodynamic compromise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary therapy for grade 2 R rejection (grades 3A in the 1990 system) not associated with hemodynamic dysfunction consists of a transient increase in the corticosteroid dose. A typical regimen is to administer oral pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for three to five days) in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/24\">",
"     24",
"    </a>",
"    ]; an alternative is intravenous pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three days) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient is generally returned to the oral steroid dose he or she was taking after the high-dose regimen is completed. Gradual steroid tapering has been recommended in the past but offers no clinical advantage.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    doses are only changed if the blood levels are subtherapeutic.",
"   </p>",
"   <p>",
"    Repeat endomyocardial biopsies are typically obtained on a weekly basis for the subsequent two weeks after the high-dose steroids are given to verify histologic resolution of rejection. Approximately 80 to 85 percent of these rejection episodes respond to the initial corticosteroid regimen. Resolution of rejection was defined as a subsequent biopsy of grade 2 (single focus of dense mononuclear cell infiltrate with myocyte injury) or less in the 1990 system without hemodynamic compromise.",
"   </p>",
"   <p>",
"    A second regimen of intravenous pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    may be given for three days if the endomyocardial biopsy shows persistent rejection, but multiple other agents are being evaluated. These include antithymocyte globulin, photopheresis, switching from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . There is no consensus on the optimal approach.",
"   </p>",
"   <p>",
"    The patient is returned to the usual regimen of routine surveillance biopsies once the rejection episode has resolved (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute cardiac allograft rejection: Diagnosis\", section on 'Surveillance biopsy schedule'",
"    </a>",
"    ). Some centers use this opportunity to switch from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    based immunosuppression (if the patient is not already on a tacrolimus maintenance regimen), while other centers consider the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . There is no consensus on the optimal approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Severe or refractory rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe rejection is defined as grade 2 R rejection (grade 3A in the 1990 system) associated with hemodynamic compromise, grade 3 R rejection (grades 3B and 4 in the 1990 system), or rejection episodes that fail to respond to corticosteroids. Either antithymocyte globulin or OKT3 can be used. Antithymocyte globulin is generally preferred since there is a less intense cytokine reaction than with OKT3; it is also preferred for those patients who have already received OKT3 induction therapy during the immediate posttransplant period to keep total OKT3 exposure below 75 mg.",
"   </p>",
"   <p>",
"    Calcineurin inhibitors and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    <strong>",
"     mofetil",
"    </strong>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) are continued at their pretreatment doses if therapeutic levels have been achieved. As an alternative,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    can be substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Tacrolimus is increasingly used as the primary immunosuppressive. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    at a dose of 500 mg is given as premedication on day one in lieu of standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    doses. Antihistamines and antipyretics are also given on day one.",
"   </p>",
"   <p>",
"    This regimen reverses 80 to 95 percent of rejection episodes. Endomyocardial biopsies are usually obtained at the end of the course and then one week later to verify both resolution of rejection and the absence of recurrence. The patient is returned to the usual regimen of routine surveillance biopsies if these goals are achieved. The management of persistent rejection is discussed below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Resistant or recurrent rejection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Therapy for rejection should be",
"    <strong>",
"     modified or stopped",
"    </strong>",
"    prior to completion of the full course of antibody therapy if the patient has a documented infection with resolution of rejection on endomyocardial biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Issues related to use of OKT3",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual dose of OKT3 is 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    intravenously for 10 to 14 days.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) are usually continued at their pretreatment doses if therapeutic levels have been achieved. As an alternative, tacrolimus can be substituted for cyclosporine. Tacrolimus is now commonly used as the primary immunosuppressive. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    at a dose of 500 mg is given as premedication on day one in lieu of standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    doses. Antihistamines, antipyretics, and diuretics are also given as premedications on day one.",
"   </p>",
"   <p>",
"    Patients treated with OKT3 should undergo CD3 testing to assess its efficacy. This is usually performed three to five days after the initiation of therapy. OKT3 should lead to a fall in CD3 positive cells in the peripheral blood as determined by flow cytometry. The goal is to reduce the number of CD3+ cells below 5 percent of the total number of leukocytes or below a total absolute number of 50 at four days.",
"   </p>",
"   <p>",
"    OKT3 administration induces human anti-mouse antibodies (HAMA) at titers &gt;1:100 in approximately 10 to 20 percent of patients. The main risk of HAMA is that they may blunt the effect of the drug; allergic IgE-mediated reactions have not been reported. Thus, screening for HAMA should be performed prior to any",
"    <strong>",
"     recurrent",
"    </strong>",
"    use of OKT3. The following general recommendations apply to recurrent OKT3 use and HAMA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      OKT3 can be given at the usual dose if HAMA are absent or if low antibody titers (&lt;1:100) are present.",
"     </li>",
"     <li>",
"      OKT3 can be given in higher dose (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or antithymocyte globulin can be substituted if higher HAMA titers are obtained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antibiotic and antiviral prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic and antiviral prophylaxis should be given to any patient treated with high-dose steroids or antilymphocyte therapy. A typical regimen includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"       Clotrimazole",
"      </a>",
"      lozenges to prevent oral candidiasis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      to prevent herpesvirus infections.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      or, in patients allergic to sulfa drugs, aerosolized",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      to prevent Pneumocystis jirovecii (carinii) pneumonia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some centers also give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    as prophylaxis against CMV infection, particularly for treatment of rejection in the first year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute antibody-mediated (humoral) rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a T cell-mediated cellular response, transplant rejection may be mediated by antibodies (eg, antiendothelial or anti-HLA antibodies). This form of rejection is also called humoral or vascular rejection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute cardiac allograft rejection: Diagnosis\", section on 'Acute antibody-mediated (humoral) rejection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the 2004 ISHLT classification, the diagnosis of acute antibody-mediated rejection (AMR) is based upon the following histologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/4,26\">",
"     4,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On light microscopy, myocardial capillary injury with intravascular macrophage accumulation; other findings may include intravascular thrombi and interstitial edema, hemorrhage, and neutrophilic infiltration in and around the capillaries.",
"     </li>",
"     <li>",
"      Positive immunofluorescence or immunoperoxidase staining for antibody-mediated rejection within the capillaries including immunoglobulins (IgG, IgM,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgA), complement (C4d, C3d,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C1q), and CD68 staining of macrophages.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AMR often occurs during the first month after transplantation, in association with antidonor antibodies, and can occur as early as two to seven days, if the recipient is presensitized to donor HLA antigens, or as late as months to years after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AMR is typically more severe hemodynamically than the more common T-cell mediated cellular rejection. Graft dysfunction is present in approximately two-thirds of early AMR episodes, with hemodynamic compromise (shock, hypotension, decreased cardiac output,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a rise pulmonary capillary wedge pressure) in approximately one-half of AMR episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. In comparison, graft dysfunction is uncommon (10 to 15 percent) with late episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AMR is associated with a worse prognosis than cellular rejection, as illustrated in a review of 587 patients at a single center: 19 percent of rejection episodes were due to vascular rejection alone, 60 percent to cellular rejection alone, and 23 percent to mixed cellular and vascular rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/27\">",
"     27",
"    </a>",
"    ]. The following findings were noted in the patients with AMR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly higher rate of overall mortality (64 versus 30 and 39 percent with cellular and mixed rejection).",
"     </li>",
"     <li>",
"      A significantly higher rate of graft loss due to acute rejection (15 versus 2.5 and 2 percent).",
"     </li>",
"     <li>",
"      A significantly higher rate of graft loss due to transplant vasculopathy than cellular rejection (15.7 versus 5.7 percent); the rate was also increased (15 percent) in patients with mixed rejection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal therapy of AMR is not well defined. A small study suggested that the outcome in patients with antibody-mediated rejection severe enough to produce hemodynamic compromise may be improved by plasmapheresis in combination with corticosteroids and antilymphocyte antibodies (antithymocyte globulin or OKT3) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/29\">",
"     29",
"    </a>",
"    ]. In this study, the administration of cyclophosphamide rather than azathioprine for maintenance therapy did not prevent further episodes of humoral rejection. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Photopheresis'",
"    </a>",
"    below.) Rituximab, a chimeric monoclonal antibody against CD20 that is found on the surface of B cells, is increasingly used in addition to the above therapies, to treat AMR [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/30-33\">",
"     30-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RESISTANT OR RECURRENT REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to resistant or recurrent acute ejection depends upon the clinical setting. Rebound rejection can occur shortly after OKT3 or antithymocyte globulin; these episodes can be treated with corticosteroids. If the patient fails to respond then another course of antibody therapy can be given.",
"   </p>",
"   <p>",
"    Alternative approaches can be used in the patient who has received two or three courses of OKT3 or antithymocyte globulin. These include photopheresis, total lymphoid irradiation, and changes in the maintenance immunosuppressive regimen. Several reports have emphasized the utility of photopheresis for reversal of recalcitrant rejection or reduction of the frequency of rejection, because it is often effective and has few side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Photopheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photopheresis, also called photochemotherapy, was first developed as immunotherapy for cutaneous T-cell lymphoma and has also been applied to the autoimmune diseases scleroderma and rheumatoid arthritis. It involves ex vivo separation of leukocytes from erythrocytes and exposure of the leukocytes to 8-methoxypsoralen and ultraviolet light. The leukocytes that are rapidly proliferating (such as T-cells responding to alloantigens) are preferentially damaged. The damaged cells are returned to the patient and presumably induce counterimmune responses such as T-cell vaccination. Photopheresis is usually performed twice per week for four weeks.",
"   </p>",
"   <p>",
"    When given to reverse cardiac transplant rejection, photopheresis appears to be as effective as high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    without the side effects of corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/34\">",
"     34",
"    </a>",
"    ]. Photopheresis has also been successful in several reports in reversing refractory rejection and in reducing the frequency of recurrence of rejection in patients who are frequent rejectors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. One report, for example, described four patients with refractory grade 3A to 4 cardiac allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/35\">",
"     35",
"    </a>",
"    ]. Three patients showed complete histologic reversal of rejection after photopheresis on two successive days. Complete recovery was more gradual in the fourth patient, occurring after three two-day treatments.",
"   </p>",
"   <p>",
"    Photopheresis may also have a role for prophylaxis against rejection when used in combination with other therapies. As an example, one study randomized 60 recipients of primary cardiac transplants to standard triple therapy consisting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , or triple therapy in conjunction with 24 photopheresis treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/37\">",
"     37",
"    </a>",
"    ]. After six months, the number of episodes of acute rejection per patient was significantly reduced by photopheresis compared to conventional therapy alone (0.91 versus 1.44) and significantly more patients in the photopheresis had no or only one rejection (82 versus 52 percent). There was no significant difference in survival at six and 12 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Total lymphoid irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total lymphoid irradiation (at a dose of 30 Gy) has been used to treat recalcitrant cardiac and renal transplant rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Side effects include leukopenia and nausea. This technique is also limited by being costly, time consuming and slow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Changes in maintenance immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative immunosuppressive agents have shown some benefit in the reversal of recurrent or recalcitrant cardiac allograft rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (5 to 20",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    in divided doses) may reduce the frequency of recurrent rejection episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. It is inexpensive and the risk of infection does not appear to be increased. The major side effects are pancytopenia and nausea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (FK506) has shown a modest benefit in a small number of patients who had recurrent or recalcitrant rejection despite therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In a study of 21 patients with recurrent episodes of steroid-resistant rejection, conversion from cyclosporine to tacrolimus reduced the number of acute rejection episodes per patient and the incidence of acute rejection per 100 patients days; tacrolimus was more cost effective than OKT3 in hemodynamically stable patients and the outcomes were similar [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/43\">",
"     43",
"    </a>",
"    ]. In contrast, when used for primary immunosuppression, tacrolimus showed no benefit compared to cyclosporine in terms of reducing the frequency of rejection episodes or improving survival [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential advantage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is that, compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , it significantly decreases the propensity to form thrombus, which suggests that it may have a favorable impact on the development of vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=see_link\">",
"     \"Pathogenesis of and risk factors for cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Mycophenolate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil has shown some benefit in reversing or preventing rejection in a small number of cardiac transplant recipients in whom it was substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition, a multicenter clinical trial comparing the efficacy of mycophenolate to azathioprine (both given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and corticosteroids) in 650 first heart transplant recipients found that, at one year, mycophenolate therapy was associated with significant reductions in mortality (6.2 versus 11.4 percent) and requirement for treatment of rejection (66 versus 74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/46\">",
"     46",
"    </a>",
"    ]. The benefit persisted at three years, as patients treated with mycophenolate had significantly lower rates of mortality or repeat transplantation (11.8 versus 18.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for these observations comes from registry data of 5600 heart transplant recipients, all of whom were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/48\">",
"     48",
"    </a>",
"    ]. Actuarial survival at three years was significantly higher in the 12 percent of patients treated with mycophenolate compared to those treated with azathioprine (91 versus 86 percent, adjusted relative risk 0.62).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    is an immunosuppressant that inhibits cellular proliferation in response to alloantigen stimulation. The efficacy of sirolimus as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    for the prevention of cardiac allograft rejection was evaluated in an open-label trial in 136 new heart transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/49\">",
"     49",
"    </a>",
"    ]. Subjects were randomly assigned to azathioprine or to one of two doses of sirolimus (3 mg or 5 mg per day); all patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and corticosteroids.",
"   </p>",
"   <p>",
"    At six months, the proportion of patients who had experienced a grade 3A or greater rejection episode was significantly lower with either the 3 mg or 5 mg dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (32 and 33 versus 57 percent). There was also a reduction in the development of transplant vasculopathy with sirolimus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link\">",
"     \"Prevention and treatment of cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    was associated with an increased incidence of anemia, thrombocytopenia, hyperlipidemia, and abnormal renal function than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . Discontinuation of study drug was quite frequent by 12 months for both the 3 and 5 mg sirolimus doses and for azathioprine (44, 32, and 40 percent). Sirolimus was most often discontinued due to adverse reactions (primarily thrombocytopenia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    is a derivative of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . In a multicenter clinical trial, 634 new heart transplant recipients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or one of two doses of everolimus (1.5 mg or 3.0 mg per day) in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At one year, significantly more patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , compared to those treated with either 1.5 mg or 3.0 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , had reached the combined end point of grade 3A rejection (now called grade 2 R, moderate rejection), rejection associated with hemodynamic compromise, death, graft loss, or loss to follow-up (53, 42, and 32 percent, respectively). This difference was almost entirely due to a reduction in the incidence of a first episode of grade 3A rejection.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    treatment was also associated with a significant reduction in the severity of transplant vasculopathy as manifested by a significantly lower average increase in maximal intimal thickness at one year on intravascular ultrasonography (IVUS). However, IVUS was only performed in about one-third of patients who were not chosen randomly; impaired renal function was a common reason not to test, which means that the sickest patients were not evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention and treatment of cardiac allograft vasculopathy\", section on 'Everolimus and sirolimus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Side effects seen more often with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    included increased serum creatinine concentration, hyperlipidemia, and thrombocytopenia. Viral infections, especially cytomegalovirus infection, were seen less often with everolimus than with azathioprine.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    was approved for clinical use in Europe in July 2003, but has not been approved in the United States. In November 2005, the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration recommended against approval of everolimus for the prevention of cardiac transplant rejection until more information is available [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14441/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=see_link\">",
"       \"Patient information: Heart transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=see_link\">",
"       \"Patient information: Heart transplantation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the following approach to the treatment of acute cardiac allograft rejection. The regimen is related to the histologic severity of the rejection episode and the patient's hemodynamic status. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'ISHLT grading system'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade 1 R (grade 1A, 1B, or 2 in the 1990 system) cellular rejection episodes are not treated if the patient is hemodynamically stable. Concomitant hemodynamic compromise, as defined above, necessitates treatment with either high-dose corticosteroids or, for profound hemodynamic compromise, antithymocyte globulin or OKT3. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hemodynamic compromise'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A typical steroids regimen is to administer oral pulse prednisone (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for three to five days) or intravenous pulse methylprednisolone (500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three days). The patient is generally returned to the oral steroid dose he or she was taking after the high-dose regimen is completed. Gradual steroid tapering to the maintenance dose has been recommended in the past but offers no clinical advantage. Cyclosporine (or tacrolimus) doses are only changed if the blood levels are subtherapeutic. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Grade 1 R'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Grade 2 R (previously called grade 3A) rejections without signs of hemodynamic compromise should be managed with oral or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      . If two courses of therapy do not reverse the rejection, then antithymocyte globulin or OKT3 should be administered. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Grade 2 R without hemodynamic compromise'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Antithymocyte globulin is generally preferred since there is a less intense cytokine reaction than with OKT3; it is also preferred in patients who have already received OKT3 induction therapy during the immediate posttransplant period to keep total OKT3 exposure below 75 mg. Corticosteroid premedication with methylprednisolone (500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      intravenously) is given on day one in lieu of the standard",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      doses. Antihistamines and antipyretics are also given on day one.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) are continued at their pretreatment doses if therapeutic levels have been achieved. As an alternative, tacrolimus can be substituted for cyclosporine.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rejection episodes resistant to corticosteroids, grade 2 R rejections associated with hemodynamic compromise, and all grade 3 R rejections should be treated with antithymocyte globulin or OKT3. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Severe or refractory rejection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endomyocardial biopsy verification of reversal of rejection is generally obtained for all treated episodes of rejection:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For corticosteroids, a biopsy is generally obtained one week after the initial biopsy that showed rejection; a second biopsy should be performed one week later to verify that recurrence has not occurred.",
"     </li>",
"     <li>",
"      For antithymocyte globulin and OKT3, the follow-up biopsies are typically obtained at the end of the course of therapy and then one week later.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapy for rejection should be modified or stopped prior to completion of the full course if the patient has a documented infection with resolution of rejection on endomyocardial biopsy.",
"     </li>",
"     <li>",
"      For resistant or recurrent rejection, a course of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      should be given followed by another course of antibody therapy, if necessary.",
"     </li>",
"     <li>",
"      For recalcitrant or frequently recurring rejection, the administration of photopheresis may be helpful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antibody-mediated rejection (AMR) is often treated with a combination of plasmapheresis, intravenous gamma globulin, anti-thymocyte antibodies, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    .",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/1\">",
"      Hunt, SA. Complications of heart transplantation. J Heart Transplant 1983; 3:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/2\">",
"      Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/3\">",
"      Winters GL, Marboe CC, Billingham ME. The International Society for Heart and Lung Transplantation grading system for heart transplant biopsy specimens: clarification and commentary. J Heart Lung Transplant 1998; 17:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/4\">",
"      Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/5\">",
"      Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/6\">",
"      Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/7\">",
"      Schleimer RP, Jacques A, Shin HS, et al. Inhibition of T cell-mediated cytotoxicity by anti-inflammatory steroids. J Immunol 1984; 132:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/8\">",
"      Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 1987; 139:4129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/9\">",
"      Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol 1982; 129:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/10\">",
"      Dinarello CA, Mier JW. Lymphokines. N Engl J Med 1987; 317:940.",
"     </a>",
"    </li>",
"    <li>",
"     Burdick JF. The biology of immunosuppression with anti-lymphocyte antibodies. In: Kidney Transplant Rejection: Diagnosis and Treatment, Williams GM, Burdick JF, Solez K (Eds), Marcel Decker, New York 1988. p.307.",
"    </li>",
"    <li>",
"     Cosimi AB, Delmonico FL. Antilymphocyte antibody immunosuppressive therapy. In: Kidney Transplant Rejection: Diagnosis and Treatment, Williams GM, Burdick JF, Solez K (Eds), Marcel Decker, New York 1988. p.335.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/13\">",
"      Abouna GM, al-Abdullah IH, Kelly-Sullivan D, et al. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation 1995; 59:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/14\">",
"      Uber WE, Uber LA, VanBakel AB, et al. CD3 monitoring and thymoglobulin therapy in cardiac transplantation: clinical outcomes and pharmacoeconomic implications. Transplant Proc 2004; 36:3245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/15\">",
"      Bia MJ, Andiman W, Gaudio K, et al. Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection posttransplantation. Transplantation 1985; 40:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/16\">",
"      Madaio MP, Spiegel JE, Levey AS. Life-threatening thrombocytopenia complicating antithymocyte globulin therapy for acute kidney transplant rejection. Evidence of in situ immune complex formation on the platelet surface. Transplantation 1988; 45:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/17\">",
"      Kammer GM, Kurrasch R, Scillian JJ. Capping of the surface OKT3 binding molecule prevents the T-cell proliferative response to antigens: evidence that this molecule conveys the activation signal. Cell Immunol 1984; 87:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/18\">",
"      Shield CF 3rd, Norman DJ. Immunologic monitoring during and after OKT3 therapy. Am J Kidney Dis 1988; 11:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/19\">",
"      Caillat-Zucman S, Blumenfeld N, Legendre C, et al. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells. Transplantation 1990; 49:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/20\">",
"      Schroeder TJ, First MR. Monoclonal antibodies in organ transplantation. Am J Kidney Dis 1994; 23:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/21\">",
"      Winters GL, Loh E, Schoen FJ. Natural history of focal moderate cardiac allograft rejection. Is treatment warranted? Circulation 1995; 91:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/22\">",
"      Lloveras JJ, Escourrou G, Delisle MB, et al. Evolution of untreated mild rejection in heart transplant recipients. J Heart Lung Transplant 1992; 11:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/23\">",
"      Brunner-La Rocca HP, S&uuml;tsch G, Schneider J, et al. Natural course of moderate cardiac allograft rejection (International Society for Heart Transplantation grade 2) early and late after transplantation. Circulation 1996; 94:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/24\">",
"      Park MH, Starling RC, Ratliff NB, et al. Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection. J Heart Lung Transplant 1999; 18:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/25\">",
"      Hosenpud JD, Norman DJ, Pantely GA. Low-dose oral prednisone in the treatment of acute cardiac allograft rejection not associated with hemodynamic compromise. J Heart Transplant 1990; 9:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/26\">",
"      Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/27\">",
"      Taylor DO, Yowell RL, Kfoury AG, et al. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 2000; 19:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/28\">",
"      Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/29\">",
"      Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant 2001; 20:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/30\">",
"      Hodges AM, Lyster H, McDermott A, et al. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation 2012; 93:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/31\">",
"      Bierl C, Miller B, Prak EL, et al. Antibody-mediated rejection in heart transplant recipients: potential efficacy of B-cell depletion and antibody removal. Clin Transpl 2006; :489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/32\">",
"      Almuti K, Haythe J, Dwyer E, et al. The changing pattern of humoral rejection in cardiac transplant recipients. Transplantation 2007; 84:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/33\">",
"      Garrett HE Jr, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant 2005; 24:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/34\">",
"      Costanzo-Nordin MR, McManus BM, Wilson JE, et al. Efficacy of photopheresis in the rescue therapy of acute cellular rejection in human heart allografts: a preliminary clinical and immunopathologic report. Transplant Proc 1993; 25:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/35\">",
"      Lehrer MS, Rook AH, Tomaszewski JE, DeNofrio D. Successful reversal of severe refractory cardiac allograft rejection by photopheresis. J Heart Lung Transplant 2001; 20:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/36\">",
"      Dall'Amico R, Livi U, Milano A, et al. Extracorporeal photochemotherapy as adjuvant treatment of heart transplant recipients with recurrent rejection. Transplantation 1995; 60:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/37\">",
"      Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998; 339:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/38\">",
"      Frist WH, Winterland AW, Gerhardt EB, et al. Total lymphoid irradiation in heart transplantation: adjunctive treatment for recurrent rejection. Ann Thorac Surg 1989; 48:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/39\">",
"      Salter MM, Kirklin JK, Bourge RC, et al. Total lymphoid irradiation in the treatment of early or recurrent heart rejection. J Heart Lung Transplant 1992; 11:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/40\">",
"      Olsen SL, O'Connell JB, Bristow MR, Renlund DG. Methotrexate as an adjunct in the treatment of persistent mild cardiac allograft rejection. Transplantation 1990; 50:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/41\">",
"      Costanzo MR, Koch DM, Fisher SG, et al. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 1997; 16:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/42\">",
"      Armitage JM, Kormos RL, Morita S, et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg 1992; 54:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/43\">",
"      Yamani MH, Starling RC, Pelegrin D, et al. Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. J Heart Lung Transplant 2000; 19:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/44\">",
"      Freudenberger R, Alexis J, Gass A, et al. Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy. J Heart Lung Transplant 1999; 18:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/45\">",
"      Renlund DG, Gopinathan SK, Kfoury AG, Taylor DO. Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. Clin Transplant 1996; 10:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/46\">",
"      Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/47\">",
"      Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/48\">",
"      Hosenpud JD, Bennett LE. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation 2001; 72:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/49\">",
"      Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/50\">",
"      Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14441/abstract/51\">",
"      Hiatt WR, Nissen SE, Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration. New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md. Circulation 2006; 113:e394.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3520 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-201.211.0.116-1851F3E721-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14441=[""].join("\n");
var outline_f14_6_14441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ISHLT grading system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DRUGS USED TO TREAT ACUTE CELLULAR REJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antithymocyte globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Monoclonal OKT3 antibody",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT OPTIONS FOR ACUTE REJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hemodynamic compromise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Grade 1 R",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Grade 2 R without hemodynamic compromise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Severe or refractory rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Issues related to use of OKT3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antibiotic and antiviral prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute antibody-mediated (humoral) rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RESISTANT OR RECURRENT REJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Photopheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Total lymphoid irradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Changes in maintenance immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Mycophenolate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Everolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=related_link\">",
"      Acute cardiac allograft rejection: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32649?source=related_link\">",
"      Induction immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=related_link\">",
"      Pathogenesis of and risk factors for cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=related_link\">",
"      Patient information: Heart transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=related_link\">",
"      Patient information: Heart transplantation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=related_link\">",
"      Prevention and treatment of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_6_14442="Surgical management of potentially resectable hepatocellular carcinoma";
var content_f14_6_14442=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical management of potentially resectable hepatocellular carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/6/14442/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14442/contributors\">",
"     Steven A Curley, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14442/contributors\">",
"     Carlton C Barnett, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14442/contributors\">",
"     Eddie K Abdalla, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/6/14442/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14442/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14442/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/6/14442/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/6/14442/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/6/14442/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) is an aggressive tumor that often occurs in the setting of chronic liver disease and cirrhosis. It is typically diagnosed late in its course, and the median survival following diagnosis is approximately 6 to 20 months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/1\">",
"     1",
"    </a>",
"    ]. The mainstay of therapy is surgical resection, but several other treatment modalities may also have a role.",
"   </p>",
"   <p>",
"    Options for surgical resection are in part determined by the severity of underlying liver disease, which is reflected by the Child-Pugh classification (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ) or the Model for End-stage Liver Disease (MELD) score, which is a prospectively developed and validated chronic liver disease severity scoring system to predict survival (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=see_link&amp;anchor=H12#H12\">",
"     \"Assessing surgical risk in patients with liver disease\", section on 'MELD score'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical resection of HCC will be reviewed here. The clinical manifestations and diagnosis of HCC, an overview of the treatment approach to HCC, nonsurgical local ablative options, liver transplantation, and adjuvant and neoadjuvant therapy are reviewed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"       \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43063?source=see_link\">",
"       \"Overview of treatment approaches for hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=see_link\">",
"       \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=see_link\">",
"       \"Liver transplantation for hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21978?source=see_link\">",
"       \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT ALGORITHMS FOR HCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general approach to treatment of HCC is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef57014 \" href=\"UTD.htm?40/37/41567\">",
"     algorithm 1",
"    </a>",
"    ). The suggested approach is useful for conceptualizing the various treatment options that are available for individual patients but may not be applicable in all settings. A discussion of these issues and an overview of available therapies for HCC are summarized elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43063?source=see_link\">",
"     \"Overview of treatment approaches for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H457344296\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF COMPREHENSIVE MULTIDISCIPLINARY CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A majority of patients with HCC have underlying liver disease, which may be related to infection with hepatitis B virus (HBV)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatitis C virus (HCV). Furthermore, patients with chronic liver disease who undergo any form of therapy for HCC are at high risk for recurrent disease and progression to liver failure. It is important that patients with more advanced liver disease have proper monitoring and assessment of their underlying liver disease, which may have a major impact on longer-term survival. Comprehensive care of patients with cirrhosis includes antiviral therapy for HBV and HCV, immunization against hepatitis A and HBV (if indicated), and endoscopic screening and surveillance for varices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREOPERATIVE ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Curative partial hepatectomy is the optimal treatment for HCC. The assessment of potential resectability of HCC focuses on two main issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The likelihood of the disease being confined to the liver",
"     </li>",
"     <li>",
"      Whether the size and location of the tumor relative to the patient&rsquo;s underlying liver function will permit resection without excess morbidity and mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients ideally suited for resection have localized HCC confined to the liver without radiographic evidence of invasion of the vasculature of the liver (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54856 \" href=\"UTD.htm?33/39/34416\">",
"     image 1",
"    </a>",
"    ), preserved hepatic function, and no evidence of portal hypertension (although a minor resection could be considered in some patients with portal hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Resection can provide benefits for rare patients with multifocal HCC and in rare patients with major vascular invasion as well [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only one-half of patients initially thought to be resectable and referred for surgery actually have resectable tumors. Among the reasons for unresectability are the extent of intrahepatic disease, extrahepatic extension, inadequate functional hepatic reserve, and involvement of the confluence of the portal or hepatic veins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite even aggressive surgical approaches, most patients have disease (either HCC or underlying chronic liver disease) that is too extensive to permit treatment with \"curative\" intent. In high-incidence regions of the world, only 10 to 15 percent of newly diagnosed patients are candidates for standard resection, whereas in low incidence areas, between 15 and 30 percent of patients have potentially resectable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/7,8,11-13\">",
"     7,8,11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Determining the extent of tumor involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic delineation of tumor extent is best achieved with dynamic multiphase computed tomography (CT), for which the nonenhanced, hepatic arterial phase is assessed separately from the portal venous phase. Small HCCs are often isodense to the liver in the portal venous phase and may be missed on a conventional \"screening\" CT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/14\">",
"     14",
"    </a>",
"    ]. In contrast, arterial phase imaging detects 30 to 40 percent more tumor nodules than conventional CT and may be the only phase needed to demonstrate the tumor in 7 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of other imaging studies in the evaluation of primary HCC, including magnetic resonance imaging (MRI) and CT arteriography, is discussed in detail elsewhere. In general, these studies add little to thin-slice, multiphasic imaging except in highly-selected cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although characterized in few reports, the recognized sites of metastatic spread of HCC are lung, bone, peritoneum, and adrenals. Although these sites of disease may be demonstrated by standard imaging techniques, peritoneal disease is frequently missed. The rate of extrahepatic disease spread at diagnosis is overall low, and staging chest CT and bone scans do not provide additional information on metastases in patients who have localized HCC. However, the risk of extrahepatic metastatic disease is higher in patients with a tumor size &gt;5 cm, and in those with vascular invasion, and these studies may be obtained in this group, particularly in the presence of worrisome symptoms such as bone pain, prior to attempted resection. The utility of 18-fluorodeoxyglucose positive emission tomography (FDG-PET) scanning for detection of otherwise occult distant metastatic disease is uncertain and not recommended in guidelines from the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/17\">",
"     17",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Patterns of metastatic spread'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'PET scanning'",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    There is no general rule regarding tumor location, size or number in selecting patients with HCC for resection; however, most consider stage IIIB, IIIC, IVA, and IVB disease to be incurable by resection (",
"    <a class=\"graphic graphic_table graphicRef63333 \" href=\"UTD.htm?1/45/1757\">",
"     table 2",
"    </a>",
"    ). These stages are defined by invasion of a major portal or hepatic vein, direct invasion of organs other than the gallbladder, perforation of the visceral peritoneum, and nodal or distant metastases. However, hepatic resection for stages IIIB, IIIC, and IVA disease may be considered in a center of excellence because clinical benefits and long-term survival can be achieved in a properly selected, though admittedly small, minority of patients. &nbsp;",
"   </p>",
"   <p>",
"    The impact of size, multifocality, regional nodal involvement, and tumor rupture on resectability is debated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with small tumors are less likely to harbor occult vascular invasion and have a better outcome after surgery. Patients with a solitary HCC without vascular invasion have a similar survival regardless of tumor size (",
"      <a class=\"graphic graphic_figure graphicRef59785 \" href=\"UTD.htm?27/54/28512\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/3,5,18-27\">",
"       3,5,18-27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although many surgeons restrict eligibility for resection to patients with tumors that are &le;5 cm in diameter, there is no general rule regarding tumor size for selection of patients for resection. Outcomes for patients with large tumors were studied in a multi-institutional series of 300 patients undergoing resection for HCC &ge;10 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/5\">",
"       5",
"      </a>",
"      ]. The five-year overall survival rate was 27 percent for all patients combined. In multivariate analysis, four clinical factors (serum alfa-fetoprotein [AFP] &ge;1000",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      multiple tumor nodules, presence of major vascular invasion, and presence of severe fibrosis) were independent predictors of poor outcome. Five-year survival rates were significantly worse for patients with one or two, or three to four risk factors compared with those with none (19, 14, and 49 percent, respectively). However, these clinical factors were not reliable predictors of outcome. Fifty-six percent of patients with one or two risk factors and 20 percent of those with three or four risk factors had T1 or T2 disease on pathologic evaluation.",
"     </li>",
"     <li>",
"      Multifocality increases the T classification (",
"      <a class=\"graphic graphic_table graphicRef63333 \" href=\"UTD.htm?1/45/1757\">",
"       table 2",
"      </a>",
"      ) and is associated with lower survival, but does not exclude a good outcome in selected patients. In several studies, resection of multifocal HCC was associated with five-year survival rates of approximately 24 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/19,28,29\">",
"       19,28,29",
"      </a>",
"      ]. Patients with multinodular HCC who appeared to benefit from resection were those with sufficient liver reserve to tolerate resection, without extrahepatic disease and without major vascular invasion. Size alone is not a contraindication for resection of multinodular HCC. Unfortunately, many patients have multifocal disease that is underestimated even by high-quality CT and MRI.",
"     </li>",
"     <li>",
"      Lymph node metastases are uncommon overall (between 1 and 8 percent), but their presence portends a worse outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/11,30,31\">",
"       11,30,31",
"      </a>",
"      ]. Preoperative detection of nodal metastases is limited by the frequent presence of benign nodal enlargement, most often involving the porta hepatis and portacaval space, in patients with cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/32\">",
"       32",
"      </a>",
"      ]. Highly suspicious nodes based on enhancement similar to the intrahepatic HCC lesions indicate the need for biopsy in a patient being considered for resection. Outcomes are worse in patients who have regional nodal involvement. Although practice is variable [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/33-36\">",
"       33-36",
"      </a>",
"      ], we consider that&nbsp;documented regional (portal) nodal involvement precludes potentially curative resection for hepatocellular carcinoma. However, lymph node involvement is",
"      <strong>",
"       not",
"      </strong>",
"      a contraindication to resection for patients with fibrolamellar HCC; these patients undergo a formal lymph node dissection. Prior to planned hepatic resection, exploratory laparoscopy and intraoperative ultrasound may help identify extrahepatic metastatic disease that precludes hepatic resection. (See",
"      <a class=\"local\" href=\"#H1061867308\">",
"       'Intraoperative staging'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Approximately 10 percent of HCC spontaneously rupture. The clinical picture is that of acute abdominal pain and distension, hypotension, and a drop in the hematocrit. Initially, these patients should be stabilized hemodynamically, followed by transarterial embolization for control of bleeding. If unsuccessful, emergency surgery may be required [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Clinical features'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Although the presence of a tumor rupture suggests a high likelihood of peritoneal seeding and usually a poor outcome from resection, this is not inevitable. If bleeding can be controlled with embolization, a formal staging evaluation should be undertaken, followed by laparoscopic exploration and a subsequent attempt at resection, if feasible [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/38\">",
"       38",
"      </a>",
"      ]. Several retrospective series suggest a low but defined long-term survival rate following resection in such situations [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/38-44\">",
"       38-44",
"      </a>",
"      ]. In a large case series, the 30-day mortality rate in 154 of 1716 patients who were newly diagnosed with HCC after presenting with spontaneous rupture was 38 percent. [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/39\">",
"       39",
"      </a>",
"      ]. After initial stabilization and clinical evaluation, 33 underwent hepatic resection. Although the median survival after hepatectomy was worse in ruptured compared with nonruptured cases (26 versus 49 months) and the rate of extrahepatic recurrence was higher (46 versus 26 percent), eight patients (24 percent) remained alive without recurrent disease after a median 45 months follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with liver-confined HCC who are not candidates for standard resection, alternative treatment modalities include interstitial therapies, transarterial chemoembolization (TACE), localized ablative techniques involving either freezing or cryoablation, chemical desiccation (eg, ethanol or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    ablation), or heating with laser, microwave, or radiofrequency ablation (RFA). These nonsurgical local ablative treatments are discussed elsewhere. A general treatment algorithm for HCC is presented in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef57014 \" href=\"UTD.htm?40/37/41567\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=see_link\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Assessment of hepatic reserve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative mortality for HCC is related to the severity of the underlying liver disease being twice as high in cirrhotic as in noncirrhotic patients (5 versus 10 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/45\">",
"     45",
"    </a>",
"    ]. With proper patient selection, operative mortality, even in cirrhotic patients, should be low [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/46\">",
"     46",
"    </a>",
"    ]. However, only about 5 to 15 percent of patients presenting with HCC will have adequate hepatic reserve to undergo resection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/47\">",
"     47",
"    </a>",
"    ]. As a general rule, patients who have complications of cirrhosis, such as bleeding, ascites, or marked portal hypertension, have insufficient hepatic reserve to withstand a partial hepatectomy.",
"   </p>",
"   <p>",
"    In patients with cirrhosis, surgical resection is most safely performed in those with Child-Pugh class A disease (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ) who have a normal bilirubin level and well-preserved liver function. However, even Child-Pugh class A patients may develop rapid hepatic decompensation following surgery due to limited functional hepatic reserve. In one study of 29 such patients with HCC who underwent resection, 11 (38 percent) developed liver failure that was unresolved three months postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/4\">",
"     4",
"    </a>",
"    ]. Although helpful, the Child-Pugh classification and other tools for assessing underlying liver disease, such as the Model for End-stage Liver Disease (MELD) score (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), are not adequate for predicting patients with sufficient hepatic reserve for major resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=see_link&amp;anchor=H12#H12\">",
"     \"Assessing surgical risk in patients with liver disease\", section on 'MELD score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The volume and function of residual liver remnant can be determined using hepatic volumetry, which can be performed prior to and following portal vein embolization, which can be used in selected patients to increase the volume of the liver remnant prior to major hepatic resection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Portal vein embolization is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H1061867819\">",
"     'Portal vein embolization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many groups (especially in Asia) use clearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32450?source=see_link\">",
"     indocyanine green",
"    </a>",
"    (ICG-15) at 15 minutes as a defining criterion for selection of resection type [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Absence of portal hypertension as measured by the wedged hepatic venous pressure gradient may also be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transarterial chemoembolization (TACE) has been proposed as a complementary procedure prior to PVE in patients with HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/52-62\">",
"     52-62",
"    </a>",
"    ]. TACE eliminates the arterial blood supply to the tumor and also embolizes potential arterioportal shunts that attenuate the effects of PVE in cirrhotic livers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/53,63\">",
"     53,63",
"    </a>",
"    ]. Most reserve the \"double embolization\" procedure for patients with HCC in patients with liver disease who require right hepatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/52,53,63\">",
"     52,53,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1061867819\">",
"    <span class=\"h2\">",
"     Portal vein embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative portal vein embolization (PVE) is a valuable adjunct to major liver resection, particularly for right-sided tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/48,64-66\">",
"     48,64-66",
"    </a>",
"    ]. PVE can initiate hypertrophy of the anticipated future liver remnant and allow a more extensive resection. Some reports have shown accelerated tumor growth in the liver after PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. However, problems with tumor growth are not seen when all of the tumor-bearing areas of the liver are embolized [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In considering the need for PVE, the ratio of future liver remnant and total estimated liver volume should be calculated. If the volume of the future liver remnant is less than 20 percent in a patient with a normal liver, or less than 40 percent in a patient with a cirrhotic liver, PVE should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/70\">",
"     70",
"    </a>",
"    ]. Systemic disease such as diabetes may limit hepatic hypertrophy and the success of the procedure.",
"   </p>",
"   <p>",
"    Two techniques can be used for PVE: transileocolic portal embolization (TIPE) and percutaneous transhepatic portal embolization (PTPE).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The TIPE procedure is performed via a minilaparotomy and requires general anesthesia.",
"     </li>",
"     <li>",
"      The percutaneous approach (PTPE), which is more commonly used [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/64\">",
"       64",
"      </a>",
"      ], can be performed in the radiology suite with local anesthesia and conscious sedation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Volumetric assessment of the liver volume with CT imaging should be done before PVE and repeated after PVE before undertaking surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Determining the extent of tumor involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H882401073\">",
"    <span class=\"h3\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are at least five potential benefits to the use of PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postresection morbidity is diminished, as evidenced by minimal reductions in post-resection liver function [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/49\">",
"       49",
"      </a>",
"      ], fewer pulmonary complications, and decreased length of intensive care unit and inpatient hospitalization.",
"     </li>",
"     <li>",
"      Patients who were initially unresectable because of insufficient remaining normal hepatic parenchyma can undergo resection for potential cure.",
"     </li>",
"     <li>",
"      Subclinical disease or rapid progression may be detected prior to definitive surgery on postembolization imaging studies, thus preventing an unnecessary operation.",
"     </li>",
"     <li>",
"      The volume of remaining liver standardized to patient size (body surface area) predicts mortality after resection in cirrhotics, and the increase in functional liver volume achieved by PVE may decrease mortality of resection in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/48,49,72\">",
"       48,49,72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The absence of compensatory hypertrophy in response to successful PVE indicates the patient is not suitable for major hepatic resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The success of PVE was addressed in a meta-analysis of data from 37 published series of PVE prior to liver resection totaling 1088 patients (265 with HCC, the remainder with cholangiocarcinoma or liver metastases) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/65\">",
"     65",
"    </a>",
"    ]. Four weeks after PVE, there was an overall 10 to 12 percent increase in liver volume that was independent of technique, and 85 percent of patients underwent planned laparotomy for attempted major hepatectomy. Reasons for not proceeding to surgery included inadequate hypertrophy of the remnant liver in 18, severe progression of liver metastases (n = 43), extrahepatic spread (n = 35), or other (refusal of surgery, poor medical condition, altered treatment approach for a variety of reasons, etc; n = 35). Of the patients who underwent laparotomy, resection was not possible in 27, because of advanced, unresectable disease. Following resection, 23 patients had transient liver failure (2.5 percent) with 7 patients dying of acute liver failure (0.8 percent).",
"   </p>",
"   <p>",
"    The benefit of PVE was further shown in a retrospective series which compared outcomes among patients who underwent major hepatic resection for HCC at a single institution with (n = 21) or without (n = 33) PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/52\">",
"     52",
"    </a>",
"    ]. In the PVE group, the median standardized future liver remnant volume pre- and post-PVE was 23 and 34 percent, respectively. Patients who underwent PVE had fewer major complications (10 versus 36 percent) and no 90-day mortality (compared with 18 percent for major resection without PVE). Overall survival at three years with and without PVE was not significantly different at 82 and 63 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1061867308\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopy and intraoperative ultrasound (IOUS) may improve the selection of patients for potentially curative resection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/10,73,74\">",
"     10,73,74",
"    </a>",
"    ]. IOUS can accurately determine the size of the primary tumor and detect lymph node or portal or hepatic vein involvement, which precludes curative resection. In one series that included 91 patients with HCC who underwent laparoscopic IOUS prior to resection, a planned laparotomy was aborted in 16 percent because of unresectable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/10\">",
"     10",
"    </a>",
"    ]. Another benefit of IOUS is the identification of major intrahepatic vascular structures, which can be used to guide segmental or nonanatomic resections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15992?source=see_link\">",
"     \"Diagnostic staging laparoscopy: General principles for staging primary digestive malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H882401841\">",
"    <span class=\"h1\">",
"     HEPATIC RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of hepatic resection depends upon the location of the lesion(s), and presence and severity of cirrhosis.",
"   </p>",
"   <p>",
"    Anatomic resection of liver is performed by following the planes of the liver segments as delineated by Couinaud (",
"    <a class=\"graphic graphic_figure graphicRef81897 \" href=\"UTD.htm?13/35/13878\">",
"     figure 2",
"    </a>",
"    ). Anatomic hepatic resection is accomplished by selective ligation of the inflow portal triad and ligation of dominant outflow hepatic veins to the segment(s) that will be resected [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/78\">",
"     78",
"    </a>",
"    ]. If subsegmental resection is planned, intraoperative ultrasonography facilitates localization of the intrahepatic vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. Nonanatomic resection may be necessary to minimize the loss of functioning parenchyma in patients with cirrhosis.",
"   </p>",
"   <p>",
"    In the noncirrhotic liver, up to two-thirds of functional parenchyma can be removed safely depending upon the age of the patient. For cirrhotic patients, the resection needs to remove the least amount of nonmalignant parenchyma possible to preserve postoperative liver function (",
"    <a class=\"graphic graphic_picture graphicRef64800 \" href=\"UTD.htm?19/17/19736\">",
"     picture 1",
"    </a>",
"    ). Nonanatomic and wedge resection are acceptable, but some studies suggest that anatomic segmental resections provide longer overall and disease-free survival when feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/82\">",
"     82",
"    </a>",
"    ]. Because the capacity for liver regeneration is impaired in cirrhotics, resection is generally limited to &lt;25 percent of the functional parenchyma. However, some patients maintain adequate functional hepatic reserve even after a hemihepatectomy, particularly if preoperative portal vein embolization (PVE) is used to induce compensatory hypertrophy in the future liver remnant (the region of liver that will remain after resection). (See",
"    <a class=\"local\" href=\"#H1061867819\">",
"     'Portal vein embolization'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H882402433\">",
"    <span class=\"h2\">",
"     No touch technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some surgeons have advocated an anterior or \"no touch\" technique to resection of HCC. This approach utilizes initial transection of the liver parenchyma to the inferior vena cava (IVC), and ligation of the inflow and outflow vessels before mobilization of the hemiliver. The advocates of this technique hypothesize that separation of the hemiliver and the tumor from the IVC before mobilization reduces the risk of vessel rupture and theoretically minimizes the potential for tumor cell dissemination. A prospective trial of 120 patients (87 percent with underlying cirrhosis or hepatitis) directly compared this technique with conventional resection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/6\">",
"     6",
"    </a>",
"    ]. Compared with the conventional technique, the anterior approach was associated with less blood loss, lower transfusion requirements, significantly longer median overall survival (&gt;68 versus 23 months), and lower hospital mortality (1.7 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/6\">",
"     6",
"    </a>",
"    ]. However, recurrence and disease-free survival rates were similar between the two groups. The results of this study have been questioned because the rates of massive blood loss (28 percent) and perioperative mortality (10 percent) using the conventional approach for HCC resection were higher than usually reported, which may reflect the larger proportion of patients with cirrhosis or hepatitis in this series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/83\">",
"     83",
"    </a>",
"    ]. We feel that further investigation of the anterior approach is required before concluding its superiority to the conventional approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H882402440\">",
"    <span class=\"h2\">",
"     Central hepatic resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management of centrally located HCC (ie, those in segments IV, V, and VIII, (",
"    <a class=\"graphic graphic_figure graphicRef81897 \" href=\"UTD.htm?13/35/13878\">",
"     figure 2",
"    </a>",
"    ) is more problematic. Extended right or left hemihepatectomy is the treatment of choice if potentially curative surgery can be undertaken safely. However, these resections can be associated with high morbidity and mortality rates due to insufficient residual functional liver parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. An alternative approach, mesohepatectomy (also called central hepatectomy), has been proposed in which the central liver segments IV",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    V, and VIII (with or without segment I) are removed, and the lateral sectors remain intact [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although randomized trials have not been conducted, the available data suggest that mesohepatectomy is a reasonable alternative to extended hepatic resection for centrally located tumors, giving acceptable oncologic outcomes with less parenchymal loss [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/87,89-92\">",
"     87,89-92",
"    </a>",
"    ]. However, in some centers, mesohepatectomy is seldom used, partly because it is a complex and technically demanding procedure that requires two hepatic resection planes and bilateral biliary reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/93\">",
"     93",
"    </a>",
"    ]. This results in a higher risk of bleeding and postoperative bile leak as well as long-term biliary stricture and biliary dysfunction. Some data suggest that portal vein embolization followed by standard hepatectomy might be a safer approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laparoscopic hepatic resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of minimally invasive resection of benign hepatic tumors has led to interest in laparoscopic approaches to surgery for HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/94-101\">",
"     94-101",
"    </a>",
"    ]. The available literature is limited by the lack of prospective trials and the paucity of information on long-term oncologic outcomes. The available data support the view that, in experienced hands, laparoscopic resection is feasible and safe, but it is also highly technically demanding and should be undertaken only in high volume centers with a program of graduated procedural complexity.",
"   </p>",
"   <p>",
"    The following represents the range of findings in patients undergoing laparoscopic resection for HCC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 116 patients who underwent laparoscopic liver resection for HCC (most with Child-Pugh A cirrhosis), 97 had less than two segments removed, while 19 had more extensive surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/96\">",
"       96",
"      </a>",
"      ]. The patients who had more extensive surgery had a longer operative time (176 versus 152 minutes), more intraoperative blood loss (329 versus 100 mL), and more required blood transfusion (16 versus 5 percent) than those who had less than two segments removed. The mean hospital stay was six days in both groups. There were no perioperative deaths, and the postoperative complication rate was low in both groups (6 versus 5 percent). At a median follow-up of 94 months, three- and five-year survival rates for the group undergoing less extensive surgery was 66 and 59 percent, respectively, while the corresponding rates for those who had more extensive resections were 74 and 62 percent, respectively.",
"     </li>",
"     <li>",
"      Somewhat less favorable operative results were noted in a report of 57 patients undergoing laparoscopic liver resection for HCC, including 46 with cirrhosis, mostly Child-Pugh A [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/95\">",
"       95",
"      </a>",
"      ]. Tumor location was anterolateral in 34 and posterosuperior in 23. Three required conversion to an open procedure intraoperatively, one for uncontrolled bleeding and two because of positive gross margins after laparoscopic resection. Patients who underwent posterosuperior laparoscopic resection had a significantly longer mean operative time (319 versus 261 minutes), but rates of blood loss, intraoperative blood transfusion, mean postoperative stay (averaging 10.6 to 12 days) and perioperative complication rates were similar. Long-term oncologic outcomes were not reported.",
"     </li>",
"     <li>",
"      Some authors have reported comparisons with historical or selected series of open hepatic resection, although the validity of such comparisons is doubtful [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/97,102\">",
"       97,102",
"      </a>",
"      ]. In one such series, outcomes of 23 consecutive cirrhotic patients undergoing laparoscopic resection for HCC were compared with a historical group of 23 patients who underwent open resection and were matched for age, gender, tumor location and size, and severity of cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/97\">",
"       97",
"      </a>",
"      ]. One patient in the laparoscopic group was converted to an open procedure because of inadequate exposure. Mean operative time was longer for laparoscopic surgery (148 versus 125 minutes), whereas the frequency of intraoperative blood transfusion (0 versus 17 percent), mean hospital stay (8.3 versus 12 days), and postoperative complication rate (13 versus 48 percent) all favored laparoscopic surgery. Perioperative mortality and two-year survival rates were comparable in both groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative morbidity and mortality is related to the extent of operative resection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/103-106\">",
"     103-106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major postoperative complications include bile leak and pleural effusion. As an example, in a series of 416 patients who underwent liver resection, the most frequent complications were bile leak (8 percent) and pleural effusion (7 percent). A postoperative intensive care unit stay more than two days was required in 18 percent of patients, and the median hospital stay was 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 30-day perioperative mortality rate in modern series of HCC resection ranges widely from 1 to 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/7,8,12,13,18,20,107-116\">",
"     7,8,12,13,18,20,107-116",
"    </a>",
"    ]. Most deaths are due to postoperative liver failure and fewer than 10 percent are due to complications from bleeding. The presence of cirrhosis is the most important predictor of postresection liver failure and death. In cirrhotics, the 30-day postoperative mortality ranges from 14 to 24 percent compared with 0.8 to 7 percent for non-cirrhotics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/109,113,115\">",
"     109,113,115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two additional factors influence the development of postoperative liver failure in cirrhotic patients: intraoperative blood loss of &gt;1500 mL and postoperative infection of any type [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/13,116\">",
"     13,116",
"    </a>",
"    ]. Mortality can be reduced by appropriate selection of patients with the inclusion of preoperative volumetry and portal vein embolization when appropriate, and meticulous surgical technique including techniques to minimize blood loss.",
"   </p>",
"   <p>",
"    Consensus is growing that 30-day operative mortality is an inadequate indicator of risk, particularly of postoperative hepatic insufficiency and failure. Using an approach similar to liver transplantation reporting, 90-day mortality rates appear to be a more valuable indicator of outcome of liver resection, especially in the cases of extended resection and resection in patients with diseased livers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/6/14442/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. This relates to the late development of slowly progressive jaundice, ascites, and eventual death, which typically occurs outside the hospital and well after 30 postoperative days in patients with marginal or inadequate liver remnants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17690277\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE AND LONG-TERM OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcomes, the benefit of adjuvant therapy, and recommendations for post-treatment surveillance after potentially curative resection are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21978?source=see_link\">",
"     \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/42/44706?source=see_link\">",
"       \"Patient information: Liver cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1061866831\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatocellular carcinoma (HCC) is an aggressive tumor that often occurs in the setting of chronic liver disease and cirrhosis. A majority of patients with HCC have underlying liver disease, and need comprehensive multidisciplinary care for proper monitoring and assessment of their disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment algorithms for HCC'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H457344296\">",
"       'Importance of comprehensive multidisciplinary care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preoperative evaluation for resection of HCC focuses on the likelihood of disease being confined to the liver, and whether the size and location of the tumor and the patient&rsquo;s underlying liver function will permit resection. The volume and function of residual liver remnant should be assessed by hepatic volumetry. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Preoperative assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Assessment of hepatic reserve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anatomic delineation of tumor extent is best achieved with dynamic multiphase computed tomography (CT), in which the nonenhanced, hepatic arterial and portal venous phases are assessed separately, or with magnetic resonance (MRI) scanning. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Determining the extent of tumor involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative portal vein embolization (PVE) is a valuable adjunct to major liver resection for HCC. PVE can initiate hypertrophy of the anticipated future liver remnant to enable an extended resection that would otherwise leave a remnant liver insufficient to support life following partial hepatectomy. (See",
"      <a class=\"local\" href=\"#H1061867819\">",
"       'Portal vein embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Curative hepatectomy for HCC can be accomplished by anatomic resection, but nonanatomic resection may be necessary to minimize the loss of functioning parenchyma in patients with cirrhosis. In non-cirrhotic patients, up to two-thirds of functional parenchyma can be removed safely whereas resection is generally limited to &lt;25 percent of the functional parenchyma in patients with cirrhosis. Laparoscopic liver resection for HCC in the hands of experienced surgeons is safe; however, larger studies with longer follow-up are required to adequately assess outcomes. (See",
"      <a class=\"local\" href=\"#H882401841\">",
"       'Hepatic resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most deaths following resection of HCC are due to postoperative liver failure. The presence of cirrhosis is the most important predictor of postresection liver failure and death. Perioperative (30-day) mortality for hepatic resection of HCC is between 0.8 and 7 percent for patients without cirrhosis, but 14 to 24 percent for those with cirrhosis (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Postoperative morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/1\">",
"      A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/2\">",
"      Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/3\">",
"      Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/4\">",
"      Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/5\">",
"      Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/6\">",
"      Liu CL, Fan ST, Cheung ST, et al. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg 2006; 244:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/7\">",
"      Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery 1993; 113:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/8\">",
"      Paquet KJ, Koussouris P, Mercado MA, et al. Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. Br J Surg 1991; 78:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/9\">",
"      Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989; 210:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/10\">",
"      Lo CM, Lai EC, Liu CL, et al. Laparoscopy and laparoscopic ultrasonography avoid exploratory laparotomy in patients with hepatocellular carcinoma. Ann Surg 1998; 227:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/11\">",
"      Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver Cancer Study Group of Japan. Ann Surg 1990; 211:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/12\">",
"      Choi TK, Edward CS, Fan ST, et al. Results of surgical resection for hepatocellular carcinoma. Hepatogastroenterology 1990; 37:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/13\">",
"      Nagorney DM, van Heerden JA, Ilstrup DM, Adson MA. Primary hepatic malignancy: surgical management and determinants of survival. Surgery 1989; 106:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/14\">",
"      Miller WJ, Baron RL, Dodd GD 3rd, Federle MP. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology 1994; 193:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/15\">",
"      Oliver JH 3rd, Baron RL, Federle MP, Rockette HE Jr. Detecting hepatocellular carcinoma: value of unenhanced or arterial phase CT imaging or both used in conjunction with conventional portal venous phase contrast-enhanced CT imaging. AJR Am J Roentgenol 1996; 167:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/16\">",
"      Baron RL, Oliver JH 3rd, Dodd GD 3rd, et al. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology 1996; 199:505.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/18\">",
"      Yang LY, Fang F, Ou DP, et al. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 2009; 249:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/19\">",
"      Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/20\">",
"      Nagasue N, Kohno H, Chang YC, et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993; 217:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/21\">",
"      Pandey D, Lee KH, Wai CT, et al. Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol 2007; 14:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/22\">",
"      Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic resection for large hepatocellular carcinoma. Am J Surg 2001; 181:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/23\">",
"      Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic resection for hepatocellular carcinoma in diameter of &gt; or = 10 cm. Hepatogastroenterology 2002; 49:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/24\">",
"      Lee NH, Chau GY, Lui WY, et al. Surgical treatment and outcome in patients with a hepatocellular carcinoma greater than 10 cm in diameter. Br J Surg 1998; 85:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/25\">",
"      Yeh CN, Lee WC, Chen MF. Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. Ann Surg Oncol 2003; 10:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/26\">",
"      Liau KH, Ruo L, Shia J, et al. Outcome of partial hepatectomy for large (&gt; 10 cm) hepatocellular carcinoma. Cancer 2005; 104:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/27\">",
"      Ariizumi S, Kotera Y, Takahashi Y, et al. Impact of hepatectomy for huge solitary hepatocellular carcinoma. J Surg Oncol 2013; 107:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/28\">",
"      Poon RT, Fan ST. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am 2003; 12:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/29\">",
"      Lei HJ, Chau GY, Lui WY, et al. Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg 2006; 203:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/30\">",
"      Ercolani G, Grazi GL, Ravaioli M, et al. The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg 2004; 239:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/31\">",
"      Sun HC, Zhuang PY, Qin LX, et al. Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol 2007; 96:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/32\">",
"      Dodd GD 3rd, Baron RL, Oliver JH 3rd, et al. Enlarged abdominal lymph nodes in end-stage cirrhosis: CT-histopathologic correlation in 507 patients. Radiology 1997; 203:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/33\">",
"      Kobayashi S, Takahashi S, Kato Y, et al. Surgical treatment of lymph node metastases from hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2011; 18:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/34\">",
"      Xiaohong S, Huikai L, Feng W, et al. Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma. World J Surg 2010; 34:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/35\">",
"      Hashimoto M, Matsuda M, Watanabe G. Metachronous resection of metastatic lymph nodes in patients with hepatocellular carcinoma. Hepatogastroenterology 2009; 56:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/36\">",
"      Grobmyer SR, Wang L, Gonen M, et al. Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy. Ann Surg 2006; 244:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/37\">",
"      Recordare A, Bonariol L, Caratozzolo E, et al. Management of spontaneous bleeding due to hepatocellular carcinoma. Minerva Chir 2002; 57:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/38\">",
"      Lang BH, Poon RT, Fan ST, Wong J. Influence of laparoscopy on postoperative recurrence and survival in patients with ruptured hepatocellular carcinoma undergoing hepatic resection. Br J Surg 2004; 91:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/39\">",
"      Liu CL, Fan ST, Lo CM, et al. Management of spontaneous rupture of hepatocellular carcinoma: single-center experience. J Clin Oncol 2001; 19:3725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/40\">",
"      Marini P, Vilgrain V, Belghiti J. Management of spontaneous rupture of liver tumours. Dig Surg 2002; 19:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/41\">",
"      Takebayashi T, Kondo S, Ambo Y, et al. Staged hepatectomy following arterial embolization for ruptured hepatocellular carcinoma. Hepatogastroenterology 2002; 49:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/42\">",
"      Yeh CN, Lee WC, Jeng LB, et al. Spontaneous tumour rupture and prognosis in patients with hepatocellular carcinoma. Br J Surg 2002; 89:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/43\">",
"      Chen MF, Hwang TL, Jeng LB, et al. Clinical experience with hepatic resection for ruptured hepatocellular carcinoma. Hepatogastroenterology 1995; 42:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/44\">",
"      Miyamoto M, Sudo T, Kuyama T. Spontaneous rupture of hepatocellular carcinoma: a review of 172 Japanese cases. Am J Gastroenterol 1991; 86:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/45\">",
"      Colleoni M, Audisio RA, De Braud F, et al. Practical considerations in the treatment of hepatocellular carcinoma. Drugs 1998; 55:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/46\">",
"      Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/47\">",
"      Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999; 19:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/48\">",
"      Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001; 88:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/49\">",
"      Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003; 237:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/50\">",
"      Hemming AW, Scudamore CH, Shackleton CR, et al. Indocyanine green clearance as a predictor of successful hepatic resection in cirrhotic patients. Am J Surg 1992; 163:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/51\">",
"      Makuuchi M, Kosuge T, Takayama T, et al. Surgery for small liver cancers. Semin Surg Oncol 1993; 9:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/52\">",
"      Palavecino M, Chun YS, Madoff DC, et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009; 145:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/53\">",
"      Ogata S, Belghiti J, Farges O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg 2006; 93:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/54\">",
"      Wu CC, Ho YZ, Ho WL, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/55\">",
"      Sasaki A, Iwashita Y, Shibata K, et al. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 2006; 32:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/56\">",
"      Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000; 7:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/57\">",
"      Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol 2009; 135:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/58\">",
"      Harada T, Matsuo K, Inoue T, et al. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 1996; 224:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/59\">",
"      Uchida M, Kohno H, Kubota H, et al. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 1996; 20:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/60\">",
"      Adachi E, Matsumata T, Nishizaki T, et al. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer 1993; 72:3593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/61\">",
"      Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg 1998; 15:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/62\">",
"      Lee KT, Lu YW, Wang SN, et al. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol 2009; 99:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/63\">",
"      Aoki T, Imamura H, Hasegawa K, et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 2004; 139:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/64\">",
"      Imamura H, Shimada R, Kubota M, et al. Preoperative portal vein embolization: an audit of 84 patients. Hepatology 1999; 29:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/65\">",
"      Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008; 247:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/66\">",
"      Yoo H, Kim JH, Ko GY, et al. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma. Ann Surg Oncol 2011; 18:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/67\">",
"      Wakabayashi H, Ishimura K, Okano K, et al. Is preoperative portal vein embolization effective in improving prognosis after major hepatic resection in patients with advanced-stage hepatocellular carcinoma? Cancer 2001; 92:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/68\">",
"      Hayashi S, Baba Y, Ueno K, et al. Acceleration of primary liver tumor growth rate in embolized hepatic lobe after portal vein embolization. Acta Radiol 2007; 48:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/69\">",
"      Ribero D, Abdalla EK, Madoff DC, et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007; 94:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/70\">",
"      Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/71\">",
"      Vauthey JN, Chaoui A, Do KA, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000; 127:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/72\">",
"      Shirabe K, Shimada M, Gion T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 1999; 188:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/73\">",
"      Hemming AW, Nagy AG, Scudamore CH, Edelmann K. Laparoscopic staging of intraabdominal malignancy. Surg Endosc 1995; 9:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/74\">",
"      Fornari F, Civardi G, Cavanna L, et al. Laparoscopic ultrasonography in the study of liver diseases. Preliminary results. Surg Endosc 1989; 3:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/75\">",
"      Makuuchi M, Hasegawa H, Yamazaki S, et al. The use of operative ultrasound as an aid to liver resection in patients with hepatocellular carcinoma. World J Surg 1987; 11:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/76\">",
"      Bismuth H, Castaing D, Garden OJ. The use of operative ultrasound in surgery of primary liver tumors. World J Surg 1987; 11:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/77\">",
"      Clarke MP, Kane RA, Steele G Jr, et al. Prospective comparison of preoperative imaging and intraoperative ultrasonography in the detection of liver tumors. Surgery 1989; 106:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/78\">",
"      Gonzalez RJ, Barnett CC Jr. A technique for safely teaching major hepatectomy to surgical residents. Am J Surg 2008; 195:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/79\">",
"      Torzilli G, Procopio F, Donadon M, et al. Anatomical right posterior sectionectomy: a further expansion of the ultrasound-guided compression technique. Updates Surg 2011; 63:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/80\">",
"      Torzilli G, Takayama T, Hui AM, et al. A new technical aspect of ultrasound-guided liver surgery. Am J Surg 1999; 178:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/81\">",
"      Takayama T, Makuuchi M, Watanabe K, et al. A new method for mapping hepatic subsegment: counterstaining identification technique. Surgery 1991; 109:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/82\">",
"      Regimbeau JM, Kianmanesh R, Farges O, et al. Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery 2002; 131:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/83\">",
"      Ishizawa T, Kokudo N, Makuuchi M. Right hepatectomy for hepatocellular carcinoma: is the anterior approach superior to the conventional approach? Ann Surg 2008; 247:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/84\">",
"      Rui JA, Wang SB, Chen SG, Zhou L. Right trisectionectomy for primary liver cancer. World J Gastroenterol 2003; 9:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/85\">",
"      Wei AC, Tung-Ping Poon R, Fan ST, Wong J. Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg 2003; 90:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/86\">",
"      Melendez J, Ferri E, Zwillman M, et al. Extended hepatic resection: a 6-year retrospective study of risk factors for perioperative mortality. J Am Coll Surg 2001; 192:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/87\">",
"      Mehrabi A, Mood ZA, Mood Z, et al. Mesohepatectomy as an option for the treatment of central liver tumors. J Am Coll Surg 2008; 207:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/88\">",
"      Scudamore CH, Buczkowski AK, Shayan H, et al. Mesohepatectomy. Am J Surg 2000; 179:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/89\">",
"      Hu RH, Lee PH, Chang YC, et al. Treatment of centrally located hepatocellular carcinoma with central hepatectomy. Surgery 2003; 133:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/90\">",
"      Jacobs M, McDonough J, ReMine SG. Resection of central hepatic malignant lesions. Am Surg 2003; 69:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/91\">",
"      Wu CC, Ho WL, Chen JT, et al. Mesohepatectomy for centrally located hepatocellular carcinoma: an appraisal of a rare procedure. J Am Coll Surg 1999; 188:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/92\">",
"      Chen XP, Qiu FZ, Lau WY, et al. Mesohepatectomy for hepatocellular carcinoma: a study of 256 patients. Int J Colorectal Dis 2008; 23:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/93\">",
"      Lang H, Sotiropoulos GC, Malag&oacute; M, Broelsch CE. Mesohepatectomy, caudate lobectomy and resection of hilar bifurcation with biliary reconstruction by 6 hepaticojejunostomies for Klatskin tumor. Hepatogastroenterology 2003; 50:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/94\">",
"      Buell JF, Thomas MT, Rudich S, et al. Experience with more than 500 minimally invasive hepatic procedures. Ann Surg 2008; 248:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/95\">",
"      Cho JY, Han HS, Yoon YS, Shin SH. Experiences of laparoscopic liver resection including lesions in the posterosuperior segments of the liver. Surg Endosc 2008; 22:2344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/96\">",
"      Chen HY, Juan CC, Ker CG. Laparoscopic liver surgery for patients with hepatocellular carcinoma. Ann Surg Oncol 2008; 15:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/97\">",
"      Belli G, Fantini C, D'Agostino A, et al. Laparoscopic versus open liver resection for hepatocellular carcinoma in patients with histologically proven cirrhosis: short- and middle-term results. Surg Endosc 2007; 21:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/98\">",
"      Dagher I, Lainas P, Carloni A, et al. Laparoscopic liver resection for hepatocellular carcinoma. Surg Endosc 2008; 22:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/99\">",
"      Cherqui D, Laurent A, Tayar C, et al. Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives. Ann Surg 2006; 243:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/100\">",
"      Vibert E, Perniceni T, Levard H, et al. Laparoscopic liver resection. Br J Surg 2006; 93:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/101\">",
"      Dagher I, O'Rourke N, Geller DA, et al. Laparoscopic major hepatectomy: an evolution in standard of care. Ann Surg 2009; 250:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/102\">",
"      Sarpel U, Hefti MM, Wisnievsky JP, et al. Outcome for patients treated with laparoscopic versus open resection of hepatocellular carcinoma: case-matched analysis. Ann Surg Oncol 2009; 16:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/103\">",
"      Nanashima A, Yamaguchi H, Shibasaki S, et al. Comparative analysis of postoperative morbidity according to type and extent of hepatectomy. Hepatogastroenterology 2005; 52:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/104\">",
"      Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 1990; 65:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/105\">",
"      Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 2009; 249:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/106\">",
"      Wayne JD, Lauwers GY, Ikai I, et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 2002; 235:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/107\">",
"      Schemmer P, Friess H, Hinz U, et al. Stapler hepatectomy is a safe dissection technique: analysis of 300 patients. World J Surg 2006; 30:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/108\">",
"      Cottone M, Virdone R, Fusco G, et al. Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. A comparison of natural history and surgical treatment. Gastroenterology 1989; 96:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/109\">",
"      Tsuzuki T, Ogata Y, Iida S, Shimazu M. Hepatic resection in 125 patients. Arch Surg 1984; 119:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/110\">",
"      Nagao T, Inoue S, Goto S, et al. Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. Ann Surg 1987; 205:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/111\">",
"      Chen MF, Jeng LB. Partial hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:S329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/112\">",
"      Ozawa K, Takayasu T, Kumada K, et al. Experience with 225 hepatic resections for hepatocellular carcinoma over a 4-year period. Am J Surg 1991; 161:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/113\">",
"      Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/114\">",
"      Bismuth H, Houssin D, Ornowski J, Meriggi F. Liver resections in cirrhotic patients: a Western experience. World J Surg 1986; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/115\">",
"      Bozzetti F, Gennari L, Regalia E, et al. Morbidity and mortality after surgical resection of liver tumors. Analysis of 229 cases. Hepatogastroenterology 1992; 39:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/116\">",
"      Takenaka K, Kanematsu T, Fukuzawa K, Sugimachi K. Can hepatic failure after surgery for hepatocellular carcinoma in cirrhotic patients be prevented? World J Surg 1990; 14:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/117\">",
"      Mullen JT, Ribero D, Reddy SK, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007; 204:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/6/14442/abstract/118\">",
"      Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2488 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14442=[""].join("\n");
var outline_f14_6_14442=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1061866831\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT ALGORITHMS FOR HCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457344296\">",
"      IMPORTANCE OF COMPREHENSIVE MULTIDISCIPLINARY CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREOPERATIVE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Determining the extent of tumor involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Assessment of hepatic reserve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1061867819\">",
"      Portal vein embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H882401073\">",
"      - Benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1061867308\">",
"      INTRAOPERATIVE STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H882401841\">",
"      HEPATIC RESECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H882402433\">",
"      No touch technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H882402440\">",
"      Central hepatic resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laparoscopic hepatic resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POSTOPERATIVE MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17690277\">",
"      POSTTREATMENT SURVEILLANCE AND LONG-TERM OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1061866831\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2488\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2488|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?40/37/41567\" title=\"algorithm 1\">",
"      Treatment algorithm for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2488|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/39/34416\" title=\"diagnostic image 1\">",
"      Hepatoma invading major vessels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2488|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/54/28512\" title=\"figure 1\">",
"      Survival by tumor size HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/35/13878\" title=\"figure 2\">",
"      Segmental anatomy of liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2488|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/17/19736\" title=\"picture 1\">",
"      HCC surgical resection Gross",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2488|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/21/8540\" title=\"table 1\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/45/1757\" title=\"table 2\">",
"      TNM staging HCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=related_link\" title=\"calculator 1\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=related_link\">",
"      Assessing surgical risk in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15992?source=related_link\">",
"      Diagnostic staging laparoscopy: General principles for staging primary digestive malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=related_link\">",
"      Liver transplantation for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21978?source=related_link\">",
"      Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43063?source=related_link\">",
"      Overview of treatment approaches for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/42/44706?source=related_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_6_14443="Causes membranous nephropathy";
var content_f14_6_14443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of membranous nephropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Idiopathic - may represent autoantibody against a podocyte antigen such as PLA2R",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus (WHO Class V)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drugs:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Penicillamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bucillamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gold salts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anti-TNF therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tiopronin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        NSAIDs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis C virus (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy (may not be causative)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematopoietic cell transplant / GVHD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Status post renal transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis (uncommon)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14443=[""].join("\n");
var outline_f14_6_14443=null;
var title_f14_6_14444="Incidence mets carcinoid size";
var content_f14_6_14444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of metastases related to the size of the primary carcinoid tumor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tumor location and size, cm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total patient numbers",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nodal metastases, number of patients (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Distant metastases, number of patients (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Small intestine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &le;1",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        5 (12)",
"       </td>",
"       <td>",
"        2 (5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1.1-1.9",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        58 (70)",
"       </td>",
"       <td>",
"        16 (19)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;2",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        50 (85)",
"       </td>",
"       <td>",
"        28 (47)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Appendix",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &le;1",
"       </td>",
"       <td>",
"        431",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1.1-1.9",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        4 (7.5)",
"       </td>",
"       <td>",
"        2 (4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;2",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        11 (33)",
"       </td>",
"       <td>",
"        4 (12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Colon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;2",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;2",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        26 (62)",
"       </td>",
"       <td>",
"        17 (40)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89:151. Copyright &copy; 2005 Wiley-Liss. Permission from John Wiley &amp; Sons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14444=[""].join("\n");
var outline_f14_6_14444=null;
var title_f14_6_14445="Developmental issues diabetes";
var content_f14_6_14445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major developmental issues and their effect on diabetes in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Developmental stage (approximate ages)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal developmental tasks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type 1 diabetes management priorities",
"       </td>",
"       <td class=\"subtitle1\">",
"        Family issues in type 1 diabetes management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infancy (0-12 months)",
"       </td>",
"       <td>",
"        Developing a trusting relationship/\"bonding\" with primary caregiver(s)",
"       </td>",
"       <td>",
"        <p>",
"         Preventing and treating hypoglycemia",
"        </p>",
"        <p>",
"         Avoiding extreme fluctuations in blood glucose levels",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Coping with stress",
"        </p>",
"        <p>",
"         Sharing the \"burden of care\" to avoid parent burnout",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toddler (13-36 months)",
"       </td>",
"       <td>",
"        Developing a sense of mastery and autonomy",
"       </td>",
"       <td>",
"        <p>",
"         Preventing and treating hypoglycemia",
"        </p>",
"        <p>",
"         Avoiding extreme fluctuations in blood glucose levels due to irregular food intake",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Establishing a schedule",
"        </p>",
"        <p>",
"         Managing the \"picky eater\" Setting limits and coping with toddler's lack of cooperation with regimen Sharing the burden of care",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preschooler and early elementary school-age (3-7 years)",
"       </td>",
"       <td>",
"        Developing initiative in activities and confidence in self",
"       </td>",
"       <td>",
"        <p>",
"         Preventing and treating hypoglycemia",
"        </p>",
"        <p>",
"         Unpredictable appetite and activity",
"        </p>",
"        <p>",
"         Positive reinforcement for cooperation with regimen",
"        </p>",
"        <p>",
"         Trusting other caregivers with diabetes management",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Reassuring child that diabetes is no one's fault",
"        </p>",
"        <p>",
"         Educating other caregivers about diabetes management",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Older elementary school-age (8-11 years)",
"       </td>",
"       <td>",
"        <p>",
"         Developing skills in athletic, cognitive, artistic, social areas",
"        </p>",
"        <p>",
"         Consolidating self-esteem with respect to the peer group",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Making diabetes regimen flexible to allow for participation in school/peer activities",
"        </p>",
"        <p>",
"         Child learning short- and long-term benefits of optimal control",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Maintaining parental involvement in insulin and blood glucose monitoring tasks while allowing for independent self-care for \"special occasions\"",
"        </p>",
"        <p>",
"         Continue to educate school and other caregivers",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early adolescence (12-15 years)",
"       </td>",
"       <td>",
"        <p>",
"         Managing body changes",
"        </p>",
"        <p>",
"         Developing a strong sense of self-identity",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Managing increased insulin requirements during puberty",
"        </p>",
"        <p>",
"         Diabetes management and blood glucose control become more difficult",
"        </p>",
"        <p>",
"         Weight and body image concerns",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Renegotiating parents and teen's roles in diabetes management to be acceptable to both",
"        </p>",
"        <p>",
"         Learning coping skills to enhance ability to self-manage",
"        </p>",
"        <p>",
"         Preventing and interventing with diabetes-related family conflict",
"        </p>",
"        <p>",
"         Monitoring for signs of depression, earing disorders, risky behaviors",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Later adolescence (16-19 years)",
"       </td>",
"       <td>",
"        Establishing a sense of identity after high school (decision about location, social issues, work, education)",
"       </td>",
"       <td>",
"        <p>",
"         Begin discussion of transition to a new diabetes team",
"        </p>",
"        <p>",
"         Integrating diabetes into new lifestyle",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Supporting the transition to independence Learning coping skills to enhance ability to self-manage",
"        </p>",
"        <p>",
"         Preventing and intervening with diabetes-related family conflict",
"        </p>",
"        <p>",
"         Monitoring for signs of depression, eating disorders, risky behaviors",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from: Silverstein, J, Klingensmith, G, Copeland, K. Care of Children and Adolescents with Type 1 Diabetes. Diabetes Care 2005; 28:186. Copyright &copy;2005 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14445=[""].join("\n");
var outline_f14_6_14445=null;
var title_f14_6_14446="Pneumoperitoneum Plain film showing free air";
var content_f14_6_14446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F66170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F66170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plain abdominal film showing free air",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAPoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKCMjB6UUUAc1rYRJjyS3Y+lcrePklduQeK7m40pXiHmy7QCWY+uTmsHUbnSLAFTIruPTnNAHAahDKHZURtpHYHmufm0m7mZl8oqOzkfpXc6p4ttE3LBbL04LHNctfeIriQsx4jPIxxigDj7/wzqE6ujIpUjg5rnbjwfqcO4eWsi4zw3WuqutfkkVt0z5Ho1UF1acRkCdhu6EmgDjLzQdRhyRZTLjk4AOKxZvtELnzY5UH+0pFenW+u3EWVeXcM9+asreW90QtzDG4PfGKAPJIbhS/ynHsasC6bndypOMeteq/8Iro92gleNU3fhmqF/wCB7bZ/o0Tx5PVTmgDgrQJLJtyFJ5APQVZuFYwhBwRznrmr+o+FL21XMA81OuBwRWEk0tv94n5ScKw6UAWkQswUcN9eKvWoVD5b7WDHHHTFUEv4p1BkwjAAEj+KtGx2SzqxG1OwXpxQB2PhfThFdxzWhYBSCVz/ACr6Y8HcaNECDuI3H8a+e/CkDrPAEbJbGR0619H6GoFjGRwQoBH9aANGvPvFFsRcTjvuJH0r0GuT8XwjzScffUc0AePa9ENzHA4rzfxPbedDKpOAa9W12D75PIrzzxFHhWxz3zQB5Rd28kDMGwVz1BqtWxq64ORzmsgjmgD9IaKKKACiiigAorlviC/iePTrNvB0cclytzuuVIjZjDsfhVdlUnfs6svAPNcYfiV4h0QY8U6AqKv35vLltAPxYSQf+Rx+PWsaleFJ2lf7m196Vl8xpXPW3UOjI4yrDBHqKSNBGiogwqgAc54rhdI+Kfh6/gE0631lH3lkg86EfWeEyRD8XrrNL1zSdXt/P0rU7G9h/wCelvcJIo/FSaqnWp1VenJP0dwaa3NCo5pkhXLsBWF4g8U6dpV5Z2Ut3El3eBzAjHHmbcbgD0z8w46nnHQ1ymteIAQQHwK0EaHiHU7iTcI5wEOeDXneq3b7mypb3FR6lrm4sC3TuTWFd6i0oO1uSDzQBnanftE5EgOMmsWfWpOQrDBHTNWL678z5JQpOOa5248tpWwmPpQBNLdkjcRjPSqr3bFcAkj1qpOqhMqWBPeo7dWLcnjpmgC1HeyAlRk1o2eovFIC+Dz09azxHGOADnHWl2FRlee9AHTw6tMWTBBHGFrqNB10KAtzyp7HtXnVizFwrdzxWtDcFJNvA70AeuwQWN+pkt8H+8vcVxXjLwXb3iSXESeW/UsoxVfTNVe1KzRyHCgZPoa7HT9Zj1eEofllA+6ejUAfOOrWFzYXBSaNlQfdOOvvVzQLx7a6jLfNDkblr2XxB4WXUizeTgdsmvPtS8Iz2swaNSnPK+1AHp3gxYrq5jmt33xqM56Ee1e3eFZme2KMc7cDJ618++B/O02OFXyjv8xBHUV7z4NmWeHcgHAwcdjQB09YfiqINbRu3QEityqOsoGsWJ/hOaAPIfEFvy+a848SRfu2b27V6x4hQfMCOMcV5p4gi3QNxkd6APIdcXBNYuBXReIUCu3vWBQB+jdFFFABRRRQAUUVGsyNNJECd8YDMCCODnBz36GgDntd8JeGb12ur/SLP7X2uYk8mf8ACRMOPzrynX/A2nXF+0tpfSpIoJX7cq3TD6SsPPH4SivVtflLswD/AExXD3nyzMzE46YxWNTD0qrvOKb/AB+8abWxw3h250S11bVLbxZqdrd28MP2b7P9oluMsxVziFzJKpG1CCHIGeORxi6zrrWeqJBoc97qelODiS+t3ikg/wBlmkCmQejY3eu7rXdXul/aGD7tg681jan4ftpU3vMARxxXBh8r9hipYmNWXvfZveP43d/O/wCGhTneNrHHPrMNz/rVaN+3pVK5u8DMTgjPatDUfDnlKxhmEg/WuXvdOvLZS2z5R1APSvVIJZpw7BpScgkE4qt8m8sGA7c1Ra6kIEb54PpUMkhIOG5oA0xECpB+Ynow7VCIl3DPr61UE7RrnOSac9ypVe7deaANu0tdw5Qsvt6VPJakZMXXH3TWZp9+YuvzdsDtWql4JeMg+1AGfMskcg3rhunAp8N0eBJjI6Y71qxsJDiRQ647/wBKo3OnxN88O5QeSDzQARPOzbsjb6Z6Vf03VJbK/QrjCkMxrG2zW7dNyeq0rSiWZWJ2sPT0oA978NX8Gs2ajK/alHKngEVcm8MpfXCjGPf2ryXwtqc9peRPG7bs8YNfSXhG7tdSsFZdplwC496AOKuPDWyJAYgGQcYrT8JSzaRPI1wf3WOR6iu9ltISo3DOOAT2rC1fTwFCqNoJyT7UAdNG6yIrocqwyD6iob4Zs5gOflpNPXZZQrnOFFTuoZGU9CMUAeX+IY8b1Hb2rzLXY8I4HvXrXiSPa78cjg15frqDEnT3oA8f8SxjeRx9a5nB9q7DxREN74PT9a5P/PSgD9FqKKKACiiigAoIyMUUUAc9rVjLhnjUsuO3auYew8ve8ynzM8Z/hr0iqd/p0N4pDjax7jvQB5FduY5HyMdfmJzmsHUJf3R3NyD1r0XXfD6RlyjNkZIJrzzUrKRQ4GSTwQRQByWozsAwhJ/wrHF35xKzEOuMbv8A69bGrWEqx7olJHeueuInil8thgjtigCpdRW7yHzAuOe1Zs62yMAqEr9atX+Ulb9azZM5agB80dpLDlA6y54+bgD6Vnvbnf8ALIAM8EmkmdlO5Dg96ijcvkMcMO9AEgMgYlTuI9KlhknDB0BJHNVlRzIQp6c1LO7QuNpIBFAHQWOoMYykgKnt6VowXDEFHOPcmuWtr+WNeG4OCc1rWV+JTiQAEDjHegDaVUb7vX0NR/Y0ncLs+bOOOMVBZTrJKEUkNnkN2rprGyfqoZ2x97FAFax0yWxfKHzc9W/pXofg7WZdPnR1YDHY85FYMMcsUe1o2zweRj9av2qxuV3AqSetAHvmk6hFqVmk8JBz1HoaS8i3MWIyB0ryTR9ZvdJmH2Y7wDkrnAPsa9c0q+h1OxjuITww5HdT3FAFi3G2BB7VJRRQBx/jCDDsccMM15Nr0RAcAcete1+L482IlwflyDXjuvB8Sb+wzx70AeP+Ko8u5zk+vSuNKnJ5rvPFoxI4wPriuFYfMfm7+tAH6IUUUUAFFFFABRRRQAEgEZPXpQenHWignHbNAGRqUHmAiUAnrmuV1PRhIwPyHJwAWAJPpXcXAj25lXaWbaAT1rNvNNjZvNcZVfmQ45RvUUAef6t4cLxp8giY8E5/pXE+IvBssbpN5qEf7POfrXqOr2crglZSRjo3rXOgz4eKZGPbnmgDw/WdHuoZ3O0OuT0Nc9cxMhwVKn0Ir1vX7JTPJsyrgmuXmso5/wB3cJ+8zw2M0AefTRkN9RVbbhjjriuu1HSI1dlRl5GcA1z17aSQNwCR9KAKAYoQT0HvU146uqPnJI59qaVyMUySItGoXPB70AMVwF5PNX9P+aZMn5SeapR25GMjJzWxpO03EauMKDigDpYo4oYoHePL9D6Guh0zWFiYLlVj7CuMurtlZY/7pPB9KfHcKyEqdp6nPegD1aHWIJlAcKe3FXkeB4yIjl8fd9PevK7bUWhiyx5b7oJrd0fWysnzHP8AtdxQB2VszQzlX5A6Hua7/wAEXvkXSoWwkvylf5GuDsZ0vI1D8sTwRW/4fLpqESe+ST6UAeu0UyB/MhRvUU+gCjrUXm6ZOMZKruH4V4zr6fLLnHPavcpFDxsjdGBBrxzxTb+VNMjKMqSMfSgDxTxSuS5INcIU5PymvRvFa/K3qOK4Jt244PegD9AqKKKACiiigAooooAjklCHn+dMS6iYZ3Y+tV74nkrnI9q52e4KTEZIyelAHXLIjjKsDVe/jxZsqE9eO9UrF/MtypO1s8Zqv4kE8WnxtbyMGz2PtQBk3bNlw/TOOe9ZTn5gxGGxgj3FVX1m4hBF2m9CcbhxU8VzbXUf7uQbu6t1oAxdZsobuRnaPk8E1zWoaVEw/d8KD3712V5lUB/hbt3rEu1Dbv7x60AcHf6G3UKCPasuTTHDfvFBTHIIr0QJGEIIBxxj/Gsy+QNLyqjjsOlAHn914dhlbfEXj46EcVVl0VQhVDiQfwkda742JdsL1PQ1RuLHyuJl5z2/xoA8+nsHhBDggjqPSktkxJkjnjtXosml29zEnmKD2yDn86wNX0M2G94TuzxjrgUAczft/pUrNx2GPSoll2539ewPen34ZW3MpNZ2dzEk80AXo7lgx3HP9K1dPuwZFwcdq59FYnIz1q5B8jZz3oA9T8NSvEVmdz5XUjOcivTPCuoxTtuKK4PA55FeE6fqhggELck8mu+8LXnlyQbJMFeT9aAPoTTsfZwUbKN93nNWqxfCt2L3SYJWASQjcU9K2qACvMviBbBNSlPZwG/MV6aa4T4kwhoredSDkFTQB89+L05kGeleeug3t16+tel+L1yJAOuK86dBvb6+lAH33RRRQAUUUUAFFFFAFK/UgZPQ9OK5eeIvcbzxjpxXYzR+YpBPFYF7D5e4heF4wT+lADrPJICk7varushU0vLn7vrUemWay2370Eg8EA4xWT43vjFAtlF0wGck/lQBw+q3PmuqKAozx6ms2SXy43ODgVOq5my+dg5NU7+YCFmPG4/KDQBH/a5iwrkuO2e1O+3xSqW4J96wLpyW3Ht39KqLP5bErn2oA6uN1d+cY9x1qlOqNO24Y9xWTZ6ifMO7IC9vWmT6gN3DdegoA2IdisUGcnkH2qaezjuEJfjjqBzWPbXfUE4HpV1LvIx69896AHixKRr5C7olBJUHn61y2sStDKrMSH5G0+nvXcJNs0xWA+dh0NcVq8InZ/tJ3EfdJ60AcfqIbzC5Vdj84HasuaESDdEAGHUZ6itq8Xy0IIDoOhHasc43Fh29KAKqEqGDfeHUd6kjly+c/jTi6SKA4BPQHvj60wwsoRkG5DQBt2amSUOf4f1ru/DGnXFxkB2RGHzSelctoNmJUjU8KOrYru7jVE07T4ba0G1sdR1AoA7zT/EptLyNIyQiDb9R716To2pR6jbiRCM4zXzJ/apVgHY7nPHsK9Y+GGufvFglb5XGOexoA9TrkPHEavo0v/TNwenTtXX1zHi6MfYb1Nud0e8UAfO3jBOZeADjjmvPGY7jyvX0r0fxep2O2OK86bG45AzQB940UUUAFFFFABRRRQAVWu7RbgDBCkdferNFADY0EaBR2GK43xTZPJJI7ITIPmz1zXaUyWJJkKyqGU+tAHjyWkp3fLwe9c1rIJuGX+EcDNe7XGi2UsJRYQnGBg1xeo+DFYuQHyDmgDyS4wflJGBWXckIvHavRtS8GSI7FWbp6Vz83hC+eU7drL970oA5WSUqsjEDOKy3u2Lje3GeK6bU9BvoreQtFnJ6A9q5G8t54+HiYHPcUAWlvZfMYkjaOhzyfWrllqYDlWO4dPxrFZjGNpI6daS3jkeeNUGdxHSgD01pSdNhUHqM1yerXQYtATnHUitW+naz09HcnhcAetcjPcb2Z36Dv6mgCs75LqcZ71l3lm+S8APTkdqu79z5Vs+1OS42MoHGeSDQBzbFoyQ64I9a19M6IhAO8gbTW5HpcOqcsuCOpFaPhzwpeHVVkniYwIflbsaALlvZ/wBmwZIzGRuB9fasm5v2kl3Bu/bpiut8XR+VpxtY/wDWKN3HYV5rLKY0KA5PT/GgDZiuBcSFwfl6LntXofgmd0ngwehB4ry/TDtOMDnse1eieELjY67OCv6UAfSGn3AubOKUHORz9azfFif8SqSQdVBH4EU/wu2dLjGCOA3PvVjX4/N0W9QAkmJjx9M0AfMXjDiF9rZJ/wA4rzhvvHnvXonipVEcmRyOledsp3HA7+lAH3nRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEE1pDN9+NT2qrLpNu5GBj1rRooA5HXvDYlTdEoOewFcVf+GApbzIhxwcrXsdQ3NtFcRlZFBz3oA+ctY8I28xZhEVJzyvFVvDvge9S5MqRvLHnCjHP1r6G/sCxL7nj3d8VZa2iiQRwRAEDjAxigD508c6e1veR2m0ghQx9hXm+oOVk2KPlXOD6ivqT4j+EU1m2+0W6f6QE8slepFfPXiLwxdaZcN5uCo6UAceJthO78PekWYu2FHUVdntYtwzIc+mKuaVpkMsybWdmJxtUc0AdJ4KsZLq6WNRlcAnjjNe66BpUdrprPcKioi/x8DNc38PvDxs7VXmTyn4Y5HOK7e5eCeEwx5OfTvQB5T4m0dmuZXtpPOMhwSoyPpXmPiHQrjTbwHZujbkex7ivoa8lhtYSn7pT05rivElpZzWjFnUhuc+hoA8r02zfeGPHY+1ej+DobVSRO4DEgDBrz6aK4eZo7d1ODjINegeAtLvWVDIu4x8kgigD3Pw5xAcHKhRjHcCtK+dDaMGOBINn51m+GkdNPG4YbpyatakSLFCOquPf1oA+a/HMRhuLqE4yhYCvMmZtx/eY59a9e+KsIj1a9+u78xmvIGVNx470AfedFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFct4r8JW+sxN5aoshHOe9dTRQB87ar8KHjujun2rnnjrWlpekad4XhDRqJJh/Ea9j8RKBp0jhcv0Brw/xMZ0lIyeuTQBoXHipo/wB40gUZ6DpWXf8Ai9zHmKXYCOQK838T3sskixKxCDrj1rMtLp0YmRiTjGDzmgDvrzXXlwAWbnnnqaSC7+12kkUhOTzXOWkwMSnPXvitfTx+8YKcKy+tAHHakktnqZwzAg5DDivVvhnq9wIsGQ7mxjcc5FcRrNgb4KUBEvbIxXW+BYTHPFGFwMAGgD33SJA1grx8eYcsB2pLmbzLK5ABISQLj8KNBIGmJj+HJqBQRpk7N/FJu+ooA8Z+LMebxmPRo1P6V4qwO4/MOte3fFk5mOO8QxXibxHe3z9/SgD7wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAiuYVnhaN+hrzTxl4dZd7YHPSvUKx9dlSS2kjyvHXNAHzB4i0Ly7kyyvtUjGMVgjTYUZiHzjpmu98YwTzXEirgKCQB61xc1hc4OEfC9aALdnaq0YTcinPrxXWaVpcJdS8gGBjiuS0zS7iRRlTgNnGea7DTrQqnlyS4kYcYNAF+30O3llLifH4d/Wup8N+GVS+jkSZApHPHeuegtmidF83gcGu08Osu1kLoWX7uKAOvWAWOniCMk7j1HeoNRCpbGPAzt5INMguTPIqHhY8Zz696qazMxXKYGeCe3NAHkfxQcNKQpziMc14u7/O3XrXrPxEnVricLtCj5QPTHFeSy7RI/B6mgD7yooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5PXsYmI3EDPIrrKydWsQ8DleB1yaAPHdeWGNt5GSe3qa565vUUMREhI7Hmuz8UWEaM3cdRXDaiYIstJjPTjk0AZ6ajPNIyxxrAR2XvSRzTxTrMWfG7aOasWE0DyqMZGRzjpXQ3mnW32NhGeRyKAKltcea3DEHr14rsvD0o3xEkhl5BHeuD02FwzBxkdiK7TRzsRAOCSBzQB6JYxMHkkUgxuMj61n6zJ5UZBFdFpEZOlRE8k/NzXK+MSUt5WU4GDk9c0AeG+PLgkyMTwzHtmvN2LliSB19a9A8cNhWIzjHI7V5o0ibj06+9AH6A0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNlQSRsjdGGKdRQB534r094nIIznofWvKNe02QzngkHkGvozVLEXiAHt2xXDeINDLFtic9DgUAeO6Zp8qT4wdp68VtK8tu5LEBevNbv2D7OZNww/rWBqIIc55IHFAEbXQFyhiATJ6DpXXaFs1BkEH+sBHA7jua85vJdiBVPzA8e3vXcfCyZv7QtzIPldwBk449aAPcbWMR2sUeOiAEfhXB+OjtHlnkZr0GvPPiAMagcdCgNAHh/jWJdjMT83oa81dH3the/rXpXjVyN4HQ15q7fO3JHNAH37RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVL638y2YICW7VbpGIUEnoKAPMtYgEbS7lx1HSuJ1SEOG8tMHHOK9B8WuzO7qowTg151qMxR26jr+IoA59rIvdICOc8k9vwrtPCMRh1CDywTggjNY9hBFIplJJYnkk8113hW2t/tcOAwZWGeaAPXUJKKT1IBrgfiGCsqORwQRXdQOGLLkZXtXB/EV8qhz91mX6cUAeC+NHAEuSc5rzpmyxO5eTXdeMZSzy4/WuAPU0AfoLRRRQAUZGcZ5oprIjMjMqlkOVJHKnGOPwoAdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFHeiigArG16+EMGwHGT1rZPNc9rkSybtw4+vSgDgtYv3ZZApzk45riri5M77HGMnqO1dzf2SuW2nOea5m50pVuC+eCc4oAy7ESRTqCAd3Neh+GLU/bEm6dD9a5/TNLEmzzGy2eoGK6/TARdpGnRBkmgDrrKUyag3JwEOfzrhviBOGt1J7yEg12Vgohs7m4fqV2g15z8QpwkEKbhkAnGaAPDvFku6SXnGD0rhyeTwa6vxRMDPKM8E1xzN8x6nn1oA/RCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAR2CqWPQVyWsSsrHJI9D2rp70kW7YbafWuSvJMlh94/nmgDnrt35AbIPvWBfeYc8tx0xXTTRpvYL0PIzzisqe3Ysw42n3oApaOrm6QO5AJxzXoGl2Wx9x4BA+YelcXpcSx3C5GSK73TpNkELE/LnJFAE2r3Ait1gXhRXkvxEuh5r+ioAe9eleIblWJIOQvO4968W8aXfmCds8knH0oA8p8QS7p3z0JyK5Yk5NbmszbnfmudPU/NQB+j9FFFABRRRQAUUUUAFFFFABRRRQAUm5d+3cN2M4zzj1paaEUOXCrvIALY5IGcDP4n86AHUUUUAFFFFABRRRQAUUUUAFFFFAFHVm2249+K4nUpCGOw85/Cux1lsQ8nArhdRlG5wcfWgCnNOCeOmKqyyE55wOp+lV2uBvZQ3OKh84kHnPqPSgDStV/erKehPJFdQ18ILdXw2BwQoya5W2ugIFXGSG4+lW5LsqPlyPloATxHfYjaKNuTyxHYV5B4tnwkmT6mu+1aYiJtxryrxZdEmRR2XmgDgdTk3M3rWVuq7qDZbPeqFAH6RUUUUAFFFFABRRRQAUUijaoGScDGTS0AFFFFABRRRQAUmTuIwcY69jS0UAFFFFABRRRQAUUUUAFFFDdDQBh65LmNuOB3rznV5x5rc8ZrvtbJ2OBj2ry3xHM0MzjsT1oAx7698qYMDgA80QX6s52k4PT0rnNTu8u3OKl0ObzA6E8ryM0Ad9puZOBg9z7VdvHwG5BHXpVPw+uLeSQ88cc07UZQsWB97qRQBz+uXRjzsxwOa8p8Uyks/Neh+IJcI4zmvLPEcu4t+tAHLXZy7VXqSc5ao6AP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erect plain film of the abdomen shows free air between the left hemidiaphragm and colon (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14446=[""].join("\n");
var outline_f14_6_14446=null;
var title_f14_6_14447="Knee dislocatn ant2";
var content_f14_6_14447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior knee dislocation with bicruciate injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lateral radiograph above shows an anterior knee dislocation with bicruciate ligament injury. Note how the alignment of the patella and the femur are no longer parallel and the close proximity of the femur and tibia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bucholz RW, Heckman JD. Rockwood &amp; Green's Fractures in Adults, 5th ed. Lippincott, Williams &amp; Wilkins, 2001. Copyright &copy; Lippincott, Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_6_14447=[""].join("\n");
var outline_f14_6_14447=null;
